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SUMMARY
The main aims of this thesis were to  investigate the e ffec ts  of the potent and 
selective /c-opioid agonist CI-977 in animal models of focal cerebral ischaemia, and 
gain insight into a possible mechanism of action underlying the anti-ischaem ic 
e fficacy  of /c-agonists. Q uantitative neuropathology was used to determ ine the 
e ffe c t of CI-977 on the  volume of ischaem ic brain damage a f te r  perm anent middle 
cerebral (MCA) occlusion in the ra t  (outcome assessed a t 24h and 4h) and c a t 
(outcome assessed a t 6h). Microdialysis techniques were employed in vivo to 
examine the  e ffec ts  of CI-977 on glutam ate re lease  a fte r MCA occlusion in the c a t 
and also on neuronal necrosis induced by exogenous glutam ate perfused into the ra t 
cerebral cortex  by reverse dialysis. The cerebral circulatory  e ffec ts  of CI-977 
were examined in the ra t  using [14C]-iodoantipyrine autoradiography in normal brain 
and a f te r  perm anent MCA occlusion, and in the  c a t a f te r  the  induction of focal 
ischaem ia using the hydrogen clearance technique. [14C]-2-Deoxyglucose in vivo 
autoradiography was employed to assess the functional consequences as reflec ted  
in alterations in local ra te s  of cerebral glucose utilisation in d iscrete  brain regions 
in conscious ra ts  following the system ic adm inistration of CI-977.
The adm inistration of CI-977 (0.03, 0.3 or 3mg/kg, s.c.) in itiated  30 min prior 
to  occlusion of the MCA in the ra t  (and a t m ultiple tim es thereafter) produced 
dose-dependent reductions in the volumes of infarction and of brain swelling when 
assessed a t 24h. The m ost marked reductions w ere noted with CI-977 (0.3mg/kg) in 
both infarction (reduced by 38% from controls) and swelling (reduced by 31%). 
There was an excellent correlation betw een th e  volume of brain swelling and 
ischaem ic damage which was sim ilar for veh icle-trea ted  and C I-977-treated animals 
(overall correlation coeffic ien t r=0.896). T reatm en t w ith CI-977 (0.3mg/kg, s.c.) 
30 min before and 30 min a fte r perm anent MCA occlusion in halothane- 
anaesthetised ra ts  significantly reduced the volume of infarction in the cerebral
14
hemisphere (reduced by 27%) and cerebral cortex  (reduced by 32%) despite a marked 
and sustained hypotension, with only minimal e ffe c t on ischaem ic damage in the 
caudate  nucleus. P re trea tm en t with CI-977 (0.3mg/kg i.v. bolus followed by 
continuous i.v. infusion of 0.15mg/kg/h until death) in itia ted  15 min prior to  MCA 
occlusion significantly reduced the volume of ischaem ic brain damage in the 
cerebral hemisphere (reduced by 33%) and cerebral cortex (reduced by 42%) in 
halothane-anaesthetised ca ts  w ithout altering  significantly any of the  key 
physiological param eters m onitored throughout th e  post-occlusion survival period.
In a parallel study, the effec ts  of CI-977 (0.3mg/kg, s.c.) on cerebral blood flow 
w ere examined 30 min a fte r  the induction of ischaem ia in halothane-anaesthetised 
ra ts . In the hemisphere con tra la tera l to the  occluded MCA, p re trea tm en t with 
CI-977 failed to  dem onstrate any significant e ffe c t on the  level of local cerebral 
blood flow in any of the  25 regions examined. In the hemisphere ipsilateral to 
MCA occlusion, CI-977 failed to produce s ta tis tica lly  significant alterations in 
e ither the level of local cerebral blood flow in 23 of the  25 regions or on the volume 
of hypoperfused tissue determ ined by frequency distribution analysis. Areas of 
hyperaem ia were observed in C I-977-treated ra ts  with MCA occlusion in both the 
m edial caudate nucleus and la tera l thalamus (local cerebral blood flow increased by 
65% and 86% respectively compared to vehicle). In an in vivo  model of g lu tam ate 
neurotoxicity in anaesthetised ra ts , pre-and post-trea tm en t with CI-977 (0.3mg/kg, 
i.v.) had no significant e ffe c t on the volume of neuronal necrosis assessed 4h a fte r  
the onset of g lu tam ate (0.5M) perfusion into the  parie tal cortex; the NMDA 
antagonist MK-801 (0.5mg/kg) and the  AMPA antagonists (2 x 30mg/kg) significantly 
reduced the  lesion volume by 30% and 23% respectively. Perm anent occlusion of 
the  MCA in halothane-anaesthetised ca ts  produced a m arked increase in 
ex tracellu lar g lu tam ate  levels, determ ined by microdialysis, when cerebral blood 
flow fell to  a threshold value of approximately 20ml 100g-1 min-1 in veh icle-treated
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control animals. The adm inistration of CI-977 (0.3mg/kg i.v. plus an i.v. infusion 
of 0.15mg/kg/h) 30 min prior to the induction of ischaemia produced no evidence of 
such a threshold for glu tam ate re lease in the ischaem ic hemisphere, and markedly 
a tten u ated  the  increase in ex tracellu lar g lutam ate concentration a t cerebral blood 
flow values of less than 20ml 100g_1 min-1.
The e ffec ts  of CI-977 upon local cerebral glucose u tilisation were examined in 
the  normal brain of conscious, lightly restrained  ra ts . The i.v. adm inistration of 
CI-977 (0.03, 0.3 or 3mg/kg) induced relatively  homogenous patterns of altered  
cerebral glucose u tilisation with m oderate s ta tistica lly  significant reductions 
(approxim ately 25%) being observed in 29 of the 45 brain regions, and a significant 
increase (approximately 40%) in one brain region, the la tera l habenular nucleus. 
Glucose use throughout the en tire  neocortex and inferior colliculus was particularly  
sensitive to reduction (approximately 35%) following CI-977 adm inistration, although 
there  was only a lim ited dose-dependency to the  response. Minimal alterations in 
glucose use w ere observed in 15 brain regions, which were located predominantely 
in the  lower brain stem  and forebrain limbic regions.
CI-977 (0.3mg/kg, i.v.) induced minimal cerebral circulatory  e ffec ts  in conscious 
ra ts . A significant reduction in local cerebral blood flow was observed in only one 
brain area, the posterior entorhinal cortex  (I). In 44 of the 45 regions examined, 
local cerebral blood flow was not a ltered  significantly with CI-977 trea tm en t, and 
no significant increases in cerebral blood flow were noted. C erebral blood flow 
rem ained tightly  coupled to oxidative m etabolism  in the  brain regions examined and 
there  was no c lear evidence th a t cerebral blood flow and glucose use could be 
uncoupled locally, num erically and neuroanatom ically a f te r  CI-977 adm inistration.
The results of the  studies within this thesis suggest th a t a m ajor component of 
the  m echanism of action which underlies the anti-ischaem ic efficacy  of CI-977 in 
animal models of ischaemia is a presynaptic inhibition of g lu tam ate  release. Thus
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/c-opioid agonists such as CI-977 may be of benefit therapeutically  for modulating 
excito toxic brain damage in cerebral ischaemia in man, and the ir use is unlikely to 
be com plicated by concerns over CNS safety  as with NMDA recep to r antagonists.
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PREFACE AND DECLARATION
The investigations in this thesis were conducted in th ree  broadly defined areas:
(1) To exam ine the neuroprotective e ffe c t of the /c-opioid receptor
agonist CI-977 following perm anent MCA occlusion in the ra t  and cat.
(2) To establish a possible mechanism of action underpinning the anti-
ischaem ic efficacy of CI-977 in animal models of focal cerebral 
ischaemia.
(3) To assess the  functional and cerebral circulatory  consequences, as
re flec ted  in local cerebral glucose use and local cerebral blood flow 
respectively of CI-977 in normal ra t  brain.
This thesis comprises my own original work and has not been presented 
previously as a thesis in any form. Some of the experim ents reported in this thesis 
were carried  out in collaboration with o ther researchers: Dr. K. Kusumoto 
perform ed perm anent MCA occlusions in the ra t  and c a t neuropathology studies; 
the g lu tam ate  neurotoxicity in vivo study was conducted with Dr. H. Fujisawa; the 
g lu tam ate re lease /cerebra l blood flow study in the  c a t was carried  out in 
conjunction with Mr. S. Galbraith and Mr. T.R. Patel.
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CHAPTER I 
INTRODUCTION
1. CEREBROVASCULAR DISEASE IN MAN
Cerebrovascular disease represents a m ajor cause of disability and 
m ortality  in the industrialised world today. Prospective epidemiological 
studies have identified cerebrovascular disease (cerebral ischaemia) as the 
third m ost common cause of death in the W estern world, surpassed only by 
heart disease and cancer, and also the m ajor cause of severe functional 
incapacity in the adult population (C am arata e t  al., 1994). It has been 
estim ated  th a t approximately 500,000 people in the  U.K. are currently  
severely disabled by the neurological consequences of cerebral ischaemia 
(Bamford e t  al., 1990). The frequency of cerebrovascular disease in modern 
society and the severity  of its sequelae serves to  highlight the im portance of 
understanding the pathophysiology of cerebral ischaem ia and the necessity to 
develop effec tive  therapeutic  agents for use in the clinic to  improve quality 
of life.
1.1 Stroke and Ischaemic Brain Damage
’’Stroke" is the principal clinical m anifestation of focal cerebral 
ischaem ic brain damage in man. The worldwide annual incidence of first 
stroke is estim ated  a t between 150-200 cases per 100,000 population, with 
m ortality  in approxim ately 40% of these patien ts (C am arata e t al., 1994). 
The underlying trend is age-dependent, with the incidence m ore than doubling 
each decade a fte r  the age of 55 (Bamford e t  al., 1990). Those who survive 
their f irs t stroke are not only often  severely disabled, but are a t a greatly  
increased risk of fu rther ischaemic episodes (Haberman, 1984).
Focal ischaem ic damage or stroke can be defined as a reduction in 
cerebral blood flow to a d iscrete  brain area resulting in the  abrupt and 
dram atic  developm ent of a focal neurological defic it. Strokes are e ither
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occlusive (due to thrombi or emboli) or haem orrhagic (due to bleeding from 
a vessel). Haemorrhage may occur a t the  brain surface (extraparenchymal) 
e.g. from rupture of vessels damaged by long-standing hypertension, resulting 
in haem atom as within the brain.
Evidence from several large stroke registries indicate th a t up to 85% 
of all strokes are thromboembolic in origin and up to 23% of these are 
cardioem bolic (Mohr e t al., 1978). About 10-15% of strokes are caused by 
in tracerebral haemorrhage, predom inantly in patien ts 55-75 years old (Foulkes 
e t al., 1988; Mohr e t al., 1978). Most of these haem orrhages occur in 
patien ts with hypertensive arteriopathy and are located m ost frequently in 
the  basal ganglia and thalamus, deep hemispheric w hite m a tte r, cerebellum  
and the  brainstem . O ther causes include haem orrhage from  arteriovenous 
m alform ations and aneurysms, amyloid angiopathy, tumours, vasculitis and 
coagulopathies. Outcome a fte r in tracerebral haem orrhage is poor, with 
approxim ately 50% of all patients dead within one year of the initial event 
(C am arata e t al., 1994).
Aneurysmal subarachnoid haem orrhage accounts for about 10% of all 
firs t strokes and is more common than prim ary in tracerebral haem orrhage in 
young adults (Kurtzke, 1985). Of all patients who arrive a t the clinic in 
rela tively  good condition a fte r subarachnoid haem orrhage, 28% will die within 
the  firs t 6 months and only 58% will have a favourable outcom e (Kassel e t 
al., 1990). In both subarachnoid haem orrhage and in tracerebral haemorrhage, 
secondary, delayed ischaemic brain damage is a crucial determ inant of 
eventual outcom e.
The CNS is extrem ely susceptible to  reductions in cerebral blood flow. 
The final ex ten t of neuronal damage and po tentia l for reversal by 
pharm acotherapy is re la ted  to the severity  of reduction of cerebral blood
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flow and the duration of the hypoperfusion. A threshold of 17ml/100g/min, 
or 35% of the basal level of cerebral blood flow, has been found in sustained 
ischaem ia (Jones e t  al., 1981). Thus, irrespective of w hether the prim ary 
cause is an occlusive or haemorrhagic stroke, the  u ltim ate  consequences of 
a severe and sustained reduction in cerebral blood flow are the sam e - 
irreversible damage to  neurones followed by infarction involving all cellular 
elem ents, and the  production of a ttendan t neurological dysfunctions.
Ischaemic damage is also a fea tu re  of head injury and brain traum a. 
It has been shown th a t in more than 85% of fa ta lities  resulting from severe 
head injuries ischaemic brain damage was found a t postm ortem  (Graham e t 
al., 1978). Furtherm ore, 40% of these patien ts had spoken a t some tim e 
a fte r the  initial injury on admission to the clinic, which is indicative of 
delayed secondary brain damage. In addition, clinical studies show th a t the 
disability found in many survivors of head injuries are a consequence of 
delayed ischaemic damage (Bullock & Teasdale, 1990). These findings suggest 
th a t these patien ts may benefit from a neuroprotective agent which reduces 
or prevents the causes of secondary brain d am ag e .'  The im pact of brain 
traum a in society is reflec ted  in th a t it is the  leading cause of death under 
the age of 45 in the  W estern world, and is the leading cause of prem ature 
m ale m ortality , predominantly as a resu lt of ischaem ic brain damage incurred 
a fte r severe head injury (Rockett & Smith, 1987).
1.2 C erebral Ischaemia in Man and Therapeutic Approaches
A number of premorbid factors presaging stroke have been identified. 
These include the  individually less well established facto rs such as smoking, 
alcohol consumption, blood cholesterol level, and obesity, all of which are 
re la ted  to  the  developm ent of the m ost im portant predisposing factors -
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atherom a and hypertension (Malmgren e t  al., 1989). O ther major contributing 
factors are heart disease, diabetes m ellitus, and transien t ischaemic a ttacks 
(TIAs) (Malmgren e t al., 1989). Thus, increasing a tten tion  is being paid to 
the identification of patien ts a t risk of stroke, so th a t appropriate 
p reventative measures, such as the  early  recognition and trea tm en t of 
hypertension, can be instituted.
Although there  has been an increasing awareness of the need to 
elim inate factors which predispose an individual to  stroke, there  is a t present 
no effec tive  neuroprotective agent for use in the  clinic to  am eliorate the 
consequences of an ischaemic stroke. Stroke therapy can be d irected a t a 
wide range of pathophysiological mechanisms, and there  are currently  a 
number of compounds in clinical trials and the ir results are eagerly awaited 
(Lipton & Rosenberg, 1994).
The dihydropyridine voltage-sensitive channel antagonist nimodipine, 
which putatively improves the level of cerebral blood flow to ischaem ic tissue 
(Mohamed e t  al., 1985), is of clear benefit to  subarachnoid patients who are 
a t high risk of delayed ischaemic brain damage due to vasospasm and reduced 
cerebral blood flow (Pickard e t al., 1989). Initial small clinical trials 
suggested no clear benefit in ischaemic stroke with nimodipine (Gelmers e t 
al., 1988). However, in a m ulti-cen tre  stroke tria l nimodipine showed 
im provem ent in a subgroup of patients trea ted  within 12 to  18 hrs a fte r the 
insult (The American Nimodipine Study Group, 1992).
Several com petitive and non-com petitive NMDA recep to r antagonists, 
which m arkedly reduce ischaemic lesion size in animal models of stroke (see 
McCulloch e t al., 1991 for review) are now in clinical trial. 
Dextrom ethorphan and m em antine are non-com petitive NMDA antagonists 
which can be given orally and have a to lerable side e ffe c t profile (Albers e t
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al., 1991; Chen e t  al., 1992b). Felbam ate, a new anti-convulsant, is a glycine 
s ite  antagonist with neuroprotective properties (McCabe e t al., 1993). The 
long-term  safety  of felbam ate appears to  be acceptable, and the  beneficial 
e ffec ts  are obtained a t w ell-to lerated  doses (White e t  al., 1992). In addition, 
CGS-19755 has recently  been shown to have to lerable neurological side 
e ffec ts  in acu te  stroke patien ts (Clarke & Coull, 1994). Thus, these agents, 
as well as o ther NMDA antagonists may o ffer both efficacy  and safety  for 
the  trea tm en t of stroke.
The ganglioside GM-1 is in clinical trials  as an anti-ischaem ic agent. 
In an Italian m ulti-centre  study, trea tm en t with GM-1 within 12h of the onset 
of stroke produced a significant improvement in the early  neurological scores, 
but by 4 months a fte r  the onset of stroke, a non-significant trend in favour 
of trea tm en t was only observed (Argentino e t  al., 1989). Studies are currently 
ongoing to see whether GM-1 m ight be effective in improving outcom e a fte r 
ischaemic stroke if given early in the course of ischaem ia and perhaps for a 
larger period (Cam arata e t al., 1994).
The 21-aminosteroids are potent antioxidants which reduce ischaemic 
damage in animal models of cerebral ischaemia w ithout glucocorticoid or 
m ineralocorticoid side effects  (Umemura e t al., 1994). T irilazad is currently 
undergoing Phase 3 (m ulti-centre study of efficacy) tria l in patients with 
stroke (Lipton & Rosenberg, 1994). Thus, lipid peroxidase inhibitors and free 
radical scavengers may offer a potential mechanism for neuroprotection in 
stroke.
There are enormous financial and research resources being devoted to 
anti-ischaem ic drug development. The im portance of cerebral ischaemic 
brain dam age in clinical p rac tice  has stim ulated the  developm ent of many 
animal models to produce experim entally an ischaem ic lesion resembling th a t
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seen in man, and thereby investigate the neuroprotective efficacy  of 
pharmacologic agents. Thus, given the in tim ate  relationship betw een /r-opioid 
system s and excitato ry  amino acid neurotransm ission in the  CNS, p a rt of this 
thesis is devoted to  evaluate system atically  the  anti-ischaem ic efficacy  of 
a novel and selective  /c-opioid agonist in experim ental models of focal 
cerebral ischaemia.
2. ANIMAL MODELS OF CEREBRAL ISCHAEMIA
2.1 General Features
In order to  system atically  investigate the  pathophysiology and 
pharm acotherapy of cerebral ischaemia, reproducible in vivo animal models 
have been developed. There are several advantages in using animal models 
of cerebral ischaemia. These include: 1) the  use of standardised animal 
strains with no pre-existing disease and uniform cerebrovascular anatomy; 
2) control over the severity  and duration of the ischaem ic episode; 3) d irect 
and instant access to  brain tissue for biochem ical and neuropathological 
analyses; 4) the  presence of cerebral vasculature for-the study of abnormal 
tissue perfusion, integral in the genesis of ischaem ic brain damage, and a 
fea tu re  lacking in in vitro  models such as brain slices or neuronal/glial cell 
cultures.
A diversity of animal species, ranging in size  from  small rodents to 
large subhuman prim ates have been used in experim ental models of cerebral 
ischaemia (Ginsberg & Busto, 1989; Hossmann, 1991). However rodent 
models, particu larly  the  ra t, are now used m ost extensively for a number of 
pertinen t reasons. These include the close resem blance of the 
cerebrovascular anatom y to th a t of higher species (Yamori e t  al., 1976), the 
detailed inform ation available concerning the  anatom ical localisation of
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neurotransm itter system s, their neurochem istry and neuropharmacology, the 
developm ent of a range of quantita tive  autoradiographic techniques to study 
various dynamic aspects of cerebrovascular function in the  ra t  (e.g. cerebral 
glucose utilisation and cerebral blood flow), and the  g rea te r acceptability  in 
using small, low cost animals when com pared to , for example, subhuman 
prim ates, from both ecologic and eth ical perspectives. However higher 
species, m ost notably the ca t, will always have an essential contribution to 
m ake in the  developm ent of anti-ischaem ic drugs as large animal models of 
ischaem ia for a number of reasons which will be discussed la te r (Section 2.3).
Animal models of cerebral ischaem ia can be broadly classified into two 
groups: 1) global or forebrain ischaemia, where th e re  is a transien t reduction 
or cessation of to ta l cerebral blood flow, and 2) focal ischaem ia, where blood 
flow to localised brain areas is compromised.
2.2 Global C erebral Ischaemia
Models of global ischaemia produce severe reductions in to ta l cerebral 
blood flow which a ffec t widespread areas of the CNS. The ischaemia is 
transien t (5-30 min) and followed by often  prolonged periods of reperfusion 
(1-7 days). This results in a p a tte rn  of diffuse neuronal necrosis within 
selectively  vulnerable areas of the  brain, e.g. CA1 region of the  hippocampus, 
neocortex and stria tum . The delayed appearance of morphological evidence 
of irreversible cell death in the hippocampus in models of global ischaemia 
has raised fundam ental questions with regard to  its relevance to  human 
stroke. Indeed, delayed cell death has been reported  in the  human 
hippocampus a f te r  cardiac a rre st (Petito  e t  al., 1987), thereby suggesting 
th a t models of global ischaemia are m ost pertinen t to  card iac a rrest in man.
There are several methods for inducing global cerebral ischaemia in
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large animal models (Hossmann, 1991) and alm ost all are associated with 
considerable interanim al variability in outcom e a f te r  a sim ilar ischaemic 
insult. The species m ost commonly used in models of transien t global 
ischaemia are the Mongolian gerbil (Meriones unguiculatus) and the ra t.
Anatom ically the gerbil is unique in th a t it  has an incom plete circ le  of 
Willis (Levy & Brierley, 1974). Thus global ischaem ia can be induced in the 
gerbil by tem porary unilateral or b ila teral common carotid  a rte ry  occlusion 
(Clifton e t  al., 1989). This results in selective neuronal necrosis in pyramidal 
cells of the hippocampal CA1-CA2 subfield. The technical ease of inducing 
ischaemia in the gerbil is far outweighed by its lim itations and on these 
grounds this model of global ischaemia has been the  subject of severe 
criticism . Hippocampal neurones undergo delayed neurodegeneration (Kirino, 
1982) and gerbils are highly susceptible to  seizures and hypothermia. As 
such, it has been proposed th a t drugs which are neuroprotective in this model 
may ac t via hypotherm ic or anti-convulsant actions, and not by the ir 
recognised pharmacological mechanism (Buchan & Pulsinelli, 1990). 
Moreover, gerbils are so small (50-80g) th a t physiologic-monitoring procedures 
routinely possible in the ra t  become technically  d ifficu lt (e.g. vessel 
cannulation) or physiologically destabilising (e.g. repeated  blood sampling as 
is required for autoradiographic tra c e r  studies). Therefore crucial 
physiological variables often go unmonitored in gerbil global ischaemia 
studies, and consequently this model is of lim ited value in evaluating anti- 
ischaem ic drug efficacy.
Two models of global cerebral ischaemia predom inate in the  ra t, the 
tw o-vessel and four-vessel occlusion models of transien t, forebrain ischaemia. 
In the tw o-vessel model, originally described by Eklof and Siesjo in 1972, 
high-grade forebrain ischaemia is produced by ligation of both common
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carotid  arte ries  e ither perm anently, or m ore usually, transiently  for periods 
of 10-60 min. In addition, this is usually combined w ith system ic hypotension 
induced by controlled a rteria l haem orrhage (K&gstrom e t  al., 1983) which is 
required to reduce cerebral blood flow sufficiently  in order to obtain 
reproducible ischaem ic brain damage (Smith e t  al., 1984). The four-vessel 
occlusion model involves perm anent b ila tera l occlusion of the vertebral 
a rteries  by electrocoagulation (under anaesthesia) followed by, usually 24 
hours la te r, transien t b ilateral occlusion of the  caro tid  a rte ries  which can be 
perform ed in conscious, freely moving ra ts  (Pulsinelli & Brierley, 1979).
The two- and four-vessel models of transien t, global ischaem ia give rise 
to ischaem ic cell change within selectively vulnerable areas of the  brain, 
including the  CA1 pyramidal neurones of the  hippocampus, neocortex and 
stria tum  (Pulsinelli e t  al., 1982; Smith e t al., 1984). There are reports, 
however, of inconsistent patterns of ischaemic dam age produced between 
laboratories in both models (see Ginsberg & Busto, 1989 for review). This 
variability in outcom e has been a ttribu ted  to variations in the co lla teral blood 
supply both betw een and within strains of ra t, and a failure to  m aintain brain 
tem perature  following the induction of ischaemia (Ginsberg & Busto, 1989), 
as m oderate reductions in brain tem perature  (2°C) have been shown to 
a tten u ate  neuronal necrosis in these animal models of ischaem ia (Busto 
e t  al., 1987).
2.3 Focal C erebral Ischaemia
The m iddle cerebral a rte ry  (MCA) is reported  to  be the  vessel most 
commonly a ffec ted  in stroke syndromes (Karpiak e t  al., 1989), and thus 
animal models of focal ischaemia are believed to  be the  m ost pertinen t in 
relation to  human stroke. The m ost widely employed models of focal
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cerebral ischaemia employ a perm anent or tem porary occlusion of a major 
in tracerebral artery , normally the  MCA. This produces localised pannecrosis 
or infarction of the te rrito ry  supplied by the  a rtery , i.e. the  neocortex and 
striatum , with the final lesion size fully established a f te r  approxim ately 3 
hours of ischaem ia (Jones e t  al., 1981; Kaplan e t  al., 1991). Although models 
of MCA occlusion were developed originally in large animals such as cats  
(O’Brien & Waltz, 1973), dogs (Suzuki e t  al., 1980) and prim ates (Hudgins 
& G arcia, 1970), r a t  models of MCA occlusion have em erged as the most 
extensively used in studies of the pathophysiology and drug e ffec ts  in cerebral 
ischaemia.
The original description of MCA occlusion in the r a t  described a distal 
occlusion of the MCA by ligation via a large frontoparietal craniectom y 
(Robinson e t  al., 1975). This resulted  in a relatively  small and highly variable 
lesion size which was res tric ted  to  the cerebral cortex. Subsequent 
refinem ents in surgical procedure include a subtem poral approach to  the 
MCA (Tamura e t al., 1981a), leaving the zygom atic arch in tac t (Shigeno e t 
al., 1985a), thereby allowing g rea ter access to  the-orig in  of the  MCA. 
Indeed this subtem poral approach with diatherm y occlusion has emerged as 
the  standard model of perm anent proximal MCA occlusion in the  ra t, where 
the  MCA is occluded with microbipolar coagulation from its origin to  the 
point where it crosses the inferior cerebral vein, and severed proximal to  the 
len ticu lostria te  a rteries. Subsequent variations in this ra t  model include: 
a m ore distal occlusion to  re s tr ic t infarction to  the  cortex  (Shigeno e t al., 
1985a), tandem  occlusion of the  MCA and ipsilateral common caro tid  artery  
(Brint e t  al., 1988) to  improve reproducibility of infarction, and a lternative  
m ethods of MCA occlusion using microclips, hooks, ligature snares or the 
abluminal application of endothelin-1 which allow reversal of th e  occlusion
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(Dietrich e t  al., 1989; Kaplan e t  al., 1991; Shigeno e t  al., 1985b; M acrae e t 
al., 1993).
Although ra t  models of focal cerebral ischaem ia are  predom inantly used 
in preference to  models in higher species (Section 2.1), large animal models, 
in particu lar the  c a t as used in this thesis, are  integral to  the  development 
of any anti-ischaem ic drug. Gyrencephalic species m ust be examined as the 
u ltim ate  ta rg e t is a gyrencephalic species (man) ra th e r than a lissencephalic 
species (such as the  ra t). Like man, the  c a t has a gyrencephalic brain. 
There has long been concern th a t the absence of sulci in rodents exaggerates 
the im portance of the  wave of spreading depression in itia ted  a t the onset of 
ischaemia. It has been argued th a t a neuroprotective drug may simply block 
this e lec trica l depolarisation and thereby reduces ischaem ic damage (Gill e t 
al., 1992a; Iijima e t al., 1992). Thus, as a resu lt of the general sim ilarity in 
the cortical a rch itec tu re  of the ca t and man, any such indirect mechanism 
(i.e. a ttenuating  spreading depression) can be discounted as having a 
disproportionate im pact on the  conclusions of a study.
The c a t also has g rea ter stability  than the  r a t  under anaesthesia. In 
studies with acute neuropathology as an endpoint, a t  least 3 hours must 
elapse from the induction of ischaemia for the  charac te ris tic  histological 
features of irreversible brain damage to  m ature  (Kaplan e t  al., 1991). During 
this period, cardiovascular and respiratory  stab ility  m ust be m aintained 
despite repe titive  sampling of blood for blood gas analysis and determ ination 
of plasma drug concentration e tc ., and despite  trachea l and bronchial 
secretions. The degree of cardiovascular and resp ira to ry  stab ility  which can 
be achieved in the  anaesthetised ca t over several hours is considerably g rea ter 
than in even the best, well controlled anaesthetised  ra t. This contributes, 
therefore, to  the certa in ty  placed on c a t (and o ther large animals) studies
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with regard to the  neuroprotective e ffec ts  of a drug.
The physical size of the c a t brain also underpins the  certa in ty  of 
conclusions derived in investigations of the  anti-ischaem ic efficacy  of a drug. 
All in tracranial interventions produce traum a a t the  surgical s ite  which in 
turn produces local tissue damage and m ore widespread disturbances of 
vascular reactiv ity . Such surgical traum a has a quite d ifferen t pharmacology 
to ischaem ic pathology. In the ca t, surgical traum a constitu tes a small 
fraction  of the  to ta l ischaem ic lesion, w hereas in the  ra t, it  may comprise 
up to  15-20% of the  to ta l lesion. Furtherm ore, the  crucial ischaemic 
penumbra and potentially  salvageable areas are  approxim ately 25mm from the 
surgical s ite  in the ca t whereas they are only about 4mm distan t in the  ra t. 
The absolute amount of the ischaem ic lesion which is potentially  salvageable 
with neuroprotective drugs is considerably g rea te r in ca ts  than in ra ts . Not 
only does this elim inate concern of m easurem ent erro r or bias from studies 
in ca t, but the use of the c a t also fac ilita tes  the  analysis of drugs which may 
have small neuroprotective effects, but which are intrinsically safer.
The nature of the  focal lesion a fte r  occlusion of-the MCA is such th a t 
it lends itse lf to  volum etric assessm ent (Osborne e t al., 1987) which is much 
more reliable than assessing the  area of ischaem ic dam age in a few coronal 
planes (see Mohamed e t al., 1985; Park e t al., 1988b as examples of how non­
volume tr ie  assessm ent could give rise to  false negative drug e ffec ts  or gross 
overestim ation of efficacy  depending on the  coronal plane studied.) Models 
of focal cerebral ischaemia, particularly  in th e  ra t  and the  ca t, are  becoming 
increasingly dominant in anti-ischaem ic drug developm ent, not just because 
of the ir relevance to  human stroke but also partly  because of the  absolute 
consistency of data  which has em erged on the  anti-ischaem ic efficacy  of the 
NMDA antagonists (see McCulloch, 1992; Meldrum, 1990 for reviews).
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2.4 Sources of V ariability
The m ajor difficulty  encountered when using animal models of cerebral 
ischaem ia in studies of neuroprotective drugs is controlling the level of 
variability in outcome. A number of d ifferen t param eters, if not rigorously 
controlled, can confound the  validity of the  model and eventual outcom e by 
exacerbating variability. These include:
Temperature
Hypothermia, of even 2°C, has been shown to  a tten u a te  ischaemic 
neuronal necrosis in models of global ischaem ia (Busto e t  al., 1987). In focal 
ischaemia, mild brain hypothermia (4°C) reduces the  volume of infarction (by 
48%) following transien t but not perm anent MCA occlusion (Ridenour e t  al., 
1992). Tem perature should therefore  be closely m onitored and m aintained, 
particularly  in brain tissue which has been surgically exposed, and in the 
whole animal during early recovery from anaesthesia.
Plasma Glucose Concentrations
Hyperglycaemia is known to increase ischaem ic brain dam age in models 
of global and focal cerebral ischaemia (Marie & Bralet, 1991). Three-fold 
increases in plasma glucose increase lesion size by up to  25% a fte r  perm anent 
MCA occlusion in the  ra t  (Duverger & MacKenzie, 1988). Thus, monitoring 
of plasma glucose levels and if necessary overnight fasting of animals should 
be built into the  study design.
Physiological Variables
Blood pressure and respiratory blood gas sta tu s  (pC 02, p02 and pH) 
outwith th e  normal limits of autoregulation will influence global cerebral
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blood flow, and hence have a major im pact on the degree of ischaem ic brain 
injury. For example, transien t hypotension (reduced to  60mmHg) in the  post- 
ischaem ic period has been shown to increase the volume of infarction by m ore 
than 50% in a r a t  model of focal ischaem ia (Osborne e t  al.,1987). These 
param eters should therefore  be closely m onitored, particularly  in 
anaesthetised animals where depth of anaesthesia and artific ia l respiratory  
ra te  represent fu rther sources of variability.
General anaesthesia is a common fea tu re  in animal models of cerebral 
ischaemia, m ost notably those of focal ischaemia where full monitoring of 
physiological variables is perform ed throughout the  post-ischaem ic period. 
Anaesthesia can modify cerebrovascular reactiv ity  and the  demands for 
substrate  (oxygen and glucose) in d iscrete  regions of the  CNS. Therefore, 
anaesthesia may have an e ffe c t on the  degree of ischaem ic damage, thereby 
introducing variability  to  the experim ental model. Moreover, the possible 
in teraction betw een any anaesthetic  and the anti-ischaem ic drug under 
investigation (synergistic or antagonistic) in re la tion  to observed 
neuroprotection is always of concern (Ginsberg & Busto, 1989; Meldrum,
1990).
Surgical reproducibility is another potential source of variability in 
outcom e in animal models of ischaemia. In the perm anent MCA occlusion 
model in the ra t, the  incidence and ex ten t of focal ischaem ic infarction is 
dependent on both the  location and the ex ten t of the  diatherm y lesion to  the 
MCA (Bederson e t  al., 1986). In addition the  stra in  of r a t  used appears to 
be an im portant fac to r. Following proximal, perm anent MCA occlusion in 
5 d ifferen t strains of ra t, Duverger and MacKenzie (1988) dem onstrated 
considerable variation between strains in the  resu ltan t volume of ischaem ic 
damage assessed 48 hours a fte r the induction of ischaem ia, despite using
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identical surgical techniques and anaesthetic  conditions.
Inter-anim al variability in outcom e, within acceptable lim its, is a 
common fea tu re  of many models of cerebral ischaem ia. A ttem pts to  reduce 
th e  variability by increasing the  severity  of the  insult e.g. lengthening the 
duration of global ischaemia, combining MCA occlusion with genetic 
hypertension and/or carotid  occlusion m ust be approached with extrem e 
caution. Whilst this achieves the objective of producing a m ore reproducible 
lesion, it  may too gross and thus less susceptible to pharmacological 
intervention.
3. PATHOPHYSIOLOGY OF ISCHAEMIC BRAIN DAMAGE
3.1 Energy Depletion and Acidosis
The energy requirem ents of cerebral tissue are derived almost 
exclusively, from the  aerobic catabolism  of glucose (Sokoloff, 1977). The 
induction of cerebral ischaemia compromises the  supply of oxygen and glucose 
to  the brain, and an im balance betw een glycolysis and oxidative 
phosphorylation results in the accum ulation of la c ta te  and H+, inducing tissue 
acidosis (Siesjo, 1992a). The accum ulation of la c ta te  and H+ results in severe 
tissue acidosis a f te r  both global and focal ischaem ia (Chopp e t al., 1988; 
Wagner e t  al., 1992b).
The severity  of lactic  acidosis is dependent upon the availability of 
glucose and the  ex ten t of ATP depletion (Siesjo, 1992a). If glucose is 
available, as it is via co lla teral blood supply and residual flow in the 
ischaem ic penumbra a fte r  MCA occlusion, the  amount of la c ta te  accum ulated 
is determ ined by the  degree of energy failure, and not by plasma glucose 
concentration (Gardiner e t al., 1982). Moreover, as ATP levels are  only 
m arginally reduced in perifocal areas a fte r  MCA occlusion (Folbergrov& e t
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al., 1992), hyperglycaemia is unlikely to enhance the  severity  of acidosis 
(Siesjo, 1992a). This is consistent with observations where hyperglycaemia 
has no e ffe c t on in farc t size following perm anent MCA occlusion (Nedergaard 
& Diemer, 1987) although there  is controversy (Marie & Bralet, 1991). In 
contrast, following global and transien t severe forebrain ischaemia, where 
cerebral blood flow and ATP levels are m arkedly reduced (Pulsinelli & Duffy, 
1983), pre-ischaem ic hyperglycaemia increases the  degree of acidosis during 
ischaemia (Siesjo, 1992a) and the  ex ten t of brain injury (Marie & Bralet,
1991).
Energy failure and acidosis during ischaem ia may cause damage to cells 
by a number of d ifferen t mechanisms. These include the fu rther inhibition 
of lac ta te  oxidation, inhibition of H+ extrusion, denaturation or inactivation 
of enzymes and other proteins, and the disruption of m itochondrial respiration 
and the associated promotion of free radical form ation through the release 
of Fe2+ (Siesjo, 1988a; 1992b). In addition, the  m aintenance of the cell 
m em brane potential (approximately -75mV) and of the non-equilibrium 
distributions of Na+, K+. Ca2+ and H+ require energy-in the form of ATP. 
Interruption of the ATP supply during an ischaem ic insult has thus two further 
consequences. F irst, ionic gradients for Na+, K+ and C a2+ are dissipated and 
the  m em brane potential is reduced towards zero (Hansen, 1985). Second, the 
energy deprived cell takes up Na+ and, when th e  m em brane potential is 
sufficiently  reduced, Cl”. The in tracellu lar accum ulation of Na+ and Cl" 
results in the  influx of w ater into the cell via th e  osm otic gradient, leading 
to  the  form ation of cytotoxic oedema (Yang e t  al., 1992). The reduction in 
ATP levels will also cause the inhibition (and even reversal) of the energy- 
dependent membrane-bound uptake carrie r mechanism s for glu tam ate, thereby 
increasing the  concentration of this neurotoxic excita to ry  amino acid in the
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extracellu lar space (Nicholls & A ttw ell, 1990). Furtherm ore, as energy 
depletion a ffec ts  both the ATP-dependent extrusion of Ca2+ and its 
in tracellu lar sequestration, the loss of ionic homeostasis will cause a massive 
elevation in the  in tracellu lar concentration of C a2+ (Hansen, 1985; Siesjo & 
Bengtsson, 1989). A lterations in Ca2+ homoeostasis are  believed to be central 
in the genesis of irreversible brain damage a f te r  global and focal cerebral 
ischaemia.
3.2 Calcium
It is well established th a t Ca2+ has an im portant role in normal cell 
function. Ca2+ has been shown to  a c t as a m em brane stabiliser, m etabolic 
regulator, second messenger, to  m odulate neurite  extension and synapse 
form ation, and e lic it long-term  potentiation (see Siesjo, 1988b; Miller, 1991 
for reviews). In the normal resting s ta te , the  in tracellu lar concentration of 
C a2+ in neurones is around 10"7M and the ex tracellu lar concentration of Ca2+ 
is about 10"3M (Choi, 1988). It is essential for normal cell function th a t this 
ionic gradient is s tric tly  m aintained. The regulation o f Ca2+ homeostasis is 
m aintained by two major membrane-bound pump mechanisms: a 3Na+/C a2+ 
an tiporter driven by the Na+ gradient c rea ted  by a Na+/K +-ATPase and a 
C a2+-dependent ATPase (Siesjo & Bengtsson, 1989). Thus, any mechanism 
which disturbs the  normal Ca2+ homeostasis may produce an increase in 
in tracellu lar Ca2+ levels and lead to cell death.
The in tracellu lar levels of C a2+ can be e levated  by the  influx of Ca2+ 
through voltage-sensitive C a2+ channels (VSCCs) and neurotransm itter 
recep to r ionophores (e.g. the  NMDA receptor), as well as by the  mobilisation 
of in tracellu lar stores. A t present, 4 types of VSCCs have been identified 
on neurones, d ifferen tia ted  on the basis of voltage dependency and ra tes  of
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inactivation : the  L-, N-, T and P-types (See Spedding & P ao le tti, 1992 for 
review). All 4 types of VSCC have been found postsynaptically, although 
only the N-type have been located on presynaptic nerve term inals, where they 
putatively control Ca2+-dependent g lu tam ate  re lease (Spedding & P aoletti, 
1992).
During ischaemia, there  is a loss of normal Ca2+ homeostasis. The 
depletion of ATP leads to the depolarisation of cell m embranes and the influx 
of Ca2+ through VSCCs, and the loss of active  sequestration of Ca2+ into 
in tracellu lar organelles (Siesjo, 1981). Both elem ents contribute to  an 
excessive rise in the intracellular concentration of Ca2+ which activates a 
cascade of Ca2+-dependent biochemical process and leads to neuronal death; 
the  firs t hypothesis to im plicate the involvement of C a2+ in the  genesis of 
ischaem ic brain damage (Siesjo, 1981). The involvement of C a2+ is supported 
by recen t experim ental evidence which describe elevations in the  levels of 
cytosolic free  C a2+ a fte r  the induction of ischaem ia (Benveniste e t  al., 1988; 
Uematsu e t  al., 1989). Although this hypothesis of neuronal necrosis is still 
viable, it  now seems more likely th a t a pathogenically- im portant p a rt of the 
Ca2+ influx occurs via glutam ate-operated calcium  channels, m ost notably the 
NMDA recep to r ionophore (Choi, 1988; Rothman & Olney, 1986; see section
3.3).
Evidence is available, however, to  suggest Ca2+ is not the  principal 
m ediator of all ischaemic cell death. In certa in  models of hypoxic-ischaemic 
injury in non-neuronal cells, there does not appear to  be a correlation  between 
cell viability and Ca2+ content (Cheung e t  al.,1986); convincingly, a rise in 
cytosolic free  Ca2+ does not precede injury in hepatocytes exposed to 
chem ical hypoxia (Lemasters e t al., 1987). In addition, in neuronal cell 
culture, where anoxia was induced by exposure to  sodium cyanide, no cell
37
damage was observed despite massive elevations in in tracellu lar Ca2+ 
concentration (Dubinsky & Rothman, 1991).
There are several observations with regard  to  hypoxic-ischaemic injury 
which support a prim ary etiological role of massive increases in the 
in tracellu lar concentration of Ca2+. Hypoxia in the cerebral cortex  is 
accompanied by a dram atic  decline in ex tracellu lar Ca2+ concentrations to 
about 10% of control levels (Nicholson e t  al., 1977); early  events in neuronal 
hypoxia, including tran sm itte r release and liberation of free  fa tty  acids 
suggest a rise in in tracellu lar Ca2+ (Siesjo, 1988b). Ca2+ accum ulation in 
hypoxic brain is correla ted  a t the regional (Dienel, 1984) and cellular (Simon 
e t al., 1984) levels with vulnerability to hypoxic injury, and in fac t may occur 
before neurones appear necrotic  under light m icroscopy (Siesjo, 1988b). In 
addition, voltage-dependent Ca2+-channel antagonists have dem onstrated anti- 
ischaem ic efficacy in some animal models of cerebral ischaemia, although 
there  is controversy (see Hossmann, 1988; Wong & Haley, 1990 for reviews).
There are probably a myriad of reasons why sustained elevations in 
cytosolic C a2+ a fte r  ischaemia are neurotoxic, reflec ting  sum m ated gross 
disturbances in the many biological processes regulated by Ca2+ availability. 
Ca2+ can impair m itochondrial function by uncoupling oxidative 
phosphorylation which results in cell dysfunction and death  (Siesjo, 1988b). 
In addition, excess in tracellu lar Ca2+ triggers the  activation of a cascade of 
specific enzym atic pathways which can be detrim ental to  cellular function 
and neuronal in tegrity  (Siesjo & Bengtsson, 1989; Siesjo, 1992a).
A good example of such a mechanism is C a2+-ac tiv a ted  proteolysis. The 
continuous stim ulation of Ca2+-activated  neural proteases (calpains) during 
ischaemia can resu lt in the abnormal degradation of cytoskeletal proteins, 
neurofilam ent proteins, membrane proteins and receptors, and several
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enzymes (Melloni & Pontrem oli, 1989). The involvement of calpains in 
ischaem ic damage is fu rther dem onstrated as a calpain inhibitor has recently  
been shown to be neuroprotective a fte r  MCA occlusion in the ra t (Hong e t 
al., 1994). C a2+ can also ac tiva te  phospholipases - phospholipase A2 and 
phospholipase C, which hydrolyse phospholipids giving rise to  free  fa tty  acid, 
lysophospholipid, and diacylglyceride accum ulation within the cell. 
Lysophospholipids and free  fa tty  acids, particu larly  the  unsaturated ones are 
reported to a ffec t m em brane function by acting as m em brane detergents and 
ionophores (Wieloch & Siesjo, 1982). Furtherm ore, Ca2+ can bind to  the 
regulatory protein calmodulin, and thereby d irectly  ac tiv a te  protein kinases 
and phosphates, resulting in further degradation of the  cell s truc tu re  (Connor 
e t al., 1988; Manev e t al., 1989). Thus, irrespective of the enzyme involved, 
sustained activation by an elevation in in tracellu lar C a2+ clearly  compromises 
neuronal survival as a resu lt of a lterations in the function of receptors, ion 
channels, and m em brane structures.
The Ca2+ hypothesis of ischaemic neuronal injury has acquired additional 
support from the  recen t establishm ent of relationships both betw een 
ischaem ic neuronal damage and glutam ate neurotoxicity, and betw een 
g lu tam ate  neurotoxicity and Ca2+-m ediated injury mechanisms (see section
3.3).
3.3 G lu tam ate and E xcitotoxicity
It is now generally accepted th a t the dicarboxylic amino acids 
L-glutamate and L-aspartate are the m ajor excitato ry  neurotransm itters ,in 
the  m ammalian CNS (Monaghan e t  al., 1989). E xcitatory  amino acid (EAA) 
receptors are the  main tran sm itte r receptors m ediating synaptic excitation 
in the CNS, and as such they are involved in many physiological phenomena
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ranging from the  processing of sensory inform ation and co-ordinated 
movem ent pa tterns to cognitive processes, learning and memory (Collingridge 
& Lester, 1989; Monaghan e t  al., 1989; Watkins & Evans, 1981). However, 
although activation of EAA receptors is integral to  the normal functioning 
of neurones, it is paradoxical th a t under conditions of excessive EAA recep tor 
stim ulation, g lu tam ate can be neurotoxic.
The fundam ental observation th a t EAAs are potentially  neurotoxic was 
made over 30 years ago by Lucas & Newhouse (1957) who found th a t prolonged 
exposure to  high concentrations of g lu tam ate  given to  m ice system ically, 
induced degeneration of re tinal neurones. This neurotoxicity was confirmed 
when it was determ ined th a t glu tam ate and re la ted  EAAs induce degeneration 
in areas of the  brain not p ro tec ted  by the blood-brain barrier, notably the 
arcuate  nucleus in the hypothalamus (Olney, 1969; Olney e t  al., 1971; Olney, 
1978). The strong correlation betw een neurotoxic potency and excitatory  
potency of a series of g lutam ate analogues suggested a convergence in the 
mechanisms underlying the two actions. Thus the excito toxic hypothesis was 
form ulated on the basis th a t overactivation of EAA recep tors was responsible 
for glutam ate-induced neuronal death  (Olney, 1978). Moreover, the 
ch arac te ris tic  "axon-sparing" nature of the  excitotoxic lesions was rem iniscent 
of brain damage found in certain  human degenerative disorders (e.g. status 
epilepticus), a sim ilarity which prom pted suggestions th a t excitotoxic 
mechanisms underlie neurodegenerative disease in man (Olney, 1978; 1985).
The actions of g lutam ate and re la ted  EAAs are m ediated by five distinct 
recep to r subtypes, each with charac te ris tic  pharm acological and physiological 
properties (Watkins e t al., 1990). The EAA subtypes a re  : N-methyl-D- 
asp arta te  (NMDA), 2-am ino-3-hydroxy-5-m ethylisoxazole-4-propionic acid 
(AMPA), kainate, m etabotropic and L-2-amino-4-phosphonobutyrate (l-AP4)
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(Collingridge & Lester, 1989; Monaghan e t  al., 1989; Watkins e t al.,1990) 
(Figure 1). The NMDA, kainate and AMPA recep tor subtypes are all 
associated with recep to r operated ion channels, whilst the m etabotropic 
subtype is thought to be linked to phosphoinositide m etabolism  as a second 
m essenger system  (Schoepp e t  al., 1990). The L-AP4 recep to r subtype signal 
transduction mechanism is not fully understood, although th e re  is evidence 
to suggest th a t it may involve cGMP hydrolysis and function as a presynaptic 
g lu tam ate au toreceptor decreasing tran sm itte r re lease (Gasic & Hollmann, 
1992).
The non-NMDA, AMPA and kainate receptors, which are  perm eable to 
Na+ and K+, are responsible for fast excita to ry  synaptic transmission 
throughout the CNS and appear to fulfil a basic signalling function a t 
excitato ry  synapses (Mayer & Westbrook, 1987). Under normal conditions, 
the NMDA recep to r ionophore which is perm eable to  Na+, K+ and Ca2+ does 
not contribute to  synaptic transmission because of voltage-dependent 
blockade a t a s ite  within the  ion channel by Mg2+ (M acDerm ott & Dale, 1987). 
However, mem brane depolarisation relieves the Mg2+ block of the NMDA ion 
channel and Ca2+ is then able to  pass freely  through the  channel into the 
postsynaptic neurone (M acDerm ott & Dale, 1987). The activation of NMDA 
receptors is intim ately involved in a number of neurophysiological events such 
as long-term  potentiation (Collingridge & Bliss, 1987), neuronal burst firing 
(Herrling e t  al., 1983), the generation of pa tterned  firing in neuronal networks 
(Dale & Roberts, 1985) and in learning (Morris e t  al., 1986).
There are a number of d istinct sites within the  NMDA recep tor ion 
channel complex a t which the  e ffec ts  of g lu tam ate  can be modulated (Foster 
& Fagg, 1987). Conceptually, the  most simple s ite  a t which NMDA recep tor 
activ ity  can be m odulated is a t the  neuro transm itter recognition s ite  for
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FIGURE 1
D iagram m atic representation  of a g lutam atergic synapse. G lutam ate 
released from the presynaptic nerve term inal m ediates fast synaptic 
transmission via the  AM PA/Kainate recep tor subtypes which are 
perm eable to Na+ and K+. Subsequent membrane depolarisation removes 
the Mg2+ blockade of the  NMDA recep to r ionophore allowing Ca2+ influx 
into the  postsynaptic neuron. The in tracellu lar concentration of Ca2+ 
can also be increased by activation of the m etabotropic receptor which 
stim ulates the  mobilisation of Ca2+ from intracellular stores. 
O veractivation of postsynaptic g lu tam ate receptors can be prevented by 
a high affinity , Na+-dependent g lu tam ate uptake mechanism present on 
neurones and glia which removes glutam ate from the extracellu lar space 
or by the action of g lu tam ate a t the  presynaptic L-AP4 autoreceptor to 
inhibit further release. Agonists a t /c-opioid receptors also putatively 
a tten u ate  g lu tam ate  re lease presynaptically.
Abbreviations:
NMDA: N-m ethyl-D-aspartate
AMPA: 2-am ino-3-hydroxy-5-m ethylisoxazole-4-propionic acid
Metab: M etabotropic
L-AP4: L-2-amino-4-phosphonobutyrate.
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glu tam ate and NMDA. C om petitive inhibition a t this s ite  can be produced 
using the  antagonists cis-4-phosphonom ethyl-2-piperidine-carboxylic acid 
(CGS-19755) and D-3(2-carboxypiperazin-4-yl)propenyl-l-phosphonic acid 
(D-CPPene) (Aebischer e t al., 1989; Lehmann e t  al., 1988). N on-com petitive 
blockade of the  actions of g lu tam ate can be produced by agonists such as 
dizocilpine (MK-801) and the dissociative anaesthetic  phencyclidine (PCP), 
which in te rac t a t a s ite  within the ionophore in a use-dependent m anner 
(Kemp e t al., 1987). In addition, the divalent cations Mg2+ and Zn2+ can bind 
to  specific sites within the ion channel to  inhibit recep to r activ ity . Glycine 
acts  as a positive allosteric m odulator a t the strychnine-insensitive glycine 
s ite  on the  NMDA receptor. Antagonists such as 7-chlorokynurenate 
and l-687,414 a tten u a te  NMDA recep to r activ ity  by acting a t this s ite  (Kemp 
e t al., 1988; Singh e t  al., 1990a). Furtherm ore, ifenprodil and re la ted  
compounds ac t as antagonists a t another positive a llosteric  m odulatory s ite  - 
the  ’'polyamine s ite ”, to m odulate NMDA recep to r function (C arter e t  al., 
1989).
There are several lines of evidence from b o th 'in  vitro  and in vivo 
studies which support the concept of g lu tam ate excito toxicity  in the genesis 
of ischaem ic brain damage. F irst, e levated levels of glu tam ate are 
neurotoxic to  neurones in vitro  as a resu lt of the  lethal influx of Ca2+ 
produced by excessive activation of NMDA receptors (Choi, 1987), although 
non-NMDA receptors may also contribute (Koh e t  al., 1990); the 
accum ulation of Ca2+ induced by g lu tam ate is closely re la ted  to  the  ex ten t 
of neuronal death in vitro  (Hartley e t  al., 1993). Second, NMDA antagonists 
(Choi, 1990) and non-NMDA antagonists (Frandsen e t  al., 1989) are 
neuroprotective against g lu tam ate toxicity  in vitro. Third, there  is a massive 
increase in the ex tracellu lar levels of g lu tam ate a f te r  the  induction of global
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and focal cerebral ischaemia (Benveniste e t  al., 1984; Matsumoto e t  al.,
1992), which has been shown to be corre la ted  to  the degree of ischaemic 
brain damage (Butcher e t al., 1990; Takagi e t  al., 1993). Fourth, lesions of 
the  perforant pathway, as well as a number of o ther chem ical and surgical 
lesions, which reduce excitatory  input, reduces ischaemia-induced neuronal 
necrosis in the  hippocampus (Johansen e t  al., 1986; Kaplan e t  al., 1989; 
Onodera e t  al., 1986; Wieloch e t  al., 1985).
The m ost convincing evidence to  support the  view th a t g lutam ate is 
excitotoxic has been obtained from studies in experim ental models of cerebral 
ischaemia where antagonists a t the NMDA and non-NMDA (AMPA) recep tor 
subtypes have been shown to reduce the amount of ischaem ic brain damage 
by up to  50% (see sections 4.1 and 4.2). However, although the  blockade 
of excitatory  amino acid receptors, m ost notably the  NMDA recep to r subtype, 
a ttenuates the  transm em brane ionic fluxes which produce neuronal death, 
the ir clinical use in man may be lim ited. This is because in animals, a t 
therapeutic  doses, they produce m arked e ffec ts  on behaviour, CNS function 
and s truc tu re  (McCulloch & Iversen, 1991; W illetts' e t  al., 1990). An 
alternative  s tra tegy  to reduce glutam ate excito toxicity  is to  inhibit the 
release of g lu tam ate. Thus, in this thesis the  e ffe c t of the k-opioid agonist 
CI-977 which putatively reduces g lu tam ate re lease  was determ ined on 
glutam ate-m ediated neuronal damage in animal models of focal ischaemia.
3.4 Ischaemic Penum bra
The induction of focal ischaemia resu lts in a range of m oderately and 
severely reduced blood flow, although the  blood flow boundary between 
normal and damaged tissue can be quite d istinc t (Tamura e t  al., 1981b; Tyson 
e t  al., 1984). This gradient in cerebral blood flow is represen tative  of a
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spectrum  of ischaemia from minimal, through m oderate to  severe ischaemia.
Neuronal injury, and the potential for reversal is re la ted  to the  duration of 
ischaem ia and the  degree of reduction in cerebral blood flow. As cerebral 
blood flow is reduced during ischaemia, a progressive series of morphological, 
electrophysiological and biochem ical alterations occur, thereby indicating 
thresholds for key events in ischaemia.
The concept of an "ischaem ic penumbra" was based on studies in the 
lightly anaesthetised  baboon. The fundam ental observation described the 
loss of evoked e lec trica l activ ity  in the  cortex  a t a threshold blood flow or 
around 20ml lOOg”1 min”1, whilst the ex tracellu lar concentration of K+ was 
preserved (Branston e t  al., 1974). The efflux of K+ from  cells was not 
observed until the  level of cerebral blood flow fell to  a threshold value of 
about 10ml lOOg'1 m in '1 (Branston e t al., 1977). These observations were 
in terpreted  to indicate the loss of neuronal function before the  loss of ionic 
homeostasis which was taken as a sign of neuronal m em brane failure and 
hence irreversible neuronal death (Astrup e t al., 1977). Absolute functional 
thresholds were subsequently dem onstrated a fte r  MCA occlusion in prim ates 
where the  developing neurological defic it progressed from  mild paresis a t a 
blood flow of 22ml lOOg'1 m in '1 to  com plete paralysis a t 8ml lOOg'1 m in '1 
(Jones e t  al., 1981). The ischaem ic penumbra was thus defined to  describe 
cerebral tissue perfused a t a level betw een the  thresholds of functional 
im pairm ent and of morphological in tegrity  which has the  capacity  to  recover 
if cerebral blood flow is reverted  to  values above the  20ml lOOg'1 m in '1 
threshold (Astrup e t  al., 1981).
Threshold-type relationships have also been reported  in the ischaemic 
penumbra of the  lissencephalic brain in the  ra t. However, it  is im portant to 
recognise th a t these threshold values may be d ifferen t in a gyrencephalic
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species for a number of reasons. F irst, basal cerebral blood flow and 
cerebral glucose m etabolism  are approxim ately 2-3 fold g rea te r in the ra t 
compared to the prim ate (Jones e t  al., 1981; Kennedy e t  al., 1978). Second, 
the r a t  brain has a higher cellular packing density re la tive  to  the prim ate 
brain (Bass e t  al., 1971; Haug, 1987). Indeed, cell packing density has been 
invoked to  justify  a species ranking of cerebral blood flow thresholds causing 
ischaem ic brain damage (Strong e t al., 1983; Tam ura e t  al., 1981b).
Mies and co-workers (1991) observed th a t in the  penumbral region lh  
a fte r perm anent MCA occlusion in the ra t, protein synthesis is depressed a t 
a threshold of approxim ately 55ml lOOg"1 min"1 despite the preservation of 
energy s ta te  (threshold of 18ml lOOg”1 min-1). The inhibition of protein 
synthesis may be associated with progressive tissue injury because with 
increasing tim e the threshold of energy depletion gradually rises up to  32ml 
lOOg”1 min-1 a t 12h post-ischaem ia, suggesting an expansion of the in farct 
core into the penumbra zone (Mies e t  al., 1991).
Spreading depression-like depolarisations have been observed in the 
penumbra of focal ischaemia, although the ir role rem ains controversial (Gill 
e t  al., 1992a; Iijima e t  al., 1992). N edergaard and Hansen (1993) have 
d ifferen tia ted  betw een short lasting (spreading depressions) and longer lasting 
ischaem ic depolarisations a fte r perm anent MCA occlusion in the  ra t. They 
concluded th a t the  penumbral depolarisations are e ith e r typical spreading 
depression waves evoked by an increase in ex tracellu lar g lu tam ate  and/or K+ 
in the core of the  in farc t, or ischaemic depolarisations e lic ited  by fluctuations 
of blood flow around the  threshold of m em brane failure within the  perifocal 
tissue (Nedergaard & Hansen, 1993).
There is evidence to suggest th a t the  penumbra is only gradually 
recru ited  into irreversible ischaemic damage. The in farc t size has been
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shown to gradually increase as the middle cerebral a rte ry  is occluded for 
longer periods, until with an occlusion tim e of 180 min, the in fa rc t size has 
reached th a t found a fte r  perm anent MCA occlusion (Kaplan e t  al., 1991; 
Memezawa e t  al., 1992). However, although in farc t size is believed to be 
fully established a t 3-4h a fte r  perm anent focal ischaem ia in the  ra t, a 24h 
post-insult survival period is necessary to  allow suffic ien t developm ent of 
ischaemic brain swelling. Thus, the  ischaem ic penumbra is an im portant 
concept in anti-ischaem ic drug developm ent. F irst, the  penumbra can be 
defined as ischaem ic tissue th a t is a t risk of infarction but is potentially 
salvageable by pharm acotherapy. Second, the  apparent tim e-dependent 
recru itm ent of the penumbral tissue to  final infarction suggests a potential 
window of therapeu tic  opportunity for intervention with neuroprotective 
agents.
4. M OD U LA TIO N  O F G L U T A M A T E R G IC  M EC H A N ISM S AND 
NEUROPROTECTION
4.1 NMDA R eceptor Blockade
4.1.1 Focal Ischaemia
In experim ental models of focal cerebral ischaem ia th e re  is compelling 
evidence th a t antagonists of the NMDA recep to r subtype p ro tec t neurones 
from the e ffec ts  of cerebral ischaemia (see McCulloch e t  al., 1991 for 
review). It is now generally accepted th a t NMDA recep to r blockade reduces 
the amount of ischaem ic damage irrespective of the  species (mouse, ra t, 
rabbit, ca t, prim ate), the model of cerebral ischaem ia, the  tim e of sacrifice 
a fte r  the induction of ischaemia, w hether ischaem ia is perm anent or 
tem porary followed by a period of reperfusion, and irrespective of the 
particu lar s ite  within the  NMDA recep tor blockade a t which blockade is
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achieved.
There has been extensive investigation of the efficacy  of NMD A 
antagonists in ra t  models of focal cerebral ischaem ia. There is overwhelming 
evidence th a t non-com petitive NMDA antagonists (CNS1102, MK-801, PCP) 
reduce the volume of ischaemic damage a f te r  perm anent MCA occlusion in 
the  r a t  (Bielenberg & Beck, 1991; Dirnagl e t  al., 1990; Gill e t  al. 1991a, 
1992a; H atfield e t. al., 1992; Iijima e t al., 1992; M inematsu & Fisher, 1993; 
Minematsu e t  al., 1993; Park e t  al., 1988b; Roussel e t  al., 1992; Sauer e t  al.,
1993). In addition the weak, non-com petitive NMDA antagonist dextrorphan, 
the  active m etabolite  of dextrom ethorphan, also affords neuroprotection a fte r 
perm anent focal ischaemia in the  ra t  (Graham e t  al., 1993b). The anti- 
ischaem ic efficacy of these agents is m aintained when adm inistered up to  lh  
(Graham e t al., 1993b; H atfield e t al., 1992; Park e t  al., 1988b) and even 3h 
(Bielenberg & Beck, 1991) a fte r the induction of ischaem ia. There is an 
increasing body of evidence dem onstrating th a t com petitive NMDA 
antagonists (AP-7, CGP40116, CGS-19755, D-CPPene) are also beneficial in 
focal ischaem ia in the ra t (Park e t  al., 1992; Roman e fa l . ,  1989; Sauer e t al., 
1993; Simon & Shiraishi, 1990; Takizawa e t  al., 1991). Moreover, 
antagonists a t the glycine (7-chlorothiokynurenate, L-687,414) and 
polyamine (SL.82.0715) allosteric sites within the  NMDA recep to r complex 
confer neuroprotection a fte r  perm anent MCA occlusion in the  ra t  (Chen e t 
al., 1993; Gill e t  al., 1991b; G otti e t  al., 1988). The volume of tissue which 
can be salvaged from irreversible ischaemic damage with NMDA antagonists 
is approxim ately 50% of the infarction volume. The maximum anti-ischaem ic 
e ffec ts  of the  drugs are broadly sim ilar irrespective of th e ir precise s ite  of 
action within the NMDA recep tor complex. Interestingly, a recen t study has 
shown th a t inhibition of NMDA-R1 recep tor protein  synthesis by
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phosphodiester antisense oligodeoxynuycleotides resu lts in the inhibition of 
NMDA recep tor expression and a reduction in volume of ischaem ic brain 
damage by over 40% following focal cerebral ischaem ia in the ra t  (W ahlestedt 
e t  al., 1993).
An interesting fea tu re  of the  neuroprotective efficacy  of NMDA 
antagonists is th a t the  magnitude of the  response to  MK-801 and kynurenate 
is markedly a ttenuated  a fte r perm anent MCA occlusion in spontaneously 
hypertensive (SHR) ra ts , where there  is a reduced co lla teral blood supply 
(Dirnagl e t al., 1990; Roussel e t al., 1990, 1992). A possible explanation is 
th a t the ischaemic insult is more severe in hypertensive animals when 
compared to the  normotensive stra in  and thus less amenable to 
pharm acotherapy (Roussel e t al., 1992).
The most convincing dem onstrations of the anti-ischaem ic efficacy of 
NMDA antagonists have emerged from investigations of the ir e ffec ts  a fte r 
perm anent MCA occlusion in the cat. P re trea tm en t w ith a non-com petitive 
antagonist (MK-801) or a com petitive antagonist (D-CPPene), and 
adm inistration of polyamine s ite  antagonists (SL.82.0715, ifenprodil) within 
5 min of the induction of ischaemia have been shown to  m arkedly reduce the 
volume of irreversible ischaemic damage in the cerebral hemisphere (Bullock 
e t  al., 1990; Chen e t al., 1991b; G otti e t  al., 1988; O zyurt e t  al., 1988). The 
adm inistration of MK-801 2h a fte r the onset of ischaem ia is as effective  as 
p re trea tm en t in reducing the volume of ischaemic brain damage in the  c a t 
MCA occlusion model (Park e t al., 1988a) whilst, in con trast, D-CPPene has 
no significant e ffe c t when trea tm en t was in itiated  lh  a f te r  occlusion of the 
MCA (Chen e t al., 1991b). Furtherm ore, recen t evidence suggests th a t the 
adm inistration of MK-801 30 min a fte r  the induction of ischaemia in a 
tem porary MCA occlusion model in the  c a t (2h occlusion followed by 4h
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reperfusion) (Dezsi e t al., 1992) confers a broadly sim ilar magnitude of 
neuroprotection to th a t observed with 6h of perm anent MCA occlusion 
(Ozyurt e t al., 1988; Park e t  al., 1988a).
4.1.2 Global Ischaemia
The influence of NMDA antagonists on pyramidal neuronal necrosis 
within the  CA1 subfield of the hippocampus in animal models of global 
ischaemia has been the subject of intense investigation whilst other 
hippocampal subfields (CA2-CA3, CA4) and o ther brain regions, such as the 
neocortex and striatum , have been less studied. These studies have yielded 
inconsistent e ffects  of NMDA antagonist adm inistration both within the same, 
and betw een different, animal models of global ischaem ia. Thus, these 
results have m et considerable controversy and been subject to much debate.
In large animal models of global ischaemia MK-801 is the only NMDA 
antagonist to date which has been investigated. In these studies, MK-801 
failed to reduce ischaem ic damage to  hippocampal CA1 neurones or a lte r 
behavioural outcome in cats  (Fleischer e t al., 1989),“dogs (M ichenfelder e t 
al., 1989; Sterz e t al., 1989) or non-human prim ates (Lanier e t al., 1990) 
subjected to  transient, but severe global ischaemia.
Following transien t global ischaemia in the  gerbil, MK-801 markedly 
a ttenuates  CA1 pyramidal neuronal damage in the  hippocampus when 
adm inistered prior to  (Gill e t  al., 1987; Warner e t  al., 1991) and 24h a fte r 
(Gill e t al., 1988) the  induction of ischaemia. P ro tection  against ischaemic 
injury to  hippocampal CA1 neurones in the  gerbil has also been observed with 
the  com petitive NMDA antagonists CGS-19755 and CPP (Boast e t al., 1988) 
and the non-com petitive antagonist ketam ine (Marcoux e t  al., 1988). In 
addition, there  is evidence th a t MK-801 and CGS-19755 can a ttenuate
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ischaem ic damage to  the stria tum  and layer III of neocortex, although no 
neuroprotection is observed in areas CA2-CA3 and CA4 of the hippocampus 
(Warner e t al., 1991). There are reports however th a t MK-801 and the 
polyamine s ite  antagonist ifenprodil confer no neuroprotective e ffec ts  a fte r 
transien t global ischaemia in the gerbil (Buchan & Pulsinelli, 1990; Sheardown 
e t  al., 1993).
There are a number of investigations in ra ts , using the  four-vessel 
occlusion or two-vessel occlusion plus hypotension models of transien t, but 
severe forebrain ischaemia, which indicate th a t NMDA recep tor blockade 
with e ither com petitive (AP-7, CGS-19755, CPP) or non-com petitive 
(dextrorphan, ketam ine, m em antine, MK-801, PCP) antagonists a ttenuates 
ischaem ic damage to hippocampal CA1 neurones (Church e t al., 1988; Rod & 
Auer, 1989; Sauer e t al., 1988; Seif el Nasr e t  al., 1990; Swan e t al., 1988; 
Swan & Meldrum, 1990). Moreover, there  are lim ited reports th a t brain 
regions other than the hippocampus (i.e. the neocortex and striatum ) can be 
p ro tected  by blockade of NMDA receptors (Rod & Auer, 1989; Wieloch e t 
al., 1989). Conversely, there  is an increasing body of evidence which suggests 
th a t the adm inistration of NMDA antagonists (com petitive and non­
com petitive) have no neuroprotective e ffe c t on hippocampal neurones in ra ts  
subjected to transien t forebrain ischaemia (Buchan e t  al., 1991b; Diemer e t 
al., 1992; Jensen and Auer, 1988; Li & Buchan, 1993; Nellgard & Wieloch, 
1992; Nellgard e t  al., 1991).
The basis for the  conflicting data regarding the  e ffec ts  of NMDA 
antagonism in animal models of global/forebrain ischaem ia is believed to  be 
a ttribu tab le  to  a t  least two key variables. F irst, small differences in brain 
tem peratu re  during and a fte r transien t global ischaem ia dram atically  modify 
the amount of delayed neuronal damage in gerbils and ra ts  (Busto e t  al.,
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1987; Minanisawa e t al., 1990), and it has been suggested th a t the 
neuroprotective e ffec ts  of NMDA antagonists are  due principally to  an 
arte fac tu a l reduction in brain tem peratu re  (Buchan & Pulsinelli, 1990; C orbett 
e t  al., 1990). Second, the severity  of the  ischaem ic insult and its im pact on 
energy s ta te  may determ ine the  efficacy  of NMDA antagonists (Siesjo & 
Bengtsson, 1989; Wieloch e t al., 1989). Following transien t, m oderate 
(incomplete) ischaemia, where the  energy s ta te  is less markedly disturbed, 
NMDA recep tor antagonists may confer neuroprotection, whilst following 
severe (complete) ischaemia, which is found in many models of global 
ischaemia (and also in the ischaemic core of a focal insult) NMDA recep tor 
blockade is not efficacious because of a com plete breakdown of energy 
production.
4.2 AMPA R eceptor Blockade
The advent of selective antagonists (such as NBQX, GYKI 52466 and 
LY-293558) for the AMPA recep tor subtype has allowed assessm ent of the 
role of this recep tor in the genesis of ischaem ic brain damage in experim ental 
animals.
4.2.1 Focal Ischaemia
Although investigations of the  anti-ischaem ic efficacy  of AMPA receptor 
antagonists in models of focal cerebral ischaem ia are  num erically lim ited, a 
consistent p a tte rn  of response is beginning to  em erge. In all studies to  date, 
AMPA recep to r blockade reduces the volume of infarction produced by 
perm anent or tem porary occlusion of the  MCA. Adm inistration of the 
quinoxalinedione NBQX a fte r the induction of ischaem ia has been shown to 
reduce the  volume of focal ischaemic damage in the  ra t  a fte r  perm anent
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MCA occlusion (Gill e t  al., 1992b). In addition, the  benzodiazepine non- 
NMDA recep tor antagonist GYKI 52466 m arkedly a ttenuates the  volume of 
infarction a fte r perm anent focal ischaemia in the  r a t  even when trea tm en t 
is delayed up to 1 hr a fte r  the  ischaemic episode (Smith & Meldrum, 1992), 
although its precise s ite  of interaction within the  AMPA recep to r ionophore 
remains to  be definitively identified. The delayed adm inistration of NBQX 
or GYKI 52466 also reduces ischaemic brain damage following tem porary 
MCA occlusion in the r a t  (2h occlusion followed by 22h reperfusion (Buchan 
e t al., 1991c; Xue e t al., 1994). The magnitude of neuroprotection afforded 
by NBQX in transien t focal ischaemia is com parable to  th a t obtained a fte r 
perm anent focal ischaemia in the ra t (approximately 30%), although the 
reductions in lesion size were sim ilar to or sm aller than NMDA receptor 
antagonists in the hands of the  same investigators (Buchan e t  al., 1992; Gill 
e t al., 1991a). A recen t study has indicated th a t p re trea tm en t with a novel 
AMPA recep to r antagonist, decahydroisoquinoline carboxylic acid (LY-293558), 
modestly reduces the volume of irreversible ischaem ic brain damage in the 
ca t a fte r  6h of perm anent MCA occlusion (Bullock e t  al., 1994). No 
neuroprotection is observed within the basal ganglia a f te r  AMPA receptor 
blockade in MCA occlusion models of focal ischaemia.
.2 Global Ischaemia
There have been convincing dem onstrations th a t AMPA receptor 
antagonists reduce ischaem ic neuronal necrosis in rodent models of global 
ischaemia. The anti-ischaem ic efficacy of AMPA recep to r antagonists 
contrasts with the lim ited and controversial efficacy  of NMDA receptor 
antagonists in the sam e global models (see McCulloch e t  al., 1991; Nellgard 
& Wieloch, 1992). The quinoxalinedione NBQX has been the  m ost extensively
investigated AMPA receptor antagonist in animal models of global cerebral 
ischaemia. In transien t (5 min duration) global ischaem ia in the gerbil, NBQX 
affords alm ost com plete protection of hippocampal CA1 neurones against 
delayed ischaem ic damage, even when adm inistered up to 24h a fte r the  onset 
of ischaemia (Sheardown e t al., 1990, 1993). Following transien t but severe 
forebrain ischaemia in ra ts, a number of investigations indicate th a t blockade 
of AMPA receptors with NBQX markedly a tten u a tes  ischaemic injury to  CA1 
neurones (Buchan e t  al., 1991a; Diemer e t  al., 1992; Frank e t al., 1993; Li & 
Buchan, 1993; Nellgard & Wieloch, 1992; Xue e t  al., 1994). Furtherm ore, this 
neuroprotective efficacy  is m aintained when tre a tm e n t with NBQX is in itia ted  
12h following the ischaemic episode (Li & Buchan, 1993). There is lim ited 
evidence available th a t cortical and s tria ta l neuronal necrosis can be reduced 
by AMPA recep tor blockade with NBQX (Le P eille t e t  al., 1992; Nellgard & 
Wieloch, 1992). In con trast to  the potent anti-ischaem ic e ffec ts  of NBQX 
in global ischaemia in rodents, post-ischaem ic tre a tm en t with NBQX does not 
improve outcom e in a canine model of com plete global cerebral ischaemia 
(Lanier e t al., 1993). In addition, it has been shown th a t  GYKI 52466 does 
not prevent the  delayed degeneration of hippocampal CA1 and CA3 neurones 
in ra ts  (Le P eille t e t  al., 1992; Xue e t al., 1994), although significant 
neuroprotective against selective cell loss in the  cortex  and stria tum  is 
observed (Le Peille t e t  al., 1992).
The reason for the apparent dichotomy betw een the  anti-ischaem ic 
efficacies of NMDA and AMPA recep tor antagonists on delayed hippocampal 
CA1 neuronal necrosis following global ischaem ia is not fully understood. 
A possible explanation as to how blockade of the  AMPA recep tor a ttenuates 
ischaem ic neuronal injury a t the cellular level is suggested by recen t 
m olecular biological studies involving the expression of AMPA recep tor
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ionophore subunits (GluRl, GluR2, GluR3 and GluR4) in oocytes which have 
shown th a t specific heterom eric combinations of subunit molecules are 
perm eable to Ca2+ ions (Hollmann e t al., 1991). Combinations of AMPA 
recep to r subunits which conduct Ca2+ have been found in re tina l bipolar cells 
(Gilbertson e t al., 1991), and some hippocampal neurones (lino e t al., 1990). 
In heterom eric assemblies, the polypeptide GluR2 d ic ta tes  the  conductance 
and perm eability properties of the channel (Hume e t  al., 1991). When 
expressed alone or in combination, GluRl and GluR3 form  receptors th a t 
have a substantial perm eability to Ca2+, but when GluR2 is co-expressed, the 
recep tor channels are virtually impermeable to  Ca2+ (Hollmann e t  al., 1991). 
The elegant observation th a t following transien t severe forebrain ischaemia 
mRNA transcription in CA1 hippocampal neurones is a ltered , resulting in 
reduced production of the GluR2 AMPA recep to r subunit (Pellegrini- 
G iam pietro e t al., 1992) suggests a switch in g lu tam ate recep tor subunit
p,
expression and a potential mechanism for a post-ischaem ic increase in Ca 
perm eability through channels linked to  AMPA receptors. This change in 
mRNA expression occurs in the CA1 subfield of the hippocampus, but not the 
CA3 zone (Pellegrini-Giam pietro e t al., 1992). Thus, an increased expression 
of Ca2+-perm eable AMPA-1 inked channels may account for the selective 
vulnerability of CA1 neurones to ischaemic injury, and the  ability of delayed 
NBQX trea tm en t to  a ttenuate  CA1 neuronal necrosis (Li & Buchan, 1993; 
Sheardown e t al., 1993). In addition, acidosis has been shown to a ttenuate
p,
the influx of Ca through NMDA recep tor-gated  ion channels (Takadera e t 
al., 1992). Thus, the  severe acidosis th a t prevails during global ischaemia 
and transien t forebrain ischaemia (Siesjo, 1988a) may lim it the contribution 
of NMDA receptor-m ediated  neurotoxicity and increase the re la tive 
im portance of AMPA receptor-m ediated mechanisms. This may also explain
why AMPA antagonists are m ore efficacious than NMDA antagonists against 
global ischaem ic brain damage.
4.3 Adverse E ffec ts
4.3.1 Cardiovascular and Respiratory System
C om petitive and non-com petitive NMDA recep to r antagonists (MK-801 
and CPP) depress respiration and induce hypercapnia (Kurumaji e t  al., 1989). 
MK-801 increases blood pressure in conscious ra ts  and chloralose- 
anaesthetised ca ts  (Hargreaves e t al., 1993b; Kurumaji e t  al., 1989; O zyurt 
e t  al., 1988) but markedly reduces blood pressure in halothane-anaesthetised 
ra ts  (Bielenberg & Beck, 1991; Park e t al., 1988b). The non-com petitive 
NMDA recep to r antagonist D-CPPene induces hypotension in chloralose- 
anaesthetised cats  a t high doses (Bullock e t al., 1990; Chen e t al., 1991b). 
Ifenprodil and SL 82.0715, agonists a t the polyamine modulatory s ite  on the 
NMDA recep to r complex, reduces blood pressure in halothane-anaesthetised  
cats  (Gotti e t  al., 1988).
R ecent evidence indicates th a t the AMPA recep tor antagonists NBQX 
and LY-293558 induced marked respiratory depression and evoke dose- 
dependent increases in p C 0 2 and decreases in p 0 2 in conscious ra ts  (Browne 
& McCulloch, 1994). It has also been shown th a t NBQX induces hypertension 
in halothane-anaesthetised ra ts  (Gill e t  al., 1992b). However, the  m ost 
serious side e ffe c t re la tes to  the low solubility of NBQX in aqueous media, 
because evidence is available which indicates th a t NBQX crystallises in renal 
tubules producing an in te rstitia l tubular nephritis and blockage of the  
glomeruli (Li & Buchan, 1993); Xue e t al., 1994).
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.2 Central Nervous System
The functional consequences of modulation of g lutam atergic mechanisms 
can be mapped using the [u C]-2-deoxyglucose autoradiographic technique 
developed by Sokoloff and colleagues (1977). The procedure allows an 
anatom ically comprehensive assessm ent of function-related  alterations in 
cerebral glucose use in vivo. Moreover, increases in function-related energy 
generation have em erged as being particularly  im portant, because they appear 
to  be a prelude to  alterations in neuronal morphology within specific regions 
of the brain.
Non-com petitive NMDA recep tor antagonists (MK-801, PCP, ketamine) 
and com petitive NMDA recep tor antagonists (CPP, CGP 37849) induce 
dissim ilar alterations in function-related glucose use in the  CNS a t doses 
broadly com parable in term s of neuroprotective and anti-convulsant efficacy. 
Marked focal increases in glucose use a fte r MK-801 are observed in regions 
of the hippocampal form ation (subicular complex, m olecular layer, dentate  
gyrus) and in components of the limbic system  (posterior cingulate cortex, 
entorhinal cortex, mamillary body, anteroventral thalam ic nucleus), with 
pronounced reductions in glucose use noted in the  neocortex and inferior 
colliculus (Hargreaves e t al., 1993b; Kurumaji e t  al., 1989; Nehls e t  al., 
1988). In con trast, CPP induces modest changes in glucose use, and only a t 
very high concentrations do a few areas of the  limbic system  (hippocampus 
m olecular layer, entorhinal cortex) increase the ir glucose use (Kurumaji e t 
al., 1989; Nehls e t  al., 1988). It is noteworthy th a t a t high doses, CGP 
37849 produces a sim ilar p a tte rn  of glucose use response in the  limbic system 
to  th a t observed a fte r  MK-801 adm inistration (Hargreaves e t  al., 1993b). 
R ecent evidence suggests th a t NMDA recep tor antagonists acting a t the 
polyamine (SL 82.0715) and glycine (L-687,414) m odulatory sites produce
numerically small and anatom ically circum scribed e ffec ts  on glucose use 
(Hargreaves e t al., 1993a; Scatton e t  al., 1991). No elevations in glucose 
use are observed in the limbic system  areas w ith e ither SL 82.0715 or 
L-687,414 a t doses in excess of those required for neuroprotection in rodent 
models of focal ischaem ia (Hargreaves e t  al., 1993a; Scatton e t  al., 1991).
The acute  adm inistration of the non-com petitive NMDA recep tor 
antagonists MK-801, phencyclidine and ketam ine induces transien t, reversible 
cellular swelling and vacuolisation in the  m ultipolar and medium to large sized 
pyramidal neurones in layers III and IV of the posterior cingulate cortex  and 
retrosplenial cortex  in ra ts  (Allen & Iversen, 1990; Auer & Coulter, 1994; Fix 
e t  al., 1993; H argreaves e t al., 1993b; Olney e t al., 1989, 1991). These 
vacuolated neurones also go on to la te r express the heat shock proteins HSP70 
and HSP72 (Sharp e t al., 1991, 1992). The reversible changes in neuronal 
s truc tu re  are noted with MK-801 a t doses sim ilar to  those a t which anti- 
ischaem ic e ffec ts  and increased glucose use are seen. Similar neuronal 
swelling and vacuolisation are also observed with the  com petitive NMDA 
recep to r antagonists (CPP, CGS 19755, CGP 37849) (Hargreaves e t  al., 1993b; 
Olney e t  al., 1991). However, unlike the situation with MK-801, these 
morphological changes occur a t drug doses th a t are  g rea te r than those 
required to reduce ischaemic brain damage. SL 82.0715 and L-687,414, 
antagonists of the  polyamine and glycine sites respectively on the NMDA 
recep to r complex, do not induce any alterations in cortical neuronal 
morphology a fte r system ic adm inistration (Duval e t  al., 1992; Hargreaves e t 
al., 1993a).
The functional consequences of AMPA recep to r blockade, as reflec ted  
in a lterations in cerebral glucose use, have only recen tly  been investigated. 
The AMPA antagonists NBQX and LY-293558 produce m arked, anatom ically
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widespread, dose-dependent reductions in glucose use throughout the  brain 
(Browne & McCulloch, 1994; Suzdak & Sheardown, 1993). The g rea tes t 
reductions in glucose use a fte r NBQX or LY-293558 occur in limbic system  
areas (particularly hippocampal regions and cingulate cortex) and the 
neocortex. The e ffec ts  of AMPA antagonists on neuronal morphology remains 
to  be established.
5. THE OPIOID SYSTEM
5.1 Discovery of Opioid Peptides
The im portance of opioid drugs is re flec ted  in the ir extraordinary long 
use in m edical p rac tice  (Benedetti & Premuda, 1990). Assyrian tab le ts  
dating to the tw en ty -first century BC describe the  ex traction  of opium from 
the  poppy. Opium is the dried exudate from unripe seed capsules of the 
opium poppy, Papaver somniferium. The analgesic property of opium was 
recognised by the ancient Greeks, and the therapeu tic  use of opium was 
described by H ippocrates during his life from 460-377 BC. There are over 
20 alkaloids of opium, which constitu te  about 25% by-weight, although only 
four - morphine, codeine, papaverine and noscapine (narcotine) have medical 
uses.
In 1803, a German pharm acist, Serturner, isolated the  chief alkaloid 
from opium and called it morphia (after Morpheus, the  Greek god of dreams). 
The name morphine is now used in accordance w ith the  convention th a t the 
names of alkaloids end in -ine. Noscapine was ex trac ted  by Robiguet in 
1817 and codeine in 1832; thebaine was ex trac ted  by P e lle tier in 1835 and 
papaverine by Merck in 1848. By the middle of the  nineteenth  century, pure 
alkaloids w ere taking the place of opium preparations in m edicinal use.
The alkaloids of opium are conventionally divided into two distinct
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chem ical classes with therapeutic  potential, th e  benzylisoqinolines and the 
phenanthrenes. The main benzylisoquinoline derivatives in opium, which are 
non-opioid in nature, are the smooth muscle relaxant, phosphodiesterase 
inhibitor papaverine (about 1% by weight of opium) and the anti-tussive 
noscapine (2-8%). More im portantly, the  main phenanthrene derivatives are 
principally the opioid 4,5-epoxymethyl morphinans thebaine (0.2%), codeine 
(0.3-4%) and morphine (9-17%), in ascending order of concentration in opium 
and potency as opioid agonists. Thebaine is virtually  inactive as an opioid 
agonist but has been an im portant chem ical precursor in the  synthesis of 14- 
hydroxy derivatives of morphine such as the agonist oxycodone and the 
antagonists naloxone and naltrexone, and of oripavine derivatives such as the 
poten t agonist etorphine, the partial agonist buprenorphine, or the antagonists 
cyprenorphine or diprenorphine (McKnight & Rees, 1991).
The knowledge th a t the opium derivative morphine was a potent 
analgesic led investigators to propose the existence of endogenous opioid­
like compounds and postulate the concept of pharm acologically relevant 
receptors for opioids (Beckett & Casey, 1954). Evidence to support this 
view em erged with the demonstrations th a t morphine reduces field-stim ulated 
muscle contraction and acetylcholine release in the  guinea-pig ileum (Paton, 
1957; Schaumann, 1957), and elec trica l stim ulation of the  ra t brain stem  
induces analgesia (Mayer e t al., 1971). The actual presence of endogenous 
opioid compounds was unequivocally established with the  ex traction  of a low 
m olecular weight substance from ra t, rabbit, pig and guinea-pig brain (Hughes, 
1975). This ex tra c t was found to inhibit stimulus-evoked contraction  of the 
mouse vas deferens and guinea-pig m yenteric plexus in a m anner sim ilar to 
morphine, and m ost im portantly was antagonised by the  opioid antagonists 
naltreone and naloxone (Hughes, 1975). Purification of the  e x tra c t revealed
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the presence to two endogenous opioid pentapeptides - [Leu5]-enkephalin (Tyr- 
Gly-Gly-Phe-Leu) and [Met5]-enkephalin (Tyr-Gly-Gly-Phe-Met) (Hughes e t al., 
1975). It was quickly recognised th a t the  [Met5]-enkephalin sequence was 
identical to  the 61-65 amino acid sequence of p-lipotropin. This discovery 
led to the  characterisation  of the opioid properties of the P-lipotropin 61- 
91 fragm ent p-endorphin in bovine p itu itary  (Bradbury e t  al., 1976; Cox e t al., 
1975). Furtherm ore, e ffo rts  to  identify a non-endorphin opioid substance in 
porcine p itu itary  ex trac ts  resulted in the  isolation of the heptacedapeptide 
dynorphin A by Goldstein and colleagues (1981).
The discovery th a t the nervous system  contained peptides th a t function 
as neurotransm itters or neuromodulators, and have pharm acological e ffects  
qualitatively sim ilar to morphine established beyond doubt th a t the actions 
of morphine are m ediated by physiologically relevant, receptor-m ediated 
mechanisms, to mimic the nature functions of the  endogenous opioid 
neuropeptides. Thus the enkephalins were im plicated in im portant aspects 
of the operation of the nervous system  including the  control of sensory 
function, mood, neuroendocrine function, respiration and gastrointestinal 
m otility (K osterlitz & McKnight, 1981).
Early evidence suggested th a t the enkephalins w ere derived from larger 
precursor molecules synthesised locally by ribosomal assembly, and not from 
P-lipotrophin or p-endorphin of p itu itary  origin (McKnight e t  al., 1979). 
However, it was established, ultim ately by recom binant techniques, th a t the 
nervous system  contains th ree  families of endogenous opioid peptides th a t are 
formed by proteolytic cleavage of th ree  d istinct precursor proteins: the 
proopiom elanocortin (POMC) precursor (also known as beta-endorphin/ACTH), 
the proenkephalin A precursor (known as proenkaphalin or enkephalin) and the 
prodynorphin precursor (also known as dynorphin/new dynorphin or
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proenkephalin B) (Akil e t al., 1984; Hollt, 1986). The first of these, 
proopiom elanocortin, contains one copy of the  [Met5]-enkephalin sequence and 
is the common precursor of a -, (3- and y-MSH, corticotropin, and (3-endorphin 
(Nakanishi e t al., 1979, 1981). Proenkephalin A contains the coding for 
several active peptides all of which are opioid in nature, i.e. six copies of 
[Met5]-enkephalin and one of [Leu5]-enkephalin (Noda e t al., 1982a,b). The 
prodynorphin precursor contains th ree  copies of the [Leu5]-enkephalin 
sequence (Kakidani e t al., 1982). The precursor molecules contain paired 
basic amino acids flanking the enkephalin sequences th a t are  believed to ac t 
as signals for tryptic-like cleavage. As a consequence, proenkephalin A is 
a potential source of extended versions of [Met5]-enkephalin, and prodynorphin 
is a source of extended versions of [Leu5]-enkephalin: the  "neo-endorphins" 
and "dynorphins" (Akil e t al., 1984).
5.2 Opioid R eceptor C lassification
The existence of a specific opioid recep to r was first suggested by early 
behavioural and clinical studies, in which a variety  of synthetic  analgesics 
based on the  struc tu re  of morphine were shown to exhibit a high degree of 
s truc tu ra l and stereochem ical specificity  (Beckett & Casey, 1954; Portoghese, 
1965; Woods, 1956). The complex clinical profiles of morphine-like drugs 
were subsequently suggested to be a ttribu tab le  to in teraction  with more than 
one type of opioid recep tor (Martin, 1967). However, the  firs t evidence for 
m ultiple opioid recep tor types is now generally accepted to  have come from 
the  behavioural and neurophysiological observations in dogs with long-term  
spinal transections (chronic spinal dog preparation) by M artin and co-workers 
(1976). They proposed the existence of th ree  types of opioid receptors - 
mu (ji), kappa (k ), and sigma (a), to account for the d iffe ren t pharmacological
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effec ts  produced by the prototypical agonists morphine (puanalgesia, miosis, 
bradycardia, hypothermia, indifference co-external stimuli), ketazocine (k: 
miosis, general sedation, depression of flexor reflexes, diuresis) and SKF- 
10,047 (N-allylnormetazocine) oimydriasis, increased respiration, tachycardia, 
delirium).
The opioid nature of the "sigma receptor" has been the  subject of much 
controversy. All the  e ffec ts  produced by SKF-10,047 in the chronic spinal 
dog w ere originally reported to  be suppressed by the  opioid antagonist 
naltrexone (Martin e t al., 1976). A subsequent study, however found th a t 
some, but not all, of the e ffec ts  produced by SKF-10,047 were actually 
antagonist by naltrexone (Martin e t al., 1980). Furtherm ore, independent 
studies using the sam e chronic spinal dog preparation failed to observe 
antagonism of the e ffec ts  of SKF-10,047 with the  opioid antagonist naltrexone 
(Vaupel, 1983). It has now been firmly established the putative "sigma 
effects" of SKF-10,047 (and other benzomorphan opioids) in several 
behavioural paradigms are not blocked by naloxone, and hence are by 
definition non-opioid (Mannalack e t al., 1986). It -is now clear th a t the 
affinities of SKF-10,047 and several o ther benzomorphans for the so-called 
sigma-binding s ite  labelled in various brain and peripheral preparations, and 
with several radioligands, reside with the (+)-isomers, and dem onstrate a 
pa tte rn  of stereoselectiv ity  th a t is the reverse of th a t seen a t opioid recep tor 
(Mannalack e t  al., 1986). Moreover, although it  was suggested th a t the 
psychtom im etic e ffec ts  of opioids may be a ttribu tab le  to  an e ffe c t a t the 
putative sigma recep tor compounds such as nalorphine (which are also 
psychotom im etic in man) have no affinity for th e  [3H]-(+) SKF10,047 binding 
sites in guinea-pig brain (Tam, 1985; P fe iffe r e t  al., 1986). Thus, as naloxone 
has low affin ity  and several non-opioid ligands e.g. haloperidol and
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phencyclidine have high affinity  for this sigma site , the sigma recep tor is 
reported  to represent a d istinct class of non-opioid binding s ite  possibly 
associated with the NMDA recep to r complex (Quirion e t  al., 1987).
The discovery of the endogenous enkephalin peptides by Hughes and 
co-workers provided the "pharmacological tools" with which to  further 
investigate opioid receptor heterogeneity . The activ ity  e ffec ts  of the 
enkephalins were subsequently compared with th a t of morphine in guinea-pig 
ileum and mouse vas deferens and the ir re la tive  resistance to  antagonism 
by the non-selective opioid antagonist naloxone com pared (Lord e t al., 1977). 
On the basis of the  observed p a tte rn  of activ ity  with the  enkephalins being 
unlike th a t of morphine, it was proposed th a t th e re  was a third receptor 
type, the delta  (6) opioid recep tor for which the  enkephalins had highest 
affin ity  (Lord e t al., 1977).
Through extensive research in in vitro  and in vivo pharmacological 
models and radioligand binding assays, unequivocal support has been gained 
for the existence of th ree types of opioid receptor, >jl, 6 and k in mammalian 
cen tral and peripheral nervous system , each with *a d istinct anatom ical 
distribution (Mansour e t al., 1988; M artin, 1984). Evidence has been 
presented, on the basis of complex radioligand binding studies, to  suggest the 
fu rther subdivision of k-opioid receptors into a t least two separa te  classes of 
pharmacologically distinguishable subtypes (see Knapp e t  al., 1993 for review). 
These subtypes, term ed ky and k2, have been distinguished on the basis of 
re la tive  sensitivity  toward the selective k-agonist U-50,488H (Von Voigtlander 
e t  al., 1983). The U-50,488H-sensitive s ite  was term ed the  k-, recep tor and 
the  U-50,488H-insensitive s ite  the k2 recep to r (Zukin e t  al., 1988). In 
addition, the existence of a k3 subtype has recently  been proposed, based on 
the  binding profile of a novel ligand naloxone benzoylhydrazone (Cheng e t al.,
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1992). However, /c-opioid recep tor subtypes have not been fully accepted and 
will require validation in in vivo functional and behavioural te sts  before this 
convention is accepted absolutely. Thus, in the  absence of unequivocal 
evidence to  support the existence of /c-opioid recep to r subtypes, the  fully 
established /c-receptor classification will be used within the  thesis.
5.3 Opioid R eceptor D istribution
Opioid receptors are widely distributed throughout the  brain and spinal 
cord. Q uantitative autoradiographic studies have dem onstrated th a t the 
distribution of opioid receptors vary markedly in both the ir re la tive  abundance 
across brain regions and their specific localisation. As comprehensive reviews 
of this subject are available (see Knapp e t  al., 1993; Mansour e t al., 1987; 
Tempel & Zukin, 1987 in ter alia ), the following is a brief summary of opioid 
recep to r distribution in ra t brain, with particu lar emphasis on /c-opioid 
receptors.
Telencephalon
In the  neocortex there  is a predominance of y. and 6 sites. Although 
there  are regional differences in lamination, sites are m ost prominent in 
layers I and III/IV of frontal, parietal and tem poral cortex , whereas 6-opioid 
receptors tend to  be diffusely localised in layers II, III, V and VI. In contrast, 
only low levels of /c-opioid receptors are observed in layers II, III, V and VI 
of frontal and parie tal cortex.
Limbic system  structures, like neocortex, have a rich distribution of 
opioid receptors. For example, in the  hippocampal form ation there  is a 
re la tive  abundance of y-opioid receptors in the pyramidal cell layer, stra tum  
lacunosum m oleculare, and the m olecular and granule cell layers of the
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den tate  gyrus. In these sam e areas, com paratively low numbers of k  and 6 
sites are observed. Interestingly, the re la tively  low number of /c-opioid 
receptors seen in the  ra t hippocampus is in con trast to the fairly rich 
dynorphin innervation observed in this brain region (Chavkin e t al., 1985).
In con trast to  the situation in the  hippocampus, all th ree  opioid receptor 
subtypes are densely distribution within the caudate-putam en and the  nucleus 
accumbens. p^Opioid receptors occur predom inantly in the sub-callosal 
region of the  caudate-putam en and in recep to r "patches" th a t extend from 
the stria tum  to the nucleus accumbens. 6 - and /c-opioid receptors, in 
contrast, are  diffusely distributed within these structures, with k -sites 
particularly  dense ventrom edially and 6-sites ventrolaterally .
Diencephalon
Compared with the telencephalon, diencephalic struc tu res show a 
predominance of pi- and /c-opioid binding. There are high levels of pi-binding 
in m ost of the  areas of the thalam us, with the  exception of the  zona incerta, 
periventricular, central la teral and ventral posterom edial nuclei. Medium 
to high levels of /c-opioid receptors are seen in the  medial regions of the 
thalam us including the periventricular, mediodorsal and reuniens nuclei. In 
the  hypothalamus the receptor distribution, is reversed with m oderate to  high 
levels of k -binding throughout m ost of the hypthalam ic nuclei (ventromedial, 
dorsomedial, arcuate, paraventricular, supraoptic) with little  or no binding to 
pi-opioid recep tors noted. A notable exception is the  m am illary body which 
contains a com parable level of both pi- and /c-opioid binding.
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Mesencephalon and Brainstem
More caudally in the mesencephalon and brainstem , pi- and /c-opioid 
receptors show largely parallel distributions with only low levels of \>-sites 
noted. Both pi- and /c-opioid receptors are observed in the periaqueductal 
grey m a tte r, superior and inferior colliculi, interpeduncular nucleus, raphe 
nuclei, locus coeruleus, parabrachial nucleus, nucleus trac tu s  solitarius, spinal 
trigem inal nucleus and substantia gelatinosa and ventral horn of the spinal 
cord. The distributions vary m arkedly in the substantia nigra where dense 
pi-opioid binding is observed in the pars com pacta, an area devoid of /c-opioid 
receptors in the ra t. Relatively low levels of 6 and k  binding are observed 
in the pars re ticu la ta . Negligible opioid recep tor binding is de tec ted  in the 
cerebellum  of the ra t.
An interesting feature regarding the distribution of opioid receptors 
is the interspecies differences exhibited by /c-opioid receptors. A t the 
sim plistic level, species have been shown to vary dram atically  in the 
abundance of /c-opioid receptors. In the ra t, /c-opioid receptors compromise 
approxim ately 10% of the to ta l number of opioid recep to r sites, whereas in 
m ost o ther species such as guinea-pig, rabbit, dog, monkey and man, they 
represen t betw een 40-50% of the  to ta l opioid recep to r population (Mansour 
e t  al., 1988; Sharif e t  al., 1990). Anatomically, interspecies differences can 
be observed within d ifferent areas of the brain. In the  cerebral cortex high 
levels of /c-opioid receptors are found in the deep co rtical layers (V-VI) of 
the  guinea-pig, dog, prim ate and human brain, with only low levels in the  ra t 
(Mansour e t  al., 1988). These differences extend to  o ther areas of the brain 
including the  hippocampus, cerebellum  and nigrostriatal system  where high 
levels of /c-binding are  found in the prim ate in comparison to  the  low levels 
of binding in the ra t (Mansour e t al., 1988).
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5.4 Kappa Opioid R eceptor Ligands and CI-977
The endogenous dynorphin family of opioid peptides, derived from the 
proteolytic  cleavage of prodynorphin, have high affin ity  for the /c-opioid 
recep tor (Chavkin & Goldstein, 1981; C orbett e t  al., 1982). However, it  was 
a non-peptide benzomorphan derivative, ketazocine, which was the compound 
used to  firs t identify the /c-opioid recep to r following behavioural studies in 
the  chronic spinal dog preparation (Martin e t  al., 1976). The developm ent 
of fu rther benzomorphan derivatives (ethylketazocine, bremazocine) and the 
oripavine ligands, etorphine and diprenorphine, rep resen t the discovery of 
non-peptide ligands which have high affin ity  for the /c-opioid recep tor (Chang 
e t  al., 1981; Gillan & K osterlitz, 1982; K osterlitz e t  al., 1981; P feiffer & 
H ertz, 1982). However, from in vitro  functional te sts , it has been shown th a t 
m embers of the benzomorphan and oripavine series are intrinsically 
non-selective and in te rac t with com parable potency a t  ji- and 6-opioid (Chang 
e t  al., 1981; Gillan & K osterlitz, 1982; K osterlitz  e t al., 1981) as well as non­
opioid (Su, 1982; Tam, 1983; Zukin & Zukin, 1981) types of receptor. Thus, 
although the  benzomorphan and oripavine ligands have-been used in tritium - 
labelled form to investigate the binding charac te ris tics  of the /c-opioid 
recep to r (Fischel & Medzihradsky, 1986; Gillan & K osterlitz , 1982; P feiffer 
e t  al., 1982), selectiv ity  was only achieved by suppressing the  binding of these 
compounds to  jjl and 6 sites by the inclusion of selective  unlabelled ligands 
for these opioid receptors (Chang e t al., 1981; K osterlitz  e t  al., 1981).
The /c-opioid recep tor is now defined by the selective, non-peptide 
arylacetam ide derivatives U-50,488H (Von Voigtlander e t  al., 1983), U-69593 
(Lahti e t  al., 1985), U-62066E (Peters e t  al., 1987), PD117302 (Leighton e t 
al., 1987) and CI-977 (Hunter e t al., 1990) (Figure 2) and also by the  selective 
antagonist nor-Binaltorphimine (Portoghese e t  al., 1987) (Figure 2).
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FIGURE 2
Chemical s truc tu res of non-peptide agonists and an antagonist a t the /c-opioid 
receptor.
CI-977 is a highly selective and potent agonist a t  the  /c-opioid receptor 
(Hunter e t al., 1990). In radioligand binding studies using guinea-pig 
forebrain homogenates CI-977 binds with high affin ity  (Ki = 0.1 InM) to the 
/c-site labelled with [3H]-U-69593 (Hunter e t al., 1990). The affinity 
of CI-977 for radiolabelled p -  and 6-sites is approxim ately 1000-fold 
(Ki =99.6nM) and 10,000-fold (Ki = 1036nM) less, respectively, than a t the 
/c-site. CI-977 also has negligible affin ity  for o ther recep to r types and most 
im portantly has only 2jaM affinity  for the  putative  sigma binding s ite  and 
g rea te r than IOvjlM affinity for the  phencyclidine s ite  (Hunter e t al., 1990). 
In autoradiographic binding studies, the distribution profile of [3H]-CI-977 
labelled sites in the guinea-pig and ra t forebrain is consistent with th a t of a 
/c-selective radioligand. In the guinea-pig, the areas m ost densely labelled 
w ere the inner layers (V-VI) of the cerebral cortex , substantia nigra, 
hippocampus and interpeduncular nucleus. By con trast, in the ra t, only low 
levels of binding were found throughout the cerebral cortex, with the highest 
densities in the nucleus accumbens, claustrum , dorsal endoperiform nucleus, 
thalam us and hypothalamus (Boyle e t al., 1990).
In antinociceptive tests CI-977 is one of the m ost poten t agents tested . 
Following the m echanical paw pressure te s t in the ra t, CI-977 was the most 
poten t antinociceptive compound of the arylacetam ide series examined 
(Hunter e t al., 1990), and in the  monkey tail withdrawal assay, CI-977 was 
found to be approxim ately 1000 tim es more po ten t than morphine as an 
analgesic when tested  against a m oderate (50°C) therm al stimulus (Davis e t 
al., 1992). It has been suggested th a t agonists selec tive  for the  k-opioid 
recep to r may be m ore beneficial as analgesic agents than pL-opioid recep tor 
agonists because a t antinociceptive doses they are devoid of the side-effects 
(emesis, constipation, respiratory depression, physical dependence) associated
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with occupation of the ]i-opioid recep to r (Millan, 1990; Pasternak, 1993). 
In vitro  bioassays confirm  the very high efficacy  of this agent compared to 
o ther /c-opioid agonists (Hunter e t al., 1990). Its re la tive  efficacy  is a t least 
10-fold g rea te r than U-62066E and U-50,488H, and may indeed approach th a t 
of the  endogenous dynorphins.
The prototype opioid antagonist naloxone has been shown to  reverse the 
e ffec ts  of /c-opioid agonists, but is not selective  for any of the  recep tor types 
(Rees e t  al., 1992). In vivo , the analgesic e ffec ts  produced by CI-977 in 
animal models of nociception are com pletely reversed by naloxone (Davis e t  
al., 1992; Hunter e t al., 1990). In addition, the  po ten t inhibition of 
electrically-evoked contractions induced by CI-977 in in vitro  bioassays 
(guinea-pig ileum and rabbit vas deferens) is also naloxone reversible (Hunter 
e t  al., 1990). These observations therefo re  dem onstrate the  opioid nature 
of these responses to CI-977. The bivalent morphine derivative nor- 
Binaltorphimine is the most selective antagonist a t the  /c-opioid recep tor to 
date (Portoghese e t al., 1987). Unfortunately, however, this compound has 
poor bioavailability and lim ited penetration to  the  cen tral nervous system, and 
thus investigations of the characteristics of /c-opioid recep tors and endogenous 
/c-opioid system s are mainly based on the actions of selec tive  /c-agonists like 
CI-977 and the endogenous dynorphin opioid peptides.
5.5 The Opioid System and C erebral Ischaemia
There is good evidence to suggest th a t the opioid system  may be 
involved in the pathophysiology of cerebral ischaem ia. H istorically, 
considerable atten tion  was first d irected  towards the  u tility  of the non- 
selective opioid antagonist naloxone as trea tm en t for ischaem ic brain damage. 
Early studies dem onstrated th a t naloxone reversed hemiplegia and
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improved speech in ischaem ic stroke patien ts (Baskin & Hosobuchi, 1981) and 
reduced neurological deficits in gerbils following perm anent unilateral 
common carotid  a rte ry  occlusion (Hosobuchi e t  al., 1982). Subsequent 
investigations observed a beneficial e ffe c t of naloxone in a variety  of animal 
models of global and focal cerebral ischaemia (Baskin e t  al., 1984b; Levy e t  
al., 1982; Wexler, 1984; Zabramski e t  al., 1984). On the  basis of these 
findings it was hypothesised th a t post-ischaem ic neuronal degeneration may 
be a consequence of excessive activation of the  endogneous opioid system  
which could be therapeutically  antagonised by opioid recep to r antagonists such 
as naloxone. This theory has not m et universal approval and the efficacy  of 
opioid antagonists for the trea tm en t of stroke questioned because the 
neuroprotective e ffec ts  of naloxone w ere not reproduced in many other 
studies in experim ental models of cerebral ischaemia (Gaines e t  al., 1984; 
Holaday & D’Amato, 1982; Hubbard & Sundt, 1983; K astin e t  al., 1982) or in 
man (Fallis e t al., 1983).
In recen t years there  has been increasing support for the view th a t 
activation of the /c-opioid receptor can am eliorate  ra th e r than exacerbate  
post-ischaem ic neuronal necrosis and prom ote neurologic recovery and 
survival. The initial study in this regard dem onstrated th a t trea tm en t with 
the  peptide dynorphin A (1-13), an endogenous /c-opioid agonist, improves 
long-term  survival in ca ts  following perm anent occlusion of the righ t MCA 
(Baskin e t  al. 1984a). In the same study, the  non-opioid dynorphin fragm ent, 
dynorphin A (3-13), was ineffective. Subsequently it was shown th a t the 
non-peptide /c-opioid agonists U-62066E and U-50,488H reduced hippocampal 
CA1 neuronal necrosis following transien t (5-10 min) b ila teral caro tid  artery  
occlusion in the gerbil (Contreras e t al., 1991; Hall & Pazara, 1988; Tang, 
1985). It is notable th a t U-54,494A, a s truc tu ra l analogue of U-50,488H with
73
no affin ity  for the /c-opioid recep tor did not afford neuroprotection (Hall & 
Pazara, 1988). In addition, there  is evidence th a t U-50,488H reduces the 
cerebral oedema and m ortality  a fte r  4 h b ila teral carotid  occlusion in Fischer 
344 ra ts  (Silvia e t al., 1987; Silvia & Tang, 1986) and also the cerebral 
oedema, cortical and s tria ta l neuronal necrosis and m ortality  resulting from 
transien t (lh) or perm anent MCA occlusion in the  c a t (Silvia & Tang, 1986; 
Tang & Silvia, 1986). Similarly the  /c-opioid agonist GR89696 has recently  
been shown to confer neuroprotection following transien t, global ischaemia 
in the gerbil and perm anent focal ischaemia in the  mouse (Birch e t al., 1991).
A precise m echanistic basis for the beneficial e ffec ts  which /c-opioid 
agonists display in some animal models of cerebral ischaem ia is presently not 
known with certain ty . Agonists a t the /c-opioid recep to r are d iuretic  (Peters 
e t  al., 1987; Slizgi e t al., 1984), and thus the prevailing view is th a t /c-opioid 
agonists are  neuroprotective by reducing post-ischaem ic cerebral oedema 
(Silvia e t  al., 1987; Silvia & Tang,1986). However, /c-agonists are also potent 
anti-convulsant agents with particular efficacy  towards NMDA receptor 
m ediated convulsant activ ity  (Singh e t al., 1990b). Indeed a m ajor role of 
dynorphin peptides in the hippocampus may be to  regulate  mossy fibre 
synaptic transm ission (Wagner e t al., 1991). Prodynorphin is synthesised in 
the granule cells of the den tate  gyrus and dynorphin peptides are densely 
represented in the  mossy fibre pathway (McGinty e t  al., 1983; Sato e t  al., 
1991). It also appears th a t the dynorphins are co-localised with 
a sp arta te /g lu tam ate  in this pathway as well as in o ther brain areas (Terrian 
e t  al., 1988). Electrophysiological studies have shown th a t /c-opioid agonists 
inhibit the  excitato ry  amino acid input to the locus coeruleus (McFadzean e t 
al., 1987), and thus it appears th a t an intriguing relationship exists between 
/c-opioid and excitatory  amino acid mechanisms. This is all the more
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intriguing given th a t the m arked reduction in the  level of the hippocampal 
dynorphin A im m unoreactivity precedes the  resu ltan t CA1 neuronal necrosis 
following transien t global ischaemia in the  gerbil (Fried & Nowak, 1987) and 
also th a t /c-opioid agonists are neuroprotective in certa in  animal models of 
cerebral ischaemia. Thus if a major role of /c-opioid peptides in the brain 
is to m odulate excitatory  amino acid transmission, this would provide a 
plausible, rational hypothesis to explain the anti-ischaem ic efficacy  of 
/c-agonists.
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6. AIMS OF THESIS
The principal objectives in this thesis will focus on investigations into 
the neuroprotective e ffec t of the selective /c-opioid recep tor agonist CI-977 
in animal models of focal cerebral ischaemia and to  identify the  mechanisms 
through which /c-opioid agonists can am eliorate ischaem ic brain damage.
The efficacy of CI-977 will be examined a f te r  perm anent MCA occlusion 
in a lissencephalic species (rat) and a gyrencephalic species (cat). Outcome 
will be assessed a t 24h a fte r  the induction of ischaem ia in the ra t  when 
infarction and brain swelling are well developed. In addition, the e ffe c t of 
CI-977 on ischaemic damage will be determ ined a t 4h and 6h post-ischaem ia 
in the ra t  and c a t respectively, where key physiological variables which are 
thought to influence outcome (e.g. MABP, tem peratu re, plasma glucose) can 
be comprehensively monitored throughout the experim ental period.
In order to establish a m echanistic basis for the  neuroprotection afforded 
by CI-977, th ree  d ifferent experim ental approaches will be employed. First, 
the e ffec t of CI-977 on cerebral blood flow a fte r  perm anent MCA occlusion 
in the r a t  will be examined using [14C]-iodoantipyrine autoradiography. 
Second, the e ffe c t of CI-977 on the relationship betw een glutam ate release 
(using the microdialysis technique) and cerebral blood flow (using the hydrogen 
clearance technique) a fte r focal ischaemia in the c a t will be studied. Third, 
the  e ffec t of CI-977 on exogenous glutam ate-induced neurotoxicity in the ra t 
cerebral cortex  (administered using reverse microdialysis) will be assessed and 
compared to  the  e ffec ts  of NMDA and AMPA recep to r blockade using MK- 
801 and NBQX respectively.
The functional consequences, as re flec ted  in alterations in cerebral 
glucose use and cerebral blood flow, in the  normal brain following system ic 
adm inistration of /c-opioid agonists has been minimally investigated hitherto.
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In this thesis, the e ffects  of CI-977 in local cerebral glucose utilisation (using 
[14C]-2-deoxyglucose autoradiography) and local cerebral blood flow (using 
[14C]-iodoantipyrine autoradiography) will be assessed in the conscious ra t to 
determ ine w hether CI-977, a t neuroprotective doses, induces alterations in 
glucose use or cerebral circulatory effects  which may confound its anti- 
ischaemic action.
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CHAPTER II 
METHODS
1. ANIMALS
1.1 R ats
All investigations using ra ts  were carried  out on adult m ale Sprague- 
Dawley ra ts  (Harlan Olac Ltd., B icester, Oxon, U.K.) weighing 300-450g. The 
animals were m aintained on a 12h light:dark cycle and allowed free  access 
to  food and w ater prior to  experim entation. Animals used in cerebral glucose 
u tilisation studies w ere deprived of food the  night preceding the experim ent 
(10-12h) in order to  obtain stable plasma glucose levels a t the  tim e of study.
1.2 C ats
All investigations using cats  were carried  out on adult ca ts  of e ither sex 
(Hillgrove Family Farm  Ltd., M inster Lovell, Oxford, U.K.) weighing 2.2- 
3.9kg. The animals were m aintained on a 12h light:dark cycle and deprived 
of food the night preceding the experim ent (15-18h), but allowed free  access 
to  w ater.
2. THE EFFECT OF CI-977 IN ANIMAL MODELS OP FOCAL CEREBRAL 
ISCHAEMIA
2.1 24h (Recovery from  Anaesthesia) Model in the  R at
2.1.1 Surgical Preparation
The ra ts  w ere anaesthetised initially with a m ixture of 4% halothane, 
30% oxygen and 70% nitrous oxide, and m aintained th e re a f te r  with a nitrous 
oxide/oxygen m ixture (70%:30%) containing 0.5-1% halothane delivered by a 
face mask. Body tem perature  was m onitored throughout the  surgical 
procedure (approximately lh) by a rec ta l therm om eter, and m aintained 
norm otherm ic (37 ± 0.5°C) via a heating blanket controlled by the 
therm om eter.
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2.1.2 Induction o f  Focal Ischaemia
All animals underwent a subtem poral craniectom y and exposure of the 
main trunk of the le ft MCA (Tamura e t al. 1981a), leaving the  zygom atic arch 
in tac t (Shigeno e t al. 1985a). The animals w ere placed in the  le ft la teral 
decubitus position, and an oblique skin incision (2cm) made half way between 
the  le ft orb it and the external auditory canal. The exposed tem poralis 
muscle was dissected from the  cranium and re tra c te d  to  expose the  infero- 
tem poral fossa. Under an operating m icroscope a t high m agnification, a 
small craniectom y was made using a saline-cooled dental drill a t the  junction 
betw een the  medial wall and the roof of the  infero-tem poral fossa, 
approxim ately 1mm dorsal to  the  foramen ovale. The underlying dura was 
opened with a fine needle to reveal the MCA. The main trunk of the MCA 
was exposed proximal to the  olfactory tra c t  to  where it crosses the  inferior 
cerebral vein (Figure 3). The exposed a rte ry  was occluded by m icrobipolar 
coagulation from its origin to the point where it crosses the  inferior cerebral 
vein. All visible len ticu lostria te  branches w ere also occluded. The trunk 
of the MCA was then severed proximal to  the  len ticu lostria te  branches to 
assure com pleteness of the  vascular occlusion and prevent recanalisation 
(Figure 3). The tem poralis muscle was sutured, the  wound closed, and an 
antiseptic  agent (Pevidine) liberally applied.
2.1.3 Post-Occlusion R ecovery
Following MCA occlusion, anaesthesia was discontinued and the  animals 
allowed to  regain consciousness under s tr ic t observation in an incubator a t 
37°C. The ra ts  were then housed singly in the  post-operative recovery room, 
where the ir overall condition was closely m onitored throughout the  survival 
period.
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FIGURE 3
Diagrammatic representation of the operative procedure for permanent occlusion 
of the MCA in the ra t. Exposure of the MCA via a subtemporal approach (upper) 
and proximal occlusion of the MCA by microbipolar coagulation (lower). Black lines 
indicate the sites of severance. (Adapted from Shigeno e t  al., 1985a.)
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2.1.4 Neuropathology and Quantitation o f  Ischaem ic Damage and Brain Swelling
Tw enty-four hours a f te r  MCA occlusion, the  animals were re ­
anaesthetised with a m ixture of 4% halothane, 30% oxygen and 70% nitrous 
oxide and decapitated . The brains were rapidly removed, frozen in 
isopentane a t -42°C and embedded in a histological medium (Tissutec). The 
brains w ere sectioned sem i-serially through th e  cerebrum  from  the anterior 
poles to  the  cerebellum  and the  sections (20pun) stained with haem atoxylin- 
eosin (H & E).
Areas of ischaem ic damage and brain swelling were determ ined directly  
from the stained histological sections using a com puter-assisted image 
analyser (Quantim et 970, Cambridge Instrum ents). This method of 
quantitative analysis allows the relationship betw een infarction and brain 
swelling to  be established in the same animals. The areas of ischaemic 
damage were delineated on those sections which corresponded m ost closely 
to 8 preselected  coronal levels of ra t brain from an terio r 10.5mm to anterior 
1mm (Table 1) re la tive  to the  interaural line from  the  a tlas of Konig & 
Klippel (1963) w ithout knowledge of the experim ental protocol. The areas 
of ischaem ic damage a t each coronal level w ere in tegrated  with the known 
distance betw een each coronal level to derive the  to ta l volume of ischaemic 
damage in each animal (Osborne e t al. 1987).
The volume of the  cerebral hemispheres ipsilateral and con tra la tera l to 
the occluded MCA was determ ined by in tegration from assessm ent of the 
to ta l surface area a t the  sam e 8 coronal levels employed in assessing areas 
of ischaem ic damage. The difference betw een the  two hemispheres 
(ipsilateral-contralateral) provided a m easure of brain swelling. End points 
for integration for cortex  and hemisphere w ere an terio r 12.5mm and posterior 
0.5mm. The areas and volumes of ischaemic dam age and brain swelling were
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TABLE 1
CORONAL LEVELS OF RAT FOREBRAIN 
AND THEIR ANTERIOR CO-ORDINATES
ANATOMICAL LANDMARK LEVEL CO-ORDINATE (mm)
O lfactory tra c t 1 10.50
Nucleus accumbens 2 8.92
Septal n u cle i 3 7.19
Globus p a llid u s 4 6.06
Anterior hypothalamus 5 5.15
Lateral habenula 6 3.75
Medial habenula 7 2.18
Aqueduct 8 1 .02
The 8 p rese lected  coronal le v e ls  o f ra t forebrain  drawn from 
the a t la s  of Konig & K lippel (1963),  with th e ir  anatomical 
landmarks and an terior  co -ord in ates, used to  quantify  areas 
of ischaem ic damage a fter  permanent MCA o cc lu sio n .
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expressed in absolute term s (mm2 and m m 3).
2.1.5 Dosing Regim en
CI-977, dissolved in a vehicle of isotonic saline, was te sted  a t 3 doses; viz. 
0.03mg/kg, 0.3mg/kg and 3mg/kg. Drug trea tm en t was in itiated  with a 
subcutaneous (s.c.) bolus injection 30 min prior to  MCA occlusion. Further s.c. 
injections w ere adm inistered a t 30 min, 6h, 12h and 18h a f te r  MCA occlusion 
until sacrifice  a t 24h. Control animals received s.c. injections of the  vehicle 
(1 ml/kg) a t the sam e tim e points.
2.2 4h (A naesthetised Throughout) Model in th e  R at
2.2.1 Surgical Preparation
The ra ts  w ere anaesthetised initially with a m ixture of 4% halothane, 30% 
oxygen and 70% nitrous oxide, a tracheostom y perform ed and the animals 
ventilated  m echanically th e rea fte r with a nitrous oxide/oxygen m ixture 
(70%:30%) containing 0.5-1% halothane. Inspired halothane concentration was 
adjusted betw een 0.5-1% to produce adequate anaesthesia and to  m aintain MABP 
a t 80mmHg and above prior to  drug/vehicle adm inistration. Polyethylene 
cathe te rs  (Portex: external d iam eter 0.96mm; internal d iam eter 0.58mm; length 
15cm) w ere inserted into both fem oral a rte ries  and one fem oral vein to  perm it 
the continuous monitoring of MABP (P231D Gould S tratham , Model 2202) and 
repeated  sampling of a rte ria l blood.
2.2.2 Induction o f  Focal Ischaemia
All animals then underwent exposure and proximal occlusion of the le ft 
MCA as described in the  24h (recovery from  anaesthesia) model (Section 2.1.2). 
Following MCA occlusion, the  tem poralis m uscle and so ft tissues were allowed
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to  fall back into place and the wound closed.
2.2.3 Physiological Variables
A rteria l blood samples were taken prior to  drug/vehicle adm inistration, a t 
the  tim e of MCA occlusion and a t hourly intervals th e rea fte r , until sacrifice  a t 
4h. These samples w ere used for determ ination of resp iratory  s ta tu s  (pC02, p 0 2 
and pH) by a blood gas analyser (238pH/Blood Gas System, Ciba Corning) and 
plasma glucose concentration by autom ated enzym e assay (Glucose Analyser 2, 
Beckman). R espiratory volume was adjusted to  m aintain pC 02 between 
34-42mmHg (normocapnia), and adequate a rte ria l oxygenation (p02 >100mmHg) 
was m aintained throughout. Body tem peratu re  was m onitored by a rec ta l 
therm om eter and the  animals m aintained norm otherm ic via a heating blanket 
controlled by a therm om eter. Extrem e caution was taken to  avoid any 
procedure (e.g. d irec t heating of the head) which could a lte r artifac tually  the 
gradient betw een deep body tem perature  and brain tem peratu re.
2.2.4 Neuropathology and Quantitation o f  Ischaemic Damage
Four hours a f te r  MCA occlusion, the ra ts  w ere perfusion fixed with FAM 
(40% formaldehyde, glacial ace tic  acid and absolute m ethanol in a ra tio  of 1:1:8) 
for assessm ent of early  ischaem ic damage. The halothane concentration was 
increased to  3% and the  animal placed in a supine position. The thorax was 
opened through a midline incision and a c a th e te r  inserted  into the ascending 
aorta  via the  le ft ventricle.
The righ t atrium  was incised and heparinised saline infused a t a pressure
*
equal to  the  MABP of the animal until the e ffusate  from the  righ t atrium  was 
bloodless (approximately 75ml). The animals w ere then perfused with FAM 
(approximately 200ml) a t the sam e pressure. The animals w ere then decapitated
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and the head stored in FAM for 24h. A t this tim e, the brain was carefully 
removed and stored in 70% methanol prior to  quan tita tive  neuropathology.
The cerebellum  and olfactory bulbs w ere removed and the forebrain cu t into 
4 equally spaced coronal slices. Each slice was processed, embedded in paraffin 
wax, and sectioned a t m ultiple levels (approxim ately 100 sections per brain). 
The sections (lOpm) were stained with H & E and by a m ethod combining cresyl 
violet and luxol fas t blue.
Those sections th a t corresponded m ost closely to  the  8 preselected  coronal 
levels (Table 1) w ere examined under light microscopy without prior knowledge 
of the  experim ental protocol. Regions showing evidence of ischaem ic cell 
change w ere delineated and transcribed onto scale drawings of each of the 8 
coronal levels (Figure 11). The areas of early  infarction in the cerebral 
hemisphere, cerebral cortex and caudate nucleus w ere quantified a t each level 
from the  scale diagrams using a com puter-assisted image analyser (Quantimet 
970, Cambridge Instruments). Total volumes of early ischaem ic damage were 
calcu lated  by integration as described previously (Osborne e t  al., 1987) with the 
exception th a t scale drawings were normalised to  a hem isphere of 575mm3 (i.e. 
for m ale ra ts  with body weight 350-400g) as d istinct to  th a t of 418mm3 (for 
fem ale ra ts  with body weight 150g) as employed by Osborne e t  al. (1987). The 
ischaem ic volumes and areas are expressed in absolute term s (mm and mm ).
2.2.5 Dosing Regim en
CI-977, a t the  neuroprotective dose of 0.3mg/kg, was given as s.c. 
injections 30 min before and 30 min a f te r  occlusion of the  MCA. Control 
animals received s.c. injections of the  vehicle (isotonic saline, lm l/kg) a t the 
sam e tim e points.
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2.3 6h (A naesthetised Throughout) Model in th e  C a t
2.3.1 Surgical Preparation
The cats w ere anaesthetised initially with saffan  (9mg/kg, i.v. to ta l 
steroids), intubated, and connected to a positive pressure ventila tor delivering 
nitrous oxide (70%) and oxygen (30%) in an open circu it. Polyethylene catheters  
(Portex: external d iam eter 1.65mm; internal d iam eter 1.0mm; length 30cm) were 
inserted into one fem oral vein and one fem oral artery  for the 
adm inistration of drugs and the continuous m onitoring of MABP and respiratory 
blood gas sta tus respectively. Anaesthesia was m aintained throughout the 
course of the  investigation with a nitrous oxide/oxygen m ixture (70%:30%) 
containing 1-1.5% halothane, in order to m aintain suffic ien t anaesthesia in each 
animal as determ ined by loss of the corneal reflex.
2.3.2 Induction o f  Focal Ischaemia
The c a t’s head was placed in a s te reo tac tic  fram e (Kopf, Clark 
Electrom edical) and the  le ft MCA occluded via a transorb ita l approach by an 
experienced neurosurgeon. With microsurgical techniques, the  le ft orbit was 
exenterated . The optic foramen was enlarged with a saline-cooled dental drill, 
and the postero lateral and superior walls of the orb it rem oved to  expose the dura 
m ater overlying the  MCA from the origin of the  a rte ry  to  its bifurcation. 
Under an operating microscope, the dura was incised and the  MCA exposed. 
The trunk of the MCA, all co llateral vessels and all visible branches of the 
len ticu lostria te  a rte ries  were coagulated with bipolar diatherm y, and the main 
trunk transected  with m icroscissors to  assure com pleteness of the vascular 
occlusion.
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2.3.3 Physiological Variables
Throughout the  experim ental period, MABP was m aintained constant 
betw een 80-90mmHg by increasing th e  inclination of the  hind limbs and/or 
intravenous infusion of H artm an’s solution (up to  approxim ately 100ml per cat). 
Regular samples of a rte ria l blood were drawn for determ ination of respiratory 
status (238pH/Blood Gas System, Ciba Corning), plasma glucose concentration 
(Glucose Analyser 2, Beckman), haem atocrit and osm olality. Normocapnia 
(pC02 betw een 28-32mmHg) was m aintained by adjusting the  stroke volume of 
the resp irator. M etabolic acidosis was co rrected  by adm inistration of sodium 
bicarbonate (8.4%). Body tem peratu re  was m onitored by a rec ta l therm om eter 
and m aintained norm otherm ic by means of a heating blanket controlled by a 
therm om eter. C are was taken to avoid any procedure (such as compromising 
extracranial flow or d irec t heating of the  head) which could a lte r the  relationship 
between core tem peratu re  and brain tem peratu re.
2.3.4 Neuropathology and Quantitation o f  Ischaem ic Damage
Six hours a fte r  the induction of ischaem ia, the  ca ts  were killed by 
transcardiac perfusion fixation with FAM. The halothane concentration was 
increased to 3%, and the c a t placed in a supine position and heparinised. A 
thoracotom y was perform ed and a cannula introduced into the  ascending aorta 
via the le f t ventricle. The right atrium  was cu t and physiological saline infused 
a t a pressure equal to  the  MABP of the animal until the  e ffu sa te  was bloodless 
(approximately 250ml). The animals were then perfused with approxim ately 1.51 
of FAM a t the  sam e pressure. The cats w ere decapita ted , and the  head stored 
in FAM a t 4°C for a t least 12h. The brain was then removed and stored in 70% 
m ethanol prior to  neuropathological exam ination.
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The le ft side of the forebrain was marked with Indian ink. The hindbrain 
was detached by a cu t through the  midbrain and the cerebral hemispheres cut 
into 5 equally spaced coronal slices. The slices were embedded in paraffin  wax 
and sections (7-8ym) cu t a t 200pun intervals throughout the  slices (approximately 
150-200 sections per forebrain). The sections w ere stained by H & E and by a 
m ethod combining cresyl violet and luxol fast blue.
Those sections th a t corresponded m ost closely to  16 preselected  coronal 
levels of c a t brain from anterior 22mm to  posterior 6mm re la tive  to  the 
in teraural line from the  atlas of Reinoso-Suarez (1961) w ere examined by light 
microscopy w ithout prior knowledge of the anim als’ history. Areas of early 
infarction were charted  onto scale anatom ical diagrams (x 2.21 actual size) a t 
each of the 16 levels (Figure 16). Areas and volumes of ischaem ic damage were 
then derived by integration in a method analogous to  th a t described for the ra t 
4h (anaesthetised throughout) model (Section 2.2.4). End points for integration 
for cortex  and hem isphere were an terior 28mm and posterior 12mm.
.5 Dosing Regim en
CI-977 (0.3mg/kg) dissolved in a vehicle of isotonic saline was adm inistered 
as a slow (3 min) intravenous (i.v.) injection 15 min before occlusion of the  MCA. 
A constant i.v. infusion of CI-977 (0.15mg/kg/h) was in itia ted  im m ediately and 
m aintained th e rea f te r until death. Control animals received a bolus injection 
of the  vehicle (lm l/kg, i.v.) 15 min prior to  the induction of ischaemia. An i.v. 
infusion of the vehicle (0.15ml/min) was in itiated  im m ediately th e rea f te r and 
m aintained until death.
Samples of a rte ria l blood were withdrawn a t  hourly intervals throughout 
the experim ental period, centrifuged, and plasma levels of CI-977 determ ined 
by radioimmunoassay.
(Determ ination of CI-977 plasma levels by radioimmunoassay was carried 
out by Dr. Steven Rose, Parke-Davis, Ann Arbor, U.S.A.).
2.4 S ta tis tica l Analysis
All data  are presented as mean ± standard errors of the  mean (SEM). 
Volumes of ischaem ic damage in the  control and drug-treated  groups were 
com pared with one-tailed S tudent’s t- te s t because of the  a priori decision to 
examine only the ability of the drug to  reduce the  volume of ischaem ic damage. 
All o ther s ta tis tica l comparisons betw een experim ental groups were perform ed 
with tw o-tailed  S tudent’s t- te s t. Analysis of variance (ANOVA) with subsequent 
intergroup comparison by Student’s t- te s t with appropriate Bonferroni correction 
was used when m ultiple groups were examined. C orrelation analysis was carried 
out by linear regression (Pearson’s).
3. INVESTIGATIONS INTO MECHANISMS UNDERLYING THE NEUROPROTECTIVE 
EFFICACY OF CI-977
3.1 C erebral Blood Flow a f te r  MCA Occlusion in th e  R at
3.1.1 Surgical Preparation
The animals w ere anaesthetised, a tracheostom y perform ed and artificially  
ventilated  under halothane anaesthesia as described elsew here (Section 2.2.1). 
Polyethylene ca th e te rs  (Portex: external d iam eter 0.96mm; internal d iam eter
0.58mm; length 15cm) were inserted into both fem oral a rte ries  (for continuous 
m onitoring of MABP and repeating sampling of a rte ria l blood) and one femoral 
vein (for adm inistration of the  radioactive tracer).
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3.1.2 Induction o f  Focal Ischaemia
All animals underwent exposure and proximal occlusion of the le ft MCA 
as described in the  4h (anaesthetised throughout) model in the r a t  (Section 2.2.2).
3.1.3 M easurement o f  Local Cerebral Blood Flow
Local cerebral blood flow (CBF) was m easured 30 min a f te r  occlusion of 
the  MCA with the  quantita tive  autoradiographic technique using [14C]- 
iodoantipyrine as a tra c e r as described by Sakurada e t  al. (1978). A ramped 
infusion of 50]iCi of [14C]-iodoantipyrine in 1.5ml of saline was infused 
intravenously over 30 sec. During the isotope infusion, 15-18 tim ed samples of 
a rte ria l blood w ere collected onto preweighed filte r  paper discs in a perspex 
carousel. The ra t  was killed by decapitation approxim ately 30 sec a fte r  the 
s ta r t  of isotope infusion. The brain was rapidly removed and frozen in 
isopentane (-42°C) for a t least 10 min for la te r processing. The filte r paper 
discs containing the blood samples were placed in preweighed glass vials, sealed, 
and reweighed to  obtain the weight of each blood sam ple. Hydrogen peroxide 
(30% wt/vol, 0.4ml) and distilled w ater (1ml) w ere added to  each vial to  bleach 
the blood sample and ex trac t the radioisotope, and the  vials le ft a t  room 
tem peratu re  for 30 min. 10ml of scin tillan t (Ecoscint A, National Diagnostics) 
was then added. The trace r concentration in each sam ple was determ ined 24h 
la te r by liquid scintillation counting (Packard Tricarb, 1900CA).
3.1.4 Physiological Variables
A rteria l blood samples were taken prior to  drug/vehicle adm inistration, a t 
the tim e of MCA occlusion and a t the tim e of cerebral blood flow m easurem ent 
for determ ination of respiratory  status (238pH/Blood Gas System, Ciba Corning) 
and plasma glucose concentration (Glucose Analyser 2, Beckman). Body
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tem perature  was m aintained in norm otherm ia by means of a heating blanket 
controlled by the rec ta l therm om eter.
3.1.5 Processing o f  Autoradiograms
The frozen brains w ere embedded in a histological medium. Coronal 
sections were cu t in a cryosta t a t -22°C, and 3 in every 13 sections were 
m ounted in glass coverslips and dried on a ho tp late  a t 60°C. Sections were 
apposed to X-ray film (Kodak GRL) along with a se t of precalibrated  [14C] 
standards (concentration range 44-1475nCi/g) in ligh t-tight X -ray cassettes for 
14 days.
3.1.6 D ensitom etric Analysis o f  Autoradiograms
M easurem ent of optical density was carried  out with two different 
approaches, using a com puter based analysis system  (Q uantim et 970, Cambridge 
Instruments).
The first approach was to  m easure the optical density in 25 
neuroanatom ically predefined brain areas identified according to  the atlas of 
Konig and Klippel (1963). Optical densities w ere determ ined in regions of 
in te rest (fram e size 0.1-0.3mm2 depending on region) in the  hemispheres 
ipsilateral and con tra la tera l to the  occluded MCA, by taking the  average of the 
results from  six adjacent sections a t each neuroanatom ical locus.
The second approach was to  determ ine the volume of cerebral tissue in both 
hemispheres perfused with various levels of cerebral blood flow using cumulative 
frequency distribution analysis. Optical density thresholds were se t th a t 
corresponded to  increm ents of cerebral blood flow, i.e. 0-10, 10-20, 20-25, 25- 
30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-250ml lOOg'1 m in '1. 
The blood flow distribution was then assessed in both hem ispheres a t each of the
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8 preselected  coronal levels used for volum etric quantification of ischaem ic brain 
dam age (Table 1, Figure 11). The area of each hem isphere was delineated with 
the image analyser over one section a t each of the  8 coronal planes, and the 
to ta l area recorded. By setting  lim its of optical densities computed to 
correspond to  particu lar ranges of cerebral blood flow, the  size of areas 
corresponding to  the regions within which cerebral blood flow was in this range, 
was obtained. The to ta l volume of cerebral tissue within each cerebral blood 
flow range in both hemispheres was then computed by in tegration in a manner 
analogous to th a t used for volum etric assessm ent of ischaem ic damage in the 
ra t  (Section 2.2.4). The volumes of cerebral blood flow within each range were 
then added in sequence to one another, to  yield volumes of each hemisphere 
perfused by increasing ranges of cerebral blood flow.
3.1.7 Calculation o f  Cerebral Blood Flow
With each densitom etric approach, local cerebral blood flow was calculated 
from (a) the tim e course history of [14C]-iodoantipyrine in a rte ria l blood, (b) [14C] 
concentration in cerebral tissue and (c) the cerebral tissuerblood partition 
coeffic ien t for iodoantipyrine (0.79), using the operational equation derived 
originally by Kety (1951) and as described by Sakurada e t  al. (1978) (Figure 4).
3.1.8 Dosing Regim en
CI-977 (0.3mg/kg), dissolved in a vehicle of isotonic saline, was 
adm inistered as a s.c. injection 30 min before occlusion of the MCA. Control 
animals received a s.c. injection of the  vehicle (1 ml/kg) a t  the  sam e tim e point.
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Ci(T) = ^KfT Cae'K(T ’l) dt 
J o
FIGURE 4
O perational equation for determ ination of the ra te  of cerebral blood flow. 
Ci(T)equals the  tissue concentration of tra ce r a t a given tim e, T, a fte r the i.v. 
injection of the tracer; A. equals the tissue:blood partition  coefficien t; Ca is the 
trace r concentration in a rte ria l blood; t  is the variable tim e. K is a constant 
defined as m F/WA.. F/W equals the  ra te  of blood flow per unit mass of tissue; m 
is a constant equal to 1 th a t represents a m easure of the unrestric ted  trace r 
diffusion across the blood-brain barrier.
The ra te  of blood flow per unit mass (F/W) can be calculated from  the final 
concentration of tra c e r in cerebral tissue (Ci(T); obtained from  autoradiograms), the 
concentration of tra ce r in a rte ria l blood from tim es 0-T, and th e  tissue:blood 
partition  coeffic ien t of 0.79. (Adapted from Sakurada e t  al., 1978).
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3.2 G lutam ate N eurotoxicity in vivo
3.2.1 Surgical Preparation
R ats were anaesthetised, a tracheostom y perform ed, and gaseous 
anaesthesia, delivered via a m echanical ventilator, m aintained th e rea f te r as 
described previously (Section 2.2.1). Polyethylene ca th e te rs  (Portex: external 
d iam eter 0.96mm; internal d iam eter 0.58mm; length 15cm) were inserted into 
both fem oral a rte ries  and one fem oral vein to  perm it the  continuous 
m onitoring of MABP and repeated  sampling of arte ria l blood, and the 
adm inistration of drugs respectively.
3.2.2 Microdialysis Probe Implantation
The animals w ere turned prone and mounted in a s te reo tac tic  fram e 
(Kopf, C larke Electrom edical). The right parie tal skull was exposed and, 
under an operating m icroscope, a craniectom y was made with a saline-cooled 
dental drill. The dura was widely opened and the pia incised using a small 
needle. A microdialysis probe (CMA12: m em brane length 3mm, outside 
d iam eter 0.5mm; Carnegie Medicine, Sweden) was "angled a t  15° to  the 
sag itta l plane and s te reo tac tica lly  implanted into the  parie ta l cortex  a t a 
depth of 3.5mm. S te reo tac tic  co-ordinates for probe placem ent were 
anteroposterior 0.0mm, m ediolateral 4.0mm re la tive  to  Bregma.
3.2.3 G lutam ate Perfusion
A fte r placem ent in the cortex , the microdialysis probe was perfused with 
mock cerebrospinal fluid (CSF) (NaCl 135mM, KC1 ImM, KH2P 0 4 2mM, CaCl2 
1.2mM, MgCl2 ImM, pH 7.4) a t a flow ra te  of 1.5pd/min using a microinfusion 
pump (CMA/100; Carnegie Medicine, Sweden) for 30 min. The probe was then 
perfused with a 0.5M glu tam ate solution (0.5M monosodium glutam ate
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dissolved in mock CSF) for 90 min, a f te r  which tim e the  probe was removed 
and the  scalp wound closely sutured.
The size and reproducibility of the lesion is re la ted  to  the glutam ate 
concentration delivered by the microdialysis probe. Thus, on the basis of a 
prior investigation characterising the  dose-dependency of g lu tam ate in this 
novel in vivo model of excito toxicity  (Landolt e t  al. 1993), 0.5M glutam ate 
was selected .
3.2.4 Physiological Variables
Body tem pera tu re  was m aintained in norm otherm ia throughout by means 
of a heating blanket controlled by a rec ta l therm om eter. A rterial blood gas 
analysis (238pH/Blood Gas System, Ciba Corning) and determ ination of plasma 
glucose concentration (Glucose Analyser 2, Beckman) w ere perform ed prior 
to drug/vehicle adm inistration, a t the s ta r t  of g lu tam ate  perfusion and a t one 
hourly intervals th e re a fte r  until sacrifice.
3.2.5 Quantitation o f  Neuronal Damage
Four hours a f te r  the  s ta r t  of g lutam ate perfusion (i.e. 2.5h a fte r  removal 
of the m icrodialysis probe) the animals were killed by decapitation, the  brain 
removed, and frozen in isopentane a t -42°C. 20pun coronal sections were cu t 
on a cryostat. Three serial sections were taken a t 200pim intervals throughout 
the  brain and stained with H & E. The areas of brain damaged w ere m easured 
directly  from the  histological sections on an image analyser (Quantim et 970, 
Cambridge Instrum ents). The damaged area a t each level was determ ined by 
calculating the  average of the 3 serial sections. The volume of dam age was 
then derived by summing the damaged areas and multiplying by the  interval 
thickness betw een sections.
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3.2.6 Dosing Regim en
CI-977 (0.3mg/kg), in a vehicle of 5.5% glucose solution, was 
adm inistered as an i.v. bolus injection 30 min before and 30 min a fte r  the 
s ta r t  of g lu tam ate perfusion. Control animals received the vehicle (lm l/kg, 
i.v.) a t  the  sam e tim e points.
The AMPA recep to r antagonist NBQX (30mg/kg i.v.; 30 min pre- and 30 
min post-onset of g lu tam ate perfusion) and the  non-com petitive NMDA 
recep to r antagonist MK-801 (0.5mg/kg i.v.; 30 min prior to  the s ta r t  of 
g lu tam ate perfusion) were also assessed for th e ir efficacy  against g lu tam ate 
toxicity  in vivo . The dosing paradigms w ere selec ted  on the basis of their 
anti-ischaem ic e ffec ts  in the  ra t perm anent MCA occlusion model (Gill e t  al., 
1992b; Park e t al., 1988b). The inclusion of NBQX necessita ted  the use of 
5.5% glucose solution as the  vehicle.
3.3 The Relationship betw een G lutam ate R elease and C erebral Blood Flow a f te r  
Focal Ischaem ia in th e  C a t
3.3.1 Surgical Preparation
The ca ts  were anaesthetised, intubated, and m aintained th e rea fte r under 
halothane anaesthesia delivered by a m echanical ven tila to r as described 
previously (Section 2.3.1). Polyethylene ca th e te rs  (Portex: external d iam eter 
1.65mm; internal d iam eter 1.0mm; length 30cm) w ere inserted into one 
femoral vein (for the  adm inistration of drugs) and two fem oral arte ries  (for 
continuous monitoring of MABP, repeated  sampling of a rte ria l blood and 
controlled withdrawal of arte ria l blood for induction of hypotension). 
Haem orrhagic hypotension increases the severity  of ischaem ia (Osborne e t  al. 
1987).
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3.3.2 Microdialysis Probe/Hydrogen Electrode Implantation
The parie ta l skull was exposed and, under an operating microscope, 
craniectom ies 7 -10mm in diam eter were m ade with a saline-cooled dental 
drill above the righ t and le ft suprasylvian gyri. A microdialysis probe (CMA 
10: m em brane length 1mm, outside d iam eter 0.5mm; Carnegie Medicine, 
Sweden) and an electrode (etched platinum /iridium  wire, d iam eter: 250)im, 
teflon coated up to  1mm of the tip; C larke E lectrom edical) w ere assembled 
with a tip -to -tip  d istance of 1mm. The dura was widely opened, and the pia 
arachnoid pierced with a small needle. Two probe/electrode assemblies were 
implanted s te reo tac tica lly  into the left suprasylvian gyrus, and one into the 
right suprasylvian gyrus, a t a depth of 1.5mm. Following placem ent, 
craniectom ies were sealed with cyanoacrylate glue, and assemblies fixed in 
place with dental cem ent.
3.3.3 D ialysate Collection
Microdialysis probes were perfused continuously with Krebs-Ringer 
bicarbonate solution (NaCl 122mM, KC1 3mM, C aC l2 I.2mM, MgS04 1.2mM, 
KH2P 0 4 0.4mM, N aH C 03 25mM, pH 7.4) a t a constant flow ra te s  of 2pd/min 
using a microinfusion pump (CMA/100; Carnegie Medicine, Sweden). The 
probes w ere then le ft for a stabilisation period of approxim ately 2h, during 
which tim e any dialysate samples collected w ere discarded.
A fter the stabilisation period dialysates were co llected  in 20 min 
fractions, to ta l volume 40pd. Two baseline sam ples w ere collected, and 
CI-977 or vehicle was adm inistered 30 min prior to  MCA occlusion. A further 
fraction was co llected  over the subsequent 20 min and th e  le ft MCA 
perm anently occluded. T hereafter, MABP was reduced in 10-15mmHg 
decrem ents by withdrawal of arteria l blood. D ialysate samples were taken
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when MABP had stabilised a t each decrem ent (approximately 10-15 min). 
This procedure was repeated  down to a minimum MABP a t 40mmHg. The 
animals were sacrificed by barb itu rate  overdose a t the  end of experim ent.
3.3.4 M easurement o f  Cerebral Blood Flow
The platinum electrodes were used to  m easure cortical cerebral bood 
flow by means of the hydrogen clearance technique. During the  stabilising 
period a f te r  assembly placem ent, the  electrodes w ere connected to  a 
reference c ircu it and polarised a t a fixed voltage of +700mV. A t the tim e 
of cerebral blood flow m easurem ent the  gaseous anaesthesia delivered was 
changed to a nitrous oxide/oxygen/hydrogen m ixture (30%:30%:30%) 
containing 1-1.5% halothane. A hydrogen satu ration  period of 10 min was 
followed by 10 min for clearance. The cerebral blood flow was calculated 
using the initial slope index method. D ata w ere co llected  over a 1 min 
period, 1 min a fte r  the hydrogen gas m ixture had been removed. The data 
were fitted  to an experim ental curve and the flow calculated  from the  slope 
(Young, 1980). The firs t m inute of the  c learance curve was discarded to 
avoid a rtifa c ts  due to recirculating hydrogen.
C erebral blood flow values were determ ined sim ultaneously with the 
collection of each sample of dialysate.
3.3.5 Induction o f  Focal Ischaemia
The c a t’s head was placed in a s te reo tac tic  fram e. The le ft MCA was 
exposed and occluded via a transorbital approach by an experienced 
neurosurgeon as described previously (Section 2.3.2).
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3.3.6 Physiological Variables
Regular samples of a rte ria l blood were taken throughout the  experim ent 
for determ ination of respiratory  blood gas sta tu s  (238pH/Blood Gas System, 
Ciba Corning) and plasma glucose concentration (Glucose Analyser 2, 
Beckman). Animals w ere m aintained norm otherm ic throughout by a 
therm ostatically  controlled heating blanket. A therm istor probe was also 
inserted periosteally, overlying the parie tal cortex , via a scalp incision 
ipsilateral to  the MCA to be occluded.
3.3.7 Dosing Regim en
CI-977 (0.3mg/kg) dissolved in isotonic saline was adm inistered as a slow 
(3 min) intravenous injection 30 min before occlusion of the  MCA. A 
constant intravenous infusion of CI-977 (0.15mg/kg/h) was initiated
im m ediately and m aintained th e rea fte r until death. Control animals received 
a bolus injection of isotonic saline (lm l/kg i.v.) 30 min prior to MCA 
occlusion. An intravenous infusion of saline (0.15ml/min i.v.) was initiated 
im m ediately th e rea f te r and m aintained until death. 'C o n tro l animals were 
trea ted  contem poraneously and randomised with the  d rug-treated  animals. 
This is th e  sam e dosing regimen employed in the  neuroprotection study in 
the c a t (Section 2.3.5).
3.3.8 D eterm ination o f  M icrodialysate Amino A cid  C ontent
D ialysate amino acids were de tec ted  fluorom etrically  following 
precolumn derivatisation with orthophthaldialdehyde according to  the method 
of Lindroth and Mopper (1979). Separation of 6 amino acids of in te rest was 
achieved under these conditions, in the following order:
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A spartate , G lutam ate, Asparagine, Serine, Glutamine, Glycine, 
Threonine, Arginine, Taurine, Alanine, GABA, Tyrosine.
(Analysis of m icrodialysate fractions was carried  out by Dr. P.K. H itchcott, 
Parke-Davis, Cambridge, U.K.).
3.4 S ta tis tica l Analysis
All data  are presented as mean ± standard errors of the  m ean (SEM). 
Comparisons betw een groups were made using tw o-tailed  S tudent’s t-tes t. 
Intergroup comparisons were made using a paired t- te s t. One-way analysis 
of variance (ANOVA) followed by Student’s t- te s t with appropriate Bonferroni 
correction was used for simultanous m ultiple comparisons.
In the  glutam ate release study the central hypothesis was prim arily to 
examine the  relationship betw een cerebral blood flow and g lu tam ate release 
a fte r perm anent MCA occlusion in the ca t, and w hether CI-977 p re trea tm en t 
had any e ffe c t on this relationship. The concept of dimensionality in 
scien tific  experim ents is commonly ignored. In th is 's tudy  for example, in 
the  control group there  are 5 cats, each with 3 microdialysis probes in the 
cortex, sampling m ore than once a t each cerebral blood flow decrem ent and 
thus it is im practical to suggest th a t each m easurem ent is independent of 
another. The data  in this investigation was therefo re  s ta tis tica lly  analysed 
using an indicative S tudent’s t- te s t, uncorrected for Bonferroni’s adjustm ent. 
P aram etric  s ta tis tic s  w ere used even although there  may have been evidence 
of an abnormal distribution of data.
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4. THE EFFECT OF CI-977 ON CEREBRAL GLUCOSE USE AND CEREBRAL 
BLOOD FLOW IN THE NORMAL BRAIN
4.1 [u C]-2-Deoxyglucose Autoradiography
4.1.1 Surgical Preparation
Polyethylene cannulae (Portex: external d iam eter 0.96mm; internal 
d iam eter 0.58mm; length 15cm) were inserted into both fem oral arteries (to 
allow continuous monitoring of MABP and sampling of a rte ria l blood) and one 
fem oral vein (for adm inistration of drugs and the  radioactive tracer) during 
a brief period (approximately 35 min) of light halothane anaesthesia (1% in 
70% nitrous oxide/30% oxygen) delivered via a face mask. The incision sites 
were in filtra ted  with a local anaesthetic  gel (xylocaine, 2%) and closed. The 
animals w ere fitted  with a loose fitting  p laster cast around the  pelvis and 
lower abdomen, with care taken not to re s tr ic t thoracic movements. The 
anaesthetic  gas m ixture was discontinued, and the  animals allowed to recover 
for a t least 2h before any fu rther manipulations were perform ed. A t this 
tim e the conscious, lightly restrained animals displayed normal grooming 
behaviour and appropriate reactions to slight auditory and sensory stim uli.
4.1.2 M easurement o f  Local Cerebral Glucose Utilisation
Local cerebral glucose use in the fully conscious r a t  was m easured by 
[14C]-2-deoxyglucose autoradiography as described by Sokoloff e t  al. (1977).
M easurem ent was in itiated  by the  i.v. adm inistration, over 30 sec, of 50)iCi 
[14C]-2-deoxyglucose in 0.7ml of physiological saline. Fourteen tim ed arteria l 
blood samples were taken throughout the following 45 min. The blood 
samples w ere centrifuged im m ediately, and th e  plasma assayed for [14C]- 
tra ce r concentration (liquid scintillation analysis) and glucose concentration 
(Glucose Analyser 2, Beckman). Approximately 35 min a f te r  isotope
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adm inistration, a sample of a rte ria l blood was taken for analysis of 
resp iratory  sta tus (238pH/Blood Gas System, Ciba Corning). A t 45 min post­
isotope adm inistration the animals were decapitated , and the  brain rapidly 
removed and frozen in isopentane a t -42°C prior to  processing for 
autoradiography.
4.1.3 Physiological Variables
Samples of arte ria l blood were taken prior to  drug/vehicle and 
radioisotope adm inistration, and approxim ately 35 min a fte r  [14C]-2- 
deoxyglucose adm inistration for analysis of resp ira tory  blood gas sta tus (p02, 
p C 0 2, pH). R ectal tem peratu re  was m easured in all animals, and 
norm otherm ia m aintained by external heating lamps. A rteria l pressure was 
m onitored continuously.
4.1.4 Processing o f  ^C]~2-Deoxyglucose Autoradiograms
20jjLm coronal sections were cu t on a c ryosta t a t -22°C, and 3 in every 
13 sections were taken and thaw-m ounted onto glass coverslips on a hotplate 
a t 60°C. The brain sections were apposed to  X -ray film (Kodak GRL) along 
with precalibrated plastic standards (concentration range 44-1475nCi/g) in a 
light-tight X-ray casse tte  for 14 days.
4.1.5 D ensitom etric Analysis
Local tissue concentrations of [14C] w ere determ ined from the 
autoradiogram s by means of a com puter-based densitom etry system  
(Quantim et 970, Cambridge Instruments). For each of the  45 brain regions 
examined in every animal, 12 b ilateral density readings w ere m ade on a series 
of 6 consecutive sections in which the s tructu re  could be defined anatom ically
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by reference to the stereotaxic atlas of Paxinos and Watson (1986).
4.1.6 Calculation o f  Glucose Use
Local cerebral glucose utilisation was determ ined in all 45 regions of 
in te rest according to the operational equation described by Sokoloff e t  al. 
(1977) (Figure 5) from  (a) the arte ria l plasma [14C] and glucose histories (b) 
the  [14C] concentration in cerebral tissue and (c) the  lumped constant and 
kinetic ra te  constants for the ra t.
4.1.7 Dosing Regim en
CI-977 (0.03, 0.3, or 3mg/kg), freshly dissolved in a vehicle of isotonic 
saline, was injected i.v. over 60 secs, 15 min prior to  the  m easurem ent of 
cerebral glucose utilisation. Control animals received a sim ilar volume of 
the vehicle (1 ml/kg) a t the sam e tim e point.
4.2 [14C]-Iodoantipyrine Autoradiography
4.2.1 Surgical Preparation
All ra ts  were surgically prepared for [14Cj-iodoantipyrine autoradiography 
exactly as described previously (Section 4.1.1). The ra ts  w ere allowed to 
recover from anaesthesia for a t least 2h prior to  any fu rther trea tm en t.
4.2.2 M easurem ent o f  Local Cerebral Blood Flow
Local cerebral blood flow was m easured by [14C]-iodoantipyrine 
autoradiography as described previously in the  halothane-anaesthetised  ra t  
(Section 3.1.3) but with a minor m odification of the  m ethod of Sakurada e t 
al. (1978). A ram ped infusion of 50jiCi of [14C]-iodoantipyrine in 0.7ml of 
saline was infused over 60 sec. The infusion ra te  during the  firs t 5 sec was
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Ci*(T) - k* e '(k* +k3)T J QCp*e ^  2+k 3 )l dt
K. [ (Cp* /Cp)dt - e "( k 2 + k 3 )T  J o(Cp*/Cp) e ( k 2 + k 3 )l dt]
FIGURE 5
O perational equation for determ ination of the ra te  of cerebral glucose utilisation. 
The ra te  of glucose utilisation, Ri, in any region of cerebral tissue is calculated 
from: the  to ta l tissue concentration of [14C] in th a t region, Ci (obtained from 
autoradiogram s), a t a given tim e T; the  concentrations of I14C]-2-deoxyglucose and 
glucose in the plasma (Cp and Cp respectively) a t given tim es, t, throughout the 
experim ent; the  ra te  constants k1 , k2 and k3 for deoxyglucose transport to  and 
from plasma and tissue precursor pools, and for phosphorylation of deoxyglucose by 
hexokinase; and from the  lumped constant, K. K is composed of the rela tive  
distribution volumes for deoxyglucose and glucose, the  ra tio  of M ichaelis-Menten 
constants, the maximal velocities of hexokinase for deoxyglucose and glucose, and 
the  fraction  of glucose-6-phosphate which continues via the  glycolytic pathway for 
fu rther m etabolism . (Adapted from Sokoloff e t al., 1977).
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13% of the final infusion ra te  and was increased progressively for each 
succeeding 5 sec interval. The ramp infusion schedule minimises 
equilibration in tissues with high cerebral blood flow with a rte ria l blood during 
the period of m easurem ent. Moreover, even in regions of low cerebral blood 
flow such as w hite m a tte r, the intravascular isotope concentration (Ohno e t 
al. 1987) leads to  only an underestim ation of cerebral blood flow of less than 
5% under control conditions (Nehls e t al. 1990).
4.2.3 Physiological Variables
Samples of arte ria l blood were analysed prior to  adm inistration of the 
drug/vehicle and radioisotope for determ ination of respiratory  status 
(238pH/Blood Gas System, Ciba Corning) and arte ria l plasma glucose 
concentration (Glucose Analyzer 2, Beckman). R ectal tem peratu re  was 
m easured in all animals, and the ra ts  m aintained norm otherm ic by external 
heating lamps.
4.2.4 Processing o f  ^Q -Io d o a n tip yr in e  Autoradiograms
20jjun coronal sections were cu t on a c ryostat a t -22°C, and 3 in every 
13 sections w ere taken and thaw-m ounted onto glass coverslips on a hotplate 
a t 60°C. Autoradiograms were generated by exposing the  brain sections 
along with a se t of precalibrated standards (44-1475nCi/g) to X-ray film 
(Kodak SB-5) in ligh t-tight X-ray cassettes for 6 days.
4.2.5 D ensitom etric Analysis
The m ean optical density was m easured for each region of in te rest as 
the  average of 12 b ila teral m easurem ents on 6 consecutive sections. A 
com puter based densitom eter (Quantim et 970, Cam bridge Instrum ents) with
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several fixed fram e sizes was made to  m easure the optical density in 45 
predeterm ined loci, defined with reference  to  the  atlas of Paxinos and Watson 
(1986).
4.2.6 Calculation o f  Cerebral Blood Flow
Local cerebral blood flow was determ ined in all 45 regions of in terest 
as described previously (Section 3.1.7; Figure 4).
4.2.7 Dosing Regim en
CI-977 (0.3mg/kg) was injected i.v. over 60 secs, 15 min prior to the 
m easurem ent of local cerebral blood flow. Control animals received an i.v. 
injection of the vehicle (isotonic saline, 1 ml/kg) a t the sam e tim e point.
4.3 S ta tis tica l Analysis
All da ta  are presented as mean ± standard errors of the  m ean (SEM). 
Comparisons betw een experim ental groups w ere made using unpaired, two- 
tailed S tudent’s t- te s t. Analysis of variance (ANOVA) with subsequent 
intergroup comparison by Student’s t- te s t with appropriate Bonferroni 
correction was used when m ultiple trea tm en t groups were examined.
The relationship betw een local cerebral blood flow and local cerebral 
glucose use in veh icle-treated  and drug-treated  (CI-977, 0.3mg/kg) animals 
was assessed using the s ta tis tica l s tra tegy  described previously (McCulloch 
e t al., 1982). This involves a repeated  m easures analysis of log transform ed 
data to  identify the  presence of heterogeneities in the  relationship between 
local cerebral blood flow and glucose use. Regions in which th e  relationship 
is altered  are  identified by two sided follow-up tests .
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CHAPTER III 
RESULTS
1. CI-977 AND ISCHAEMIC BRAIN DAMAGE
1.1 24h (Recovery from  Anaesthesia) Model in th e  R at
1.1.1 Post-O perative R ecovery
During the 24h post-occlusion survival period, all animals exhibited 
piloerection and adopted a hunched posture. The animals generally appeared 
apathetic  and re luc tan t to  move e ither spontaneously or in response to  tac tile  
stim ulation; normal grooming behaviour and exploratory sniffing m ovements 
were absent in all animals.
Following cessation of anaesthesia, m oderate to  deep sedation (i.e. the 
animal was arousable with painful stim ulation) and delayed awakening from 
anaesthesia was observed with the  highest dose of CI-977 (3mg/kg) examined. 
Mild sedation (i.e. arousable with gently ta c tile  stim ulation and positive 
spontaneous activity) resulted  from trea tm en t with 0.3mg/kg CI-977, whilst 
no sedation was noted with the  lowest dose of CI-977 (0.03mg/kg).
1.1.2 Neuropa thology Examina tion
Perm anent occlusion of the le ft MCA produced ischaem ic damage 
predominantly within the frontal, sensory m otor and parie ta l co rtices, and the 
dorsolateral caudate nucleus. When outcom e is assessed a t 24h a f te r  the 
induction of ischaemia, the  boundary betw een infarcted  brain tissue and 
normal brain tissue is easily seen w ithout m agnification in the  H & E stained 
sections (Figure 6). The area  of pannecrosis in the  cortex  and caudate 
nucleus, and the ex ten t of hemispheric swelling are readily delineated and 
quantified in the hemisphere ipsilateral to  the occluded MCA.
Areas of g rea te r infarction re la tive  to  swelling w ere observed in the 
rostra l s te reo tac tic  coronal planes betw een anterior 10.5mm and anterior 
6.06mm (Figure 6). In contrast, areas of g rea te r swelling re la tive  to
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FIG U RE 6
A representative photomicrograph (x7) of a coronal ra t  brain section taken a t the 
level of the caudate nucleus and stained with H & E 24h a fte r  permanent MCA 
occlusion in a vehicle-treated control animal (upper) and the areas of infarction and 
areas of swelling a t  each of the 8 pre-determined s tereo tac tic  levels in all (n=8) 
control animals (lower). Data are presented as mean ± SEM. The region of the 
ischaemic infarct is evident as an area of pallor with a discrete boundary. In 
addition, note the exten t of swelling in the ipsilateral hemisphere when compared 
to the contralateral hemisphere.
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infarction w ere noted in the caudal coronal planes towards the  m argins of 
MCA te rrito ry , i.e. s te reo tac tic  planes posterior to  plane 6.06mm an terio r to 
the in teraural line (Figure 6).
1.1.3 Volumetric Assessm ent o f  Ischaemic Damage and Brain Swelling
The s .c . adm inistration of CI-977 (0.03, 0.3 or 3mg/kg) 30 min before 
and 30 min a f te r  MCA occlusion and a t 6 hourly intervals th e re a f te r  produced 
dose-dependent reductions in the  volume of infarction in the  cerebral 
hemisphere, the m ost m arked reduction in infarction (reduced by 38% from 
veh icle-treated  controls; p<0.02) was observed with CI-977 (0.3mg/kg) 
(Figure 7).
T reatm ent with CI-977 in itiated  30 min prior to MCA occlusion (and 
repeated a t m ultiple tim es thereafter) produced dose-dependent reductions 
in the volume of brain swelling, with the  m ost m arked reduction in swelling 
(reduced by 31% from veh icle-treated  controls; p<0.01) being observed with 
CI-977 (0.3mg/kg) (Figure 7). The volume of the  hem isphere con tra la tera l 
to MCA occlusion was unaltered by CI-977 trea tm en t a t  any of the  doses 
studied, e.g. control 562 ± 10mm3; CI-977 (0.3mg/kg) 572 ± 12mm3.
There was an excellent linear relationship betw een the  volume of 
ischaemic dam age and the volume of swelling (Figure 8) which was sim ilar for 
vehicle-treated  control animals and all C I-977-treated groups with an overall 
concentration coeffic ien t r  = 0.896 (p<0.001), and the  slope of the  relationship 
being 0.489.
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FIGURE 7
The effec t of CI-977 upon the volume of infarction (upper) and the volume of brain 
swelling (lower) assessed 24h afte r  permanent MCA occlusion in the ra t .  Data are 
presented as mean ± SEM with controls n=8; CI-977, 0.03mg/kg n=5; 0.3mg/kg n=8; 
3mg/kg n=7. *P<0.02, **P<0.01 compared to vehicle-treated control animals
(ANOVA followed by one-tailed t- tes t  with Bonferroni correction).
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FIG URE 8
The relationship between the volume of infarction and the volume of swelling in 
individual animals 24h after the induction of ischaemia. There is an excellent 
(P<0.001) linear correlation between the two variables (r = Pearson’s correlation 
coefficient, m = slope) which is similar for all trea tm ents.
# ,  Vehicle; O, CI-977 (0.03mg/kg); □ ,  CI-977 (0.3mg/kg); A, CI-977 (3mg/kg).
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1.2 4h (A naesthetised Throughout) Model in th e  R at
1.2.1 Cardiovascular and Respiratory Status
The s.c. adm inistration of CI-977 (0.3mg/kg) induced a m arked and 
sustained hypotension. Five m inutes a f te r  the  firs t injection of CI-977, 
MABP was reduced by 30% of control levels (control: 93 ± 5mmHg; CI-977: 
64 ± 3mmHg, p<0.001) (Figure 9). Significant hypotension persisted 
throughout the post-occlusion period. The second injection of CI-977 
(0.3mg/kg) 30 min a fte r  MCA occlusion produced no fu rther reduction in 
MABP (Figure 9). The adm inistration of the  vehicle (isotonic saline, lm l/kg) 
did not a lte r MABP. There w ere no significant differences betw een the two 
groups with respect to respiratory  blood gas s ta tu s  or rec ta l tem perature, 
but the adm inistration of CI-977 induced a significant reduction (10%; p<0.05) 
in arte ria l plasm a glucose in the post-occlusion period (Table 2).
1.2.2 Neuropa thology Examina tion
All brains w ere judged to be well perfusion fixed as evidenced by good 
neuronal morphology, the absence of in travascular blood and the  lack of 
cytological a r tifa c ts  such as "dark cells" or "hydropic cells" (Brown & Brierly, 
1968; Cam m erm eyer, 1961). Perm anent occlusion of the le f t MCA resulted 
in ischaem ic dam age only within the  te rrito ry  of the  occluded MCA, i.e. in 
the  dorsolateral cortex  and neostriatum . These areas showed the 
morphological characteristics of early ischaem ic cell change, with 
m icrovacuolation, shrinkage and triangulation of the  nucleus and cytoplasm, 
increased basophilia of cytoplasm , perineuronal swollen astrocytes, and 
vacuolation of the  neuropil (Figure 10). The border betw een normal cells and 
cells showing the  morphological characteristics of early  infarction was not 
apparent without m agnification (Figure 10), but under light m icroscopy the
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TABLE 2
CARDIOVASCULAR. RESPIRATORY AND OTHER VARIABLES 
DURING THE PERIOD OF SURVIVAL AFTER MCA OCCLUSION IN THE RAT:
EFFECTS OF CI-977
TIME
AFTER
MCAO
(hrs)
TEMPERATURE
(°C)
GLUCOSE
(mM)
nOO pCOo
(mmHg)(mmHg) pH
CONTROL GROUP
0 36.8 ± 0.1 11.0 ± 0.5 134 ± 5 43.5 ± 1.4 7.44 ± 0.01
1 36.9 ± 0.1 10.7 ± 0.5 153 ± 10 39.4 ± 1.6 7.46 ± 0.02
2 36.9 ± 0.1 11.0 ± 0.5 164 ± 10 38.8 ± 1 .1 7.43 ± 0.02
3 37.0 ± 0.2 11.0 ± 0.4 168 ± 9 38.5 ± 0.8 7.42 ± 0.02
4 37.0 ± 0.2 10.5 ± 0.3 171 ± 8 40.2 ± 1 .0 7.43 ± 0.02
CI-977 TREATMENT GROUP
0 36.8 ± 0.2 10.8 ± 0.4 137 ± 8 40.9 ± 1.5 7.50 ± 0.04
1 36.8 ± 0.1 8.9 ± 0.4* 160 ± 5 38.0 ± 1 .4 7.47 ± 0.01
2 37.0 ± 0.1 8.9 + 0.4* 160 ± 8 37.1 ± 0.9 7.46 ± 0.01
3 36.9 ± 0.1 9.4 ± 0.4* 150 ± 9 37.8 ± 0.6 7.44 ± 0.01
4 37.0 ± 0.1 9.6 ± 0.3* 157 ± 7 38.5 ± 0.5 7.44 ± 0.01
Data are presented as mean ± SEM (n=7 in each group). -Data rep resen ts values  
at time of MCA o cclu sion  and a t hourly in te r v a ls  th erea fter . CI-977 
(0.3mg/kg, s . c . )  or v e h ic le  were adm inistered 30 min before and 30 min a fte r  
the induction of ischaem ia. *P<0.05 for s t a t i s t i c a l  comparison between 
v e h ic le -tr ea ted  co n tro ls  and C I-977-treated  animals a t the same time p o in ts  
(unpaired, tw o -ta iled  Student's t - t e s t ) .
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FIGURE 10
Low power (x7) photomicrograph of a coronal section perfusion fixed and stained 
with H & E 4h after permanent MCA occlusion in the ra t  showing poor macroscopic 
delineation of ischaemic cell change (left side of section) (upper) and a high power 
(x200) view of the same section showing a distinct border between the ischaemic 
lesion and morphologically normal tissue in the cerebral cortex (lower). Within the 
lesion, neurones tha t have undergone ischaemic cell change are triangular in shape 
with intensely stained nuclei, and the neuropil surrounding these neurones is pale and 
spongy in appearance. In contrast, neurones within the normal tissue are spherical 
with less densely stained nuclei and cytoplasm.
border was easily dem arcated, thus enabling the delineation of areas of 
ischaemic damage from these H & E stained sections. The distribution of 
ischaemic brain damage when assessed a t 4h post-occlusion is illustra ted  in 
Figure 11. The histological appearance of the ischaem ic brain tissue in ra ts  
trea ted  with CI-977 (0.3mg/kg) was sim ilar to  th a t in veh ic le-trea ted  control 
animals.
1.2.3 Volumetric Assessm ent o f  Ischaemic Damage
The adm inistration of CI-977 (0.3mg/kg) 30 min before and again 30 min 
a fte r MCA occlusion significantly reduced the volume of ischaem ic damage 
in the cerebral hemisphere (reduced by 27% from veh ic le-trea ted  controls; 
p<0.05) and cerebral cortex  (reduced by 32%; p<0.05) (Figure 12). The 
volume of ischaemic damage in the caudate nucleus was minimally influenced 
by trea tm en t with CI-977 (Figure 12). The areas of ischaem ic damage in the 
cerebral cortex and hemisphere was reduced by CI-977 to a sim ilar degree a t 
each coronal plane examined with a s ta tistica lly  significant reduction being 
noted only a t plane anterior 3.75mm anterior ^ to th e  in teraural line 
(Figure 13). The areas of ischaemic damage in the caudate  nucleus were not 
modified by the drug in any plane studied.
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FIGURE 11
Distribution of ischaem ic brain damage 4h a fte r perm anent MCA occlusion in a 
vehicle-treated  control ra t. Regions showing ischaemic cell change (shaded black) 
were determ ined a t 8 defined coronal planes from plane an terior 10.5mm to anterior 
1.02mm relative to the interaural line. The volumes of ischaem ic dam age in this
3 3animal were: cerebral hemisphere 131mm , cerebral cortex  109mm and caudate 
nucleus 34mm3.
119
150-1
cn
I  100
o
<DcdJCocn • ^
<+HO
<DaZ3
’o
>
I | Control 
■  CI-977
Cerebral
Hemisphere
Cerebral
Cortex
Caudate
Nucleus
FIGURE 12
The e ffec t of CI-977 upon the volume of ischaemic brain damage in the cerebral 
hemisphere, cerebral cortex and caudate nucleus assessed 4h a fte r  perm anent MCA 
occlusion in halothane-anaesthetised ra ts. CI-977 (0.3mg/kg, s.c.) was adm inistered 
30 min before and 30 min a fte r the onset of ischaemia. D ata was presented as 
mean ± SEM (n=7 vehicle, n=7 CI-977). *P<0.05 (Student’s one-tailed t-test).
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FIGURE 13
The e ffec t of CI-977 upon the areas of ischaemic brain damage in the cerebral 
hemisphere (upper) and cerebral cortex (lower) a t 8 pre-determ ined coronal planes 
assessed 4h a fte r perm anent MCA occlusion in halothane-anaesthetised ra ts . Data 
are presented as mean ± SEM (n=7 vehicle, n=7 CI-977). **P<0.01 (Student’s two-
tailed t-test).
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1.3 6h (A naesthetised Throughout) Model in th e  C at
1.3.1 Physiological Variables
There were no significant d ifferences betw een the  veh icle-treated  
control group and C I-977-treated group in key system ic variables th a t are 
thought to  influence the amount of ischaem ic brain damage, e.g. MABP, 
a rte ria l plasm a glucose, core tem peratu re  and haem atocrit a t  MCA occlusion 
and in the  post-occlusion survival period (Figure 14, Table 3). There were 
no significant differences in a rte ria l blood gas sta tu s  (p02, p C 0 2, pH) between 
the two groups a t any tim e point (Table 3). There were also no differences 
betw een the control and C I-977-treated  groups in e ith e r the  inspired 
halothane concentration or the  amount of H artm an’s solution adm inistered.
The bolus adm inistration of CI-977 elicited  a significant reduction in 
MABP by approxim ately 25% of control values only within the  initial 5 min 
post-injection period (p<0.01, S tudent’s unpaired t-tes t) (Figure 14). The 
hypotension was relatively  transien t such th a t there  was no difference 
between the  two groups in the level of MABP a t the tim e of MCA occlusion 
or during the  post-occlusion survival period. T he 'adm in istration  of the 
vehicle (isotonic saline) did not a lte r MABP (Figure 14).
The plasma level of CI-977 increased slowly but progressively throughout 
the post-occlusion period (Figure 15). CI-977 induced a progressive increase 
in plasma osm olality throughout the post-occlusion period, which was 
significantly d ifferen t from controls a t 240 min (p<0.01) and 360 min (p<0.05) 
only (Figure 15).
1.3.2 Neuropa thology Examina tion
All brains were judged to  be well perfusion fixed as evidenced by good 
neuronal morphology, the absence of intravascular blood and the  lack of
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FIGURE 15
Plasma levels of CI-977 presented on a log scale (upper) and the  e ffe c t of CI-977 
upon plasma osmolality (lower). T reatm ent was in itiated 15 min prior to MCA 
occlusion (MCAO a t tim e zero) in halothane-anaesthetised cats . D ata are 
presented as mean ± SEM (n=3 control, n=7 CI-977). *P<0.05, **P<0.01 (Student’s
tw o-tailed t - test).
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cytological a rtifac ts  such as ’’dark cells” or "hydropic cells" (Brown and 
Brierly, 1968; Cam m erm eyer, 1961). Coronal sectioning of the brains 
revealed the in terior of the brains to  be well fixed other than in the deeper 
portions of the le ft hemisphere where zones of pink discolouration could be 
seen. Ischaemic damage was observed only within the  te rrito ry  of the 
occluded MCA, i.e. in the  dorsolateral cortex  and in the  neostriatum . These 
areas showed the  morphological characteristics of early  infarction 
(microvacuolation, shrinkage of the neuropil, triangulation and hyperchromasia 
of the cell body and nucleus exactly as observed in ra t  ischaem ic te rrito ry  
(Figure 10). The distribution of ischaem ic damage in the  c a t forebrain a t 
6h a fte r  the  induction of ischaemia is shown in Figure 16. The histological 
appearance of the ischaem ic tissue was sim ilar in all animals (vehicle-treated 
controls and C I-977-treated).
1.3.3 Volumetric A ssessm ent o f  Ischaemic Damage
The adm inistration of CI-977 in itiated  15 min before MCA occlusion 
reduced the  volume of ischaemic damage due to  occlusion of the  MCA in the 
cerebral hemisphere (reduced by 33% from veh icle-trea ted  controls) and 
cerebral cortex  (reduced by 42%) (Figure 17). The volume of ischaemic 
damage in the caudate nucleus was not altered  by trea tm en t with CI-977 
(Figure 17). The areas of ischaemic damage in the  cerebral cortex and 
hemisphere were reduced by CI-977 to  a sim ilar degree a t each coronal plane 
examined, with s ta tistica lly  significant reductions being noted betw een planes 
an terior 14mm and posterior 2mm (Figure 18). The areas of ischaemic 
damage in the  caudate nucleus were not modified by the  drug in any plane 
studied.
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FIGURE 16
D istribution of ischaem ic brain damage 6h a fte r perm anent MCA occlusion in a 
veh icle-trea ted  control cat. Regions showing ischaem ic cell change (shaded black) 
w ere determ ined a t 16 coronal planes from plane an terior 22mm to  posterior 8mm 
re la tive  to the interaural line. The volume of ischaemic damage in this animal
3 3were: cerebral hemisphere 2415mm , cerebral cortex  1857mm and caudate nucleus 
257mm3.
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FIGURE 17
The e ffe c t of p re trea tm en t with CI-977 (0.3mg/kg, i.v.) upon the volume of 
ischaem ic brain damage in the cerebral hemisphere, cerebral cortex and caudate 
nucleus 6h afte r perm anent MCA occlusion in halothane-anaesthetised cats. Data 
are presented as mean ± SEM (n=8 control, n=7 CI-977). *P<0.05, **P<0.01
(Student’s one-tailed t-test).
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FIGURE 18
The e ffec t of CI-977 (0.3mg/kg, i.v.) adm inistered 15 min prior to  MCA occlusion 
upon the areas of ischaemic brain damage in the  cerebral hemisphere (upper) and 
cerebral cortex  (lower) a t 16 defined coronal planes 6h a fte r  the induction of 
ischaemia in halothane-anaesthetised cats. D ata are presented as mean ± SEM (n=8 
control, n=7 CI-977). *P<0.05, **P<0.01 (Student’s tw o-tailed t-test).
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2. MECHANISMS UNDERLYING THE ANTI-ISCHAEMIC EFFICACY OF CI-977
2.1 CI-977 on C erebral Blood Flow a f te r  MCA Occlusion in th e  R at
2.1.1 Cardio vascular and R  espira tory S t a tus
The adm inistration of CI-977 (0.3mg/kg) e ffec ted  a marked reduction 
in MABP (from 92 ± 3mmHg prior to  drug adm inistration to 67 ± 3mmHg 5 
min a fte r  adm inistration; p<0.01). T hereafter, MABP returned  gradually 
tow ard its pre-adm inistration levels. A t the  tim e of MCA occlusion, MABP 
in C I-977-treated animals was still 20% lower than its  pre-adm inistration 
value, and a t this stage was significantly d ifferen t from  vehicle-trea ted  
controls (Table 4). Significant hypotension persisted throughout the  post­
occlusion period, such th a t a t the tim e of cerebral blood flow m easurem ent, 
MABP was still significantly reduced by 16% of control levels. The 
adm inistration of the  vehicle (isotonic saline, 1 ml/kg) did not a lte r MABP. 
There were no significant differences between the  two groups with respect 
to respiratory  blood gas status or rec ta l tem perature, but the  adm inistration 
of CI-977 induced a significant reduction (15%) in a rte ria l plasma glucose 
concentration (Table 4). The e ffec ts  of CI-977 on m onitored physiological 
variables in the present cerebral circulatory study w ere sim ilar to  those 
observed in a parallel neuropathology study of the  neuroprotective e ffec ts  of 
CI-977 in the sam e model (Section 1.2.1).
2.1.2 Cerebral Blood Flow in Neuroanatomically D efined Regions
Visual inspection of the  autoradiogram s from  both veh icle-trea ted  
and C I-977-treated groups showed marked reductions in local cerebral 
blood flow in the  hemisphere ipsilateral to  the  MCA occlusion as 
compared with the  con tra la tera l hemisphere. The reductions w ere m ost 
obvious in the  neocortex and caudate nucleus.
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TABLE 4
CARDIOVASCULAR. RESPIRATORY AND OTHER PHYSIOLOGICAL VARIABLES 
FOR INVESTIGATION OF CEREBRAL BLOOD FLOW 
AFTER MCA OCCLUSION IN THE RAT: EFFECTS OF CI-977
MCAO CBF
VARIABLE CONTROL CI--977 CONTROL CI--977
R ectal
Temperature
(°C) 36.7 ± 0.1 36.9 ± 0.1 36.9 ± 0.1 36.9 ± 0.1
MABP (mmHg) 82 ± 4 71 ± 3* 82 ± 3 69 ± 3*
A rter ia l  
Plasma 
Glucose (mM) 10.2 ± 0.2 8.3 ± 0.2* 10.4 ± 0.2 8.1 * 0.2*
pCOg (mmHg) 38.1 ± 1 .1 40.8 ± 1 .2 37.6 ± 0.5 39.4 ± 0.7
PO2 (mmHg) 141 ± 8 132 ± 7 145 ± 8 142 ± 8
PH 7.46 ± 0.02 7.45 ± 0.01 7.46 ± 0.01 7.44 ± 0.01
Data are presented as mean ± SEM (n=7 control; n=8 CI-977).  MCAO, data 
measured at time of MCA occlu sion ; CBF, data measured a t time of CBF 
measurement. CI-977 (0.3mg/kg, s . c . )  adm inistered 30 min p rior to  the
induction  of ischaem ia. *P<0.05 for s t a t i s t i c a l  comparison between v e h ic le -  
trea ted  con tro ls and C I-977-treated  animals at the same time p o in ts  (unpaired 
tw o -ta iled  Student's t - t e s t ) .
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In the non-ischaem ic hemisphere, the adm inistration of CI-977 
(0.3mg/kg) 30 min prior to  the induction of ischaem ia, failed to produce a 
significant e ffe c t on local cerebral blood flow in any of the  25 areas examined 
(Table 5).
In the ischaem ic hemisphere, CI-977 failed to  dem onstrate  a significant 
alterations in the level of cerebral blood flow in 23 of the 25 regions 
examined (Table 5). However, significant increases in cerebral blood flow 
were observed in the la te ral thalam us and medial caudate  nucleus a t the 
boundary of the severe hypoperfusion (local cerebral blood flow increased by 
86% and 65% respectively when compared to  vehicle) (Figure 19, Table 5). 
In regions in which the  blood supply is derived from the  occluded MCA (i.e. 
frontal, sensory m otor, parie tal and auditory cortices and caudate nucleus 
(dorsolateral)), no s ta tistica lly  significant differences in blood flow were 
dem onstrated betw een veh icle-treated  and C I-977-treated  animals (Table 5).
2.1.3 Frequency Distribution Analysis o f  Cerebral Blood Flow
CI-977 failed to produce a significant e ffe c t oh the  amount of 
hypoperfused tissue or weighted average cerebral blood flow in e ither the 
hemisphere ispilateral to  MCA occlusion or in the co n tra la tera l hemisphere 
(Figure 20). The was a negligible amount of tissue (less than 1%) with blood 
flow less than 30ml 100g-1 min “1 in the con tra la tera l hem isphere in e ither 
veh icle-treated  or C I-977-treated  animals (Figure 20).
Median blood flow in the ipsilateral hemisphere was 53 ± 6ml lOOg”1 
min"1 in veh icle-trea ted  animals and 72 ± 9ml 100g-1 min"1 in C I-977-treated 
animals (p=0.119). In the  con tra la tera l hemisphere median blood flow was 
106 ± 17ml lOOg"1 min"1 in veh icle-treated  animals and 113 ± 10ml lOOg"1 
min”1 in C I-977-treated animals (p=0.742).
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TABLE 5
EFFECTS OF CI-977 ON CEREBRAL BLOOD FLOW 
AFTER PERMANENT MCA OCCLUSION IN THE RAT
IPSILATERAL TO MCAO CONTRALATERAL TO MCAO
STRUCTURE CONTROL CI- 977 CONTROL CI--977
Frontal Cortex 40 ± 6 64 ± 10 127 ± 13 129 ± 15
Sensory Motor Cortex 30 ± 5 38 ± 11 130 ± 12 116 ± 12
P a r ie ta l Cortex 42 ± 6 71 ± 13 120 ± 12 124 ± 8
Auditory Cortex 46 ± 8 68 l 13 120 ± 14 125 ± 13
V isual Cortex 53 ± 4 69 ± 12 111 ± 14 135 ± 9
Thalamus, 
Mediodorsal 101 ± 15 122 ± 10 127 ± 16 153 ± 14
Thalamus, Lateral 
Hyperaemic Zone 105 ± 15 195 ± 21 ** 105 ± 11 121 ± 10
Lateral Habenula 161 + 16 195 ± 6 166 ± 18 200 ± 6
Hypothalamus 80 ± 9 108 i 9 89 ± 11 115 ± 10
Hippocampus, 
Molecular Layer 100 ± 11 112 ± 9 103 ± 17 97 ± 9
Caudate Nucleus, 
Lateral 10 ± 2 9 ± 3 126 ± 20 134 ± 16
Caudate Nucleus, 
Medial 12 ± 1 18 ± 4 121 ± 16 138 ± 16
Caudate Nucleus, 
Hyperaemic Zone 121 ± 12 200 ± 13*** 102 ± 12 111 ± 9
Globus P a llid u s 133 + 18 159 ± 13 95 ± 10 100 ± 8
Red Nucleus 130 ± 17 146 ± 13 137 ± 17 161 i 15
Subthalamic Nucleus 168 ± 23 190 ± 13 167 ± 20 185 ± 15
V estibular Nucleus 171 ± 20 178 ± 13 177 ± 20 184 ± 13
Superior O live 187 ± 25 215 ± 14 188 ± 23 225 ± 22
In fer ior  C o llicu lu s 151 ± 20 180 1 15 155 ± 18 189 ± 17
In fer io r  O live 166 + 16 170 ± 15 177 ± 19 179 ± 16
C erebellar Hemisphere 88 ± 8 96 ± 10 81 ± 8 85 ± 8
C erebellar Nucleus 193 ± 19 202 ± 18 191 ± 16 191 ± 17
Corpus Callosum 47 ± 6 61 ± 8 47 ± 6 60 ± 8
Genu 37 ± 3 53 ± 9 49 ± 5 58 i 8
Internal Capsule 64 ± 9 75 i 5 63 ± 9 77 ± 6
Data are presented as mean ± SEM (n=7 con tro l; n=8 CI-977) and expressed as 
ml 100g min . MCAO 30 min prior to  CBF determ ination. CI-977 (0.3mg/kg) 
adm inistered 30 min p r ior  to  MCAO. **P<0.01, ***P<0.001 for  s t a t i s t i c a l  
comparison between v e h ic le -tr e a te d  con tro ls  and C I-977-treated  group in  each 
structure (unpaired, tw o -ta iled  Student's t - t e s t ) .
133
VEHICLE CI-977
FIGURE 19
[14C]-Iodoantipyrine autoradiogram s illustrating the e ffec t of CI-977 upon the  
pa tte rn  of cerebral blood flow a t the level of the medial caudate nucleus (upper) and 
la tera l thalamus (lower) 30 min a fte r perm anent MCA occlusion in halothane- 
anaesthetised ra ts . CI-977 (0.3mg/kg, s.c.) was adm inistered 30 min before MCA 
occlusion. Relative levels of local cerebral blood flow are directly  re la ted  to 
re la tive  optical density. Note the areas of hyperaemia (indicated by arrows) a t 
the boundaries of the zones of severe hypoperfusion. Bar = 2.5mm.
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FIGURE 20
The e ffe c t of CI-977 (frequency distribution analysis) upon the  hem ispheric volume, 
both ipsilateral (upper) and con tra la tera l (lower) to MCA occlusion, perfused by 
sequentially higher ranges of cerebral blood flow. CI-977 (0.3mg/kg, s.c.) was 
adm inistered 30 min prior to  perm anent occlusion of the  MCA in halothane- 
anaesthetised ra ts , and cerebral blood flow determ ined 30 min subsequently. D ata 
are  presented as m ean ± SEM (n-7 vehicle, n=8 CI-977). There was no significant 
d ifference betw een veh icle-trea ted  controls and C I-977-treated animals a t any 
cerebral blood flow range in e ither hemisphere. Note the  larger volume of the 
ipsilateral hem isphere re la tive  to  the  con tra la tera l hem isphere perfused with lower 
levels of cerebral blood flow.
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2.2 CI-977 on G lutam ate N eurotoxicity in vivo
2.2.1 Cardiovascular and R espiratory Status
The physiological variables m onitored throughout the study are shown 
in Table 6. There were no significant differences in a rte ria l blood gas 
studies (p02 p C 0 2, pH), rec ta l tem peratu re  or plasm a glucose concentration 
betw een veh icle-trea ted  controls and any of the d rug-treated  (MK-801, NBQX, 
CI-977) groups a t any tim e point.
The adm inistration of CI-977 (0.3mg/kg, i.v.) 30 min before and 30 min 
a fte r  the s ta r t  of g lu tam ate (0.5M) perfusion induced a m odest reduction in 
MABP, which was significantly d ifferen t from veh icle-trea ted  controls a t 120 
min (p<0.05) and 240 min (p<0.01) only (Figure 21). NBQX produced a 
m oderate, sustained increase in MABP throughout the  period of g lu tam ate 
perfusion and in the  post perfusion period, and MK-801 trea tm en t induced a 
modest, non-significant reduction in MABP (Figure 21).
2.2.2 Histology Examination
The perfusion of g lu tam ate (0.5M) produced an ' area of pallor in the 
cerebral cortex  which was visible on the H & E stained sections without 
m agnification (Figure 22). This area of pannecrosis, with a clearly  defined 
border, represents the  cortical lesion produced around the  microdialysis probe. 
The lesion extends in an terior and posterior directions re la tive  to  the  probe 
(approximately 2mm in each direction (Figure 22). The histopathological 
features in the  area of pallor have been previously described (Landolt e t  al., 
1993), i.e. triangulation of the  nucleus, shrinkage of neurones and neuropil, 
and swelling of perineuronal astrocytes. No histological abnorm alities were 
found in brain regions rem ote from the  dialysis probe.
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FIGURE 21
The e ffec ts  of drug trea tm en t on mean arteria l blood pressure (MABP) in halothane- 
anaesthetised ra ts  during the g lutam ate neurotoxicity in  v i v o  study. D ata are 
presented as mean ± SEM (n=10 vehicle; n=5 each drug-treated  group). *P<0.05, 
**P<0.01 rela tive to contem poraneous vehicle trea tm en t (ANOVA followed by 
unpaired Student’s t- te s t with Bonferroni correction). Solid bar indicates period of 
glu tam ate perfusion (0 - 90 min).
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FIGURE 22
Histological assessm ent of glutam ate-induced necrosis. Upper: a representative  
coronal section (x7) stained with H & E illustrating the area of neuronal damage 
produced in the same coronal plane as the microdialysis probe in a vehicle-treated  
control animal. Lower: the areas of damage a t 200pLm intervals assessed 4h a fte r 
the onset of g lutam ate perfusion in vehicle-treated  animals. D ata are presented as 
mean ± SEM (n=10).
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Vehicle MK-801 NBQX CI-977
FIGURE 23
The e ffe c t of drug trea tm en t on the volume of neuronal dam age produced by 
in tracortical glutam ate perfusion in halothane-anaesthetised ra ts . D ata are 
presented as mean ± SEM (n=10 vehicle; n=5 each d rug-treated  group). *P<0.05 
re la tive  to contemporaneous veh icle-treated  controls (ANOVA followed by 
independent tw o-tailed t- te s t with Bonferroni correction).
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2.2.3 Volumetric A ssessm ent o f  Histological Damage
The adm inistration of CI-977 30 min before and 30 min a fte r  the 
initiation of in traco rtica l g lu tam ate perfusion produced no significant 
reduction in the  volume of glutam ate-induced damage when compared to 
veh icle-trea ted  controls (Figure 23). P re-trea tm en t with NBQX (2 x 
30mg/kg) and MK-801 (0.5mg/kg) each significantly reduced the  volume of 
dam age produced by in tracortical g lu tam ate perfusion. The m agnitude of 
the  reductions in lesion volume produced by NBQX and MK-801 w ere broadly 
sim ilar, being 23% and 30% respectively (Figure 23).
2.3 G lutam ate R elease and C erebral Blood Flow a f te r  MCA Occlusion in the  
C at: E ffec t of CI-977
2.3.1 Physiological Variables
There were no significant differences betw een the  veh icle-treated  
control group and C I-977-treated  group in respiratory  blood gas sta tus (p02, 
p C 0 2, pH), tem perature  (rectal or periosteal), plasma glucose concentration 
and haem atocrit a t the  tim e of MCA occlusion and during the  subsequent 3h 
post-occlusion period (Appendix Table).
The bolus adm inistration of CI-977 30 min prior to  the induction of 
ischaem ia elicited  a significant reduction in MABP by approxim ately 27% of 
control values only within the  initial 5 min post-injection period (control: 90 
± 6mmHg, CI-977: 66 ± 3mmHg; p<0.05 S tudent’s unpaired t-test). The 
hypotension was rela tively  transien t such th a t there  was no difference 
betw een the two groups in the  level of MABP a t the  s ta r t  of dialysate 
collection and concom itant cerebral blood flow m easurem ent 20 min prior 
to  MCA occlusion (control: 89 ± 4mmHg; CI-977: 81 ± 5mmHg).
141
2.3.2 Cerebral Blood Flow
The adm inistration of CI-977 had no significant e ffe c t on the  level of 
cerebral blood flow in the  suprasylvian gyrus during the  control period prior 
to  occlusion of the MCA in e ither the  ipsilateral or con tra la tera l hem isphere 
(Figure 24). Following the induction of ischaemia, th e re  was a significant 
reduction (approxim ately 60%) in cortical cerebral blood flow in the  ischaem ic 
hemisphere in both the  veh icle-trea ted  and d rug-treated  groups (p<0.05 
S tudent’s paired t-te s t)  (Figure 24). A minimal, non-significant reduction 
(approximately 18%) in cerebral blood flow was observed in the non-ischaem ic 
hemisphere of both groups (Figure 24). CI-977 trea tm en t failed to
dem onstrate any significant a lte ration  in the level of post-ischaem ic cerebral 
blood flow in e ither the  ipsilateral or con tra latera l hemisphere (Figure 24).
2.3.3 Am ino A cid  Levels in Dialysate
A t normal control cerebral blood flow values, th e re  was no difference 
in the  concentration of glutam ate in the ipsilateral hemisphere in e ither the 
veh icle-trea ted  control or C I-977-treated groups (Figure 25). A fte r the 
induction of ischaem ia, there  was a m arked increase in g lu tam ate levels when 
cerebral blood flow fell to a threshold value of approxim ately 20ml lOOg”1 
min-1 in veh icle-trea ted  control animals (Figure 25). In the  C I-977-treated  
group, there  was no evidence of such a threshold for g lu tam ate  re lease  in the  
ischaemic hem isphere (Figure 25). In the hemisphere con tra la tera l to  MCA 
occlusion, th e re  was no increase in g lutam ate levels a f te r  the induction of 
ischaem ia in e ither the  veh icle-trea ted  control or C I-977-treated  groups 
(Figure 26). Similarly, there  was no elevation in the  levels of any of the 
o ther 11 amino acids examined in the  con tra latera l hemisphere in e ith e r 
group a fte r  the  onset of ischaemia.
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FIGURE 24
The e ffe c t of CI-977 adm inistration (admin.) on the level of cerebral blood flow in 
the ipsilateral (upper) and con tra la tera l (lower) hemispheres im m ediately before and 
im m ediately a fte r perm anent MCA occlusion in halothane-anaesthetised cats. D ata 
are presented as mean ± SEM and represent 4-15 m easurem ents in cerebral blood 
flow in 5 veh icle-treated  control and 4 C I-977-treated animals. *P<0.05 (paired 
t-test) re la tive  to pre-ischaem ic cerebral blood flow level.
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FIGURE 25
Scatterp lo ts of the relationships between cerebral blood flow and the ex tracellu lar 
concentration of glu tam ate in the ipsilateral hemisphere pre- and post-MCA 
occlusion in veh icle-treated  control (n=5) and C I-977-treated (n=4) animals. Each 
d ata  point represents all values obtained throughout the course of the investigation.
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Scatterp lo ts of the relationships between cerebral blood flow and the extracellu lar 
concentration of g lutam ate in the con tra lateral hemisphere pre- and post-MCA 
occlusion in veh icle-treated  control (n=5) and C I-977-treated (n=3; one probe 
malfunctioned) animals. Each data point represents all values obtained throughout 
the course of the investigation.
145
There was evidence of an elevation in the  levels of g lu tam ate in the 
ipsilateral hem isphere when cerebral blood flow fell to  values of less than 
30ml 100g-1 min"1 in veh icle-trea ted  control animals (Figure 27). This 
increase in g lu tam ate concentration was a ttenuated  significantly by CI-977 
a t cerebral blood flow of less than 20ml lOOg"1 min”1 (Figure 27). There was 
no difference betw een the  two groups in the  tim e elapsed a fte r  MCA 
occlusion for cerebral blood flow values to  fall to  less than 30ml lOOg”1 
min”1, where increases in g lutam ate levels w ere observed (CBF bin; 0- 
10ml lOOg”1 min”1: control 123 ± 10 min (n=23), CI-977: 124 ±11 min (n=35); 
CBF bin 10-20ml lOOg”1 min”1: control 83 ± 21 min (n=ll),  CI-977: 78 ± 17 
min (n= 14); CBF bin 20-30ml lOOg”1 min”1: control: 57 ± 10 min (n=13), 
CI-977: 51 ± 18 min (n=l 1)). The extracellu lar concentration of the 
excitato ry  amino acid L-aspartate was also markedly increased a t low flow 
levels (Figure 27). A dm inistration of CI-977 significantly reduced this 
elevation such th a t the  levels of asparta te  did not increase over basal levels 
in the  d rug-treated  group (Figure 27). There was also an increase in the 
levels of the inhibitory neurotransm itter GABA a t cereb ra l blood flow values 
of less than 10ml lOOg”1 min”1 which was reduced following trea tm en t with 
CI-977 (Figure 28). There was no marked elevation in the levels of tyrosine 
a f te r  the induction of ischaem ia, although a t low flow values there  was 
evidence to suggest an attenuation  in C I-977-treated animals (Figure 28).
The e ffec ts  of CI-977 on the ischaemia-induced re lease  of asparagine, 
serine, glutam ine, glycine, threonine, arginine, taurine and alanine are 
illustra ted  in Appendix Figures and summarised approxim ately in Table 7. 
The cerebral blood flow bin 0-10ml 100”1 min-1 was selected  for comparison 
betw een control and C I-977-treated animals because in this cerebral blood 
flow bin the  response is robust with n numbers typically 20-25. In contrast,
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The e ffe c t of p re trea tm en t with CI-977 on the extracellu lar concentrations of 
glu tam ate (upper) and asparta te  (lower) in the ipsilateral hem isphere before and 
a fte r perm anent MCA occlusion in halothane-anaesthetised cats. D ata are 
presented as mean ± SEM and represent 3-26 determ inations in 5 veh icle-treated  
control and 4 C I-977-treated animals. *P<0.05, **P<0.01, ***P<0.001 (Student’s 
tw o-tailed t-test).
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FIGURE 28
The e ffe c t of p re trea tm en t with CI-977 on the ex tracellu lar concentrations of 
GABA (upper) and tyrosine (lower) in the ipsilateral hemisphere before and a fte r 
perm anent MCA occlusion in halothane-anaesthetised cats. D ata are presented 
as mean ± SEM and represent 3-23 determ inations in 5 veh icle-trea ted  control and 
4 C I-977-treated animals. *P<0.05 (Student’s tw o-tailed t-test).
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TABLE 7
INCREASES IN AMINO ACID LEVELS 
IN THE CAT SUPRASYLVLAN GYRUS 
AFTER CEREBRAL ISCHAEMIA
ALTERATION AFTER ISCHAEMIA
AMINO ACID CONTROLS CI-977
Glutamate 8 fo ld 0 .5  fo ld
Aspartate 8 fo ld 0
Alanine 8 fo ld 3 fo ld
Taurine 6 fo ld 3 fo ld
GABA 5 fo ld 1.5 fo ld
Threonine 4 fo ld 2 fo ld
Serine 2 .5  fo ld 1.5 fo ld
G lycine 1.5 fo ld 0.5 fo ld
Tyrosine 1 fo ld 0
Arginine 1 fo ld 0
Asparagine 0 0
Glutamine 0 0
Approximate in creases in  amino acid  le v e ls  r e la t iv e  to  control 
basal va lu es in  the CBF range 0 -10ml 100g min a fter  
permanent MCA occlu sion  in  the c a t , and the e f f e c t  of 
CI-977 pretreatm ent. 0 = no change from b asal le v e ls .  
Actual values are i l lu s tr a te d  in  Figures 27 and 28 and in  
Appendix F igures.
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the cerebral blood flow bin 40-50ml 100g-1 min-1, where there  is an apparent 
increase a f te r  CI-977, is not a robust response, with n numbers approximately 
3-4, arising as a consequence of the design of the  study. Thus, in such a 
small group one large value will make a huge im pact on the m ean of the  data 
in th a t cerebral blood flow bin.
3. FUNCTIONAL CONSEQUENCES OF CI-977 ADMINISTRATION
The functional consequences of CI-977 as re flec ted  in local cerebral 
glucose u tilisation and local cerebral blood flow w ere examined in conscious, 
lightly restra ined  animals. However, the use of hind limb res tra in t 
introduces the  possibility th a t the  behavioural responses and CNS e ffec ts  of 
CI-977 may be d ifferen t from those in freely moving animals. Moreover, 
although indirect indices of acu te  stress (plasma glucose, p C 0 2, MABP) are 
within normal lim its in these lightly restrained ra ts  prior to drug/vehicle 
adm inistration, chronic, mild stress (and its in teraction with CI-977) cannot 
be discounted entirely. Thus, extrem e caution should be exercised in the 
extrapolation of neuropharmacological data obtained in restra ined  animals to 
freely moving animals.
3.1 C erebral Glucose Use a f te r  CI-977
3.1.1 Behaviour and Physiological Variables
The intravenous adm inistration of CI-977 (0.03, 0.3, 3mg/kg) resulted 
in prom inent changes in the  overt behaviour of the  animals. Prior to  drug 
adm inistration, the lightly restra ined  animals w ere generally quiescent and 
displayed normal grooming behaviour and appropriate reactions to  slight 
auditory and sensory stim uli. The behavioural responses following CI-977 
w ere characterised  initially by a dose-dependent (although of a minor nature
150
with 0.03mg/kg) ca ta lep tic  s ta te  which appeared within 2 min of drug 
adm inistration, and persisted throughout the  m easurem ents of 2-deoxyglucose 
with the highest dose of CI-977 examined (3mg/kg). The ra ts  stre tched  their 
necks, adopted a rigid body posture, gazed in one direction, and exhibited 
pronounced extension of the forelimbs with splayed-out paws. Moreover, the 
ra ts  had pinned back white ears, piloerection of the whiskers and a rigid, 
straightened  ta il. Grooming, sniffing and exploratory m ovem ents of the 
head and forelimbs (which all control ra ts  displayed) w ere absent in animals 
tre a ted  with CI-977, characterising signs of CNS depression. In animals 
tre a ted  with the in term ediate  dose of CI-977 (0.3mg/kg), the  behavioural 
response was replaced progressively (approxim ately 15-20 min post-injection) 
by one consisting of abnormal m otor activ ity  characterised  by in te rm itten t 
periods of jerky head movements, arching of the  neck and upper portion of 
the body, and frequent vocalisations which persisted until sacrifice. The 
animals rem ained conscious throughout, even a t the highest concentration 
studied (3mg/kg).
T reatm ent with CI-977 produced minor alterations in the monitored 
physiological variables (Table 8). The injection of CI-977 induced no 
significant changes in respiratory  blood gas sta tu s (pC 02, p 0 2, pH) a t any dose 
over the tim e course of the experim ents when com pared to  veh icle-trea ted  
control animals (Table 8). CI-977 had no significant e ffe c t on MABP
im m ediately a fte r intravenous adm inistration or a t any tim e point during the 
experim ent (Table 8). In control animals, vehicle injection had no e ffec t on 
MABP.
CI-977 produced a dose-dependent, m oderate reduction in rec ta l 
tem peratu re  which was sustained throughout the  experim ental period with 
CI-977 a t the  in term ediate  (0.3mg/kg) and highest (3mg/kg) doses examined
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TABLE 8
GLUCOSE UTILISATION STUDY:
CARDIOVASCULAR. RESPIRATORY AND OTHER PHYSIOLOGICAL VARIABLES 
AFTER ADMINISTRATION OF CI-977 TO CONSCIOUS RATS
TIME AFTER 
DRUG (min)VARIABLE CONTROL 0.03 0 .3 3
R ectal Temperature 0 36.9±0.2 37 .0±0.2 36.9±0.3 3 7 . 0±0.1
<°C) 10 36.9±0.1 36 .7±0.1 3 6 . 5±0.1 * 3 6 . 4±0.1**
50 37 . 0±0.2 36.8±0.2 3 6 . 5±0.3* 3 6 . 5±0.1**
Mean A rter ia l 0 135 ± 3 125 ± 3 134 ± ‘6 137 ± 3
Blood Pressure 10 131 ± 7 124 ± 4 133 ± 4 141 ± 6
(mmHg) 50 133 ± 4 128 ± 5 130 ± 5 140 ± 7
A rter ia l Plasma 0 6 . 6±0.2 6 . 7±0.3 7.1±0.4
** 6.9±0.3
Glucose (mM) 10 6. 7±0.2 8 . 3±0.4 10.2±1.4 
** 8 . 0±0.3
50 6 . 8±0.3 8 . 7±0 . 5 12 .8±1.3 10.1±0.6*
PCO2 0 41.0±1 .1 40 .6±0.8 3 7 . 6±1.4 4 0 . 0±1.0
(mmHg) 10 40 .0±1 .2 40.8±1.0 37 . 8±1.5 41 . 7±0. 6
50 38 .6±1.3 41 .2±0 .9 36.9±1.4 4 0 . 6±1.6
pc>2 0 93 ± 1 95 ± 2 -95 * 3 94 ± 1
(mmHg) 10 94 ± 3 96 ± 3 100 ± 3 95 ± 2
50 97 ± 3 99 ± 2 103 ± 3 104 ± 3
PH 0 7 . 40±0.01 7.41±0.01 7.41±0.01 7 . 39±0.01
10 7 . 40±0.02 7 . 40±0.01 7 . 39±0.02 7 . 38±0.02
50 7.41±0.01 7 . 39±0.01 7 . 40±0.01 7 . 37±0.02
Number of Animals 6 6 6 6
Data are presented as mean ± SEM. Data represent va lu es a t tim es 0, 10 and 50 
min fo llow in g  intravenous adm inistration  of CI-977 or v e h ic le  (c o n tr o ls ) . *P<0.05,  
**P<0.01 for  s t a t i s t i c a l  comparison between each drug-treated  group and v e h ic le -  
trea ted  co n tro ls  a t each time point (ANOVA, followed by S tu d en t's unpaired t - t e s t  
with Bonferroni c o r r e c t io n ) .
152
(Table 8). CI-977 a t the lowest dose of 0.03mg/kg had no e ffe c t on rec ta l
tem perature. However, the  use of external heating lamps throughout the 
experim ent makes accura te  in terp re ta tion  of drug-related  tem peratu re  e ffects  
difficult.
The adm inistration of CI-977 produced significant changes in a rteria l 
plasma glucose concentration (Table 8). CI-977 (0.03mg/kg) had no e ffec t
on plasma glucose over the tim e course of the  experim ents. Plasm a glucose 
levels were significantly increased by CI-977 a t 10 min (0.3mg/kg) and 50 min 
(0.3 and 3mg/kg) post-injection when compared to  veh icle-trea ted  control 
animals.
3.1.2 Local Cerebral Glucose Utilisation
The e ffec ts  of CI-977 (0.03, 0.3 and 3mg/kg) upon local cerebral glucose 
utilisation were examined in 45 anatom ically d iscrete  regions of the  CNS 
(Tables 9-12). In 15 of the 45 regions examined, no significant alterations 
in glucose use were observed with any dose of CI-977. In one region of the 
CNS, CI-977 significantly increased glucose with th e  in term ediate  and highest 
doses studied. The adm inistration of CI-977 significantly reduced glucose 
utilisation, generally with little  dose-dependency, in 29 regions of the  CNS. 
Of the 29 regions, 18 displayed significant reductions in glucose utilisation 
over the en tire  range of doses studied. The alterations in glucose use 
following CI-977 adm inistration are considered fu rther below in relation  to 
the functional organisation of the  CNS.
Prim ary Auditory and Visual Areas
The adm inistration of CI-977 reduced glucose u tilisation in the  visual 
and auditory cortices (layer IV), superior colliculus, medial geniculate body
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and inferior colliculus (Table 9). In these 5 regions the 3 doses of CI-977 
were equipotent. Glucose use in the la teral geniculate body, superior olivary 
nucleus and cochlear nucleus was minimally changed by CI-977 (Table 9).
Extrapyram idal and Sensory Motor Areas
CI-977 trea tm en t resulted in widespread reductions in glucose utilisation 
in m ost of the regions examined involved in m otor function (Table 10, Figure 
29). In the  cerebellar nucleus and cerebellar hem isphere, the  highest dose 
of CI-977 failed to  induce a significant decrease in glucose use (Table 10). 
Glucose u tilisation in 3 m otor areas, the inferior olivary nucleus, red nucleus 
and vestibular nucleus was minimally a ltered  by CI-977 (Table 10).
Following CI-977 adm inistration, prom inent decreases in glucose 
utilisation (about 30%) were observed in frontal and posterior parie ta l cortices 
(layer IV) and ven tro la teral thalamus (Table 10, Figure 29). Glucose use was 
m ost markedly depressed (by 35%) by CI-977 in the  sensory m otor cortex 
(Figure 29), although in all neocortical areas examined, glucose utilisation was 
decreased by a sim ilar degree with each of the 3 doses studied.
Limbic System and other Brain Areas
Increased glucose utilisation (about 40%) was observed in the  la teral 
habenular nucleus following adm inistration of CI-977 a t th e  in term ediate 
(0.3mg/kg) and highest (3mg/kg) doses examined (Table 11, Figures 29 & 30). 
In contrast, CI-977 produced significant reductions in glucose use in the 
hippocampus (dentate  gyrus and stratum  lacunosum m oleculare), amygdala, 
hypothalamus, interpeduncular nucleus, allocortical regions and dorsal raphe 
nucleus (Table 11, Figure 29). Of the allocortical regions examined, glucose 
use was m ost markedly depressed in the an terior entorhinal co rtex  (by 45%)
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TABLE 9
PRIMARY VISUAL AND AUDITORY AREAS:
GLUCOSE UTILISATION FOLLOWING THE ADMINISTRATION OF CI-977
CI-977 (mg/kg)
STRUCTURE CONTROL 0.03 0.3 3
Primary V isual System
V isual Cortex (IV) 91 ± 4 70 ± 4** 69 ± 2** 68 ± 4**
L ateral G eniculate Body 70 ± 3 59 ± 4 61 ± 1 60 ± 3
Superior C o llicu lu s 82 ± 8 60 ± 4* 68 ± 1 63 ± 4*
Primary Auditory System
Auditory Cortex (IV) 137 ± 4 95 ± 8** 98 ± 3** 91 ± 5**
Medial G eniculate Body 105 ± 6 79 ± 6** 82 ± 2** 78 ± 3**
In fer io r  C o llicu lu s 162 ± 6 117 ± 11* 106 ± 9** 105 ± 10**
Superior Olivary Nucleus 124 ± 9 98 ± 8 98 ± 5 112 ± 9
Cochlear Nucleus 137 t 7 122 ± 8 135 ± 7 130 ± 7
Rates o f g lucose u t i l i s a t io n  (jimol 100g min ) are derived from 24 animals and 
presented as mean ± SEM (n=6 per group). Roman numerals in d ica te  the c o r t ic a l
layer examined. *P<0.05, **P<0.01 for s t a t i s t i c a l  comparison between each 
C I-977-treated group and v e h ic le -tr e a te d  co n tro ls  (ANOVA follow ed by Student's  
unpaired t - t e s t  with Bonferroni c o r r e c t io n ) .
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TABLE 10
EXTRAPYRAMIDAL AND SENSORY MOTOR AREAS:
GLUCOSE UTILISATION FOLLOWING THE ADMINISTRATION OF CI-977
CI-977 (mg/kg)
STRUCTURE CONTROL 0. 03 0. 3 3
Caudate Nucleus 101 ± 4 76 ± 5** 74 ± 4** 76 ± 4**
Globus P a llid u s 51 ± 2 38 ± 2** 40 ± 3* 37 ± 2**
Substantia Nigra:
Pars compacta 64 ± 3 49 ± 3** 54 ± 3* 52 ± 2*
Pars r e t ic u la ta 50 ± 2 38 ± 2** 42 ± 2* 38 ± 1 **
Red Nucleus 77 ± 3 62 ± 4 69 ± 4 68 ± 3
V entrolateral Thalamus 81 ± 4 58 ± 5** 57 ± 4** 59 ± 2*
Subthalamic Nucleus 77 ± 3 62 ± 3* 68 ± 2 63 ± 5*
In fer ior  Olivary Nucleus 69 ± 2 61 ± 4 66 ± 1 67 ± 4
V estibular Nucleus 101 ± 4 90 ± 5 92 ± 3 96 ± 6
Cerebellar Nucleus 86 ± 4 69 ± 4* 71 ± 1* 75 ± 3
C erebellar Hemisphere 49 ± 2 40 ± 3* 41 ± 2 44 ± 2
Frontal Cortex (IV) 101 ± 6 75 ± 6** 82 ± 1 71 ± 5**
Sensory Motor Cortex (IV) 113 ± 6 79 ± 6** 75 ± 2** 70 ± 4**
P osterior P a r ie ta l Cortex 
(IV) 96 ± 5 70 ± 3** 74 ± 2** 68 ± 2 **
Rates of g lucose u t i l i s a t io n  ()imol 100g min ) are derived from 24 animals and 
presented as mean ± SEM (n=6 per group). Roman numerals in d ica te  the c o r t ic a l  
layer examined. *P<0.05, **P<0.01 for s t a t i s t i c a l  comparison between each CI-
977-treated  group and v e h ic le -tr e a te d  co n tro ls  (ANOVA follow ed by Student's  
unpaired t - t e s t  with Bonferroni c o r r e c t io n ) .
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TABLE 11
LIMBIC SYSTEM AND OTHER BRAIN AREAS:
GLUCOSE UTILISATION FOLLOWING THE ADMINISTRATION OF CI-977
CI-977 (mg/kg)
STRUCTURE CONTROL 0. 03 0. 3 3
Hippocampus, Molecular Layer 71 ± 3 57 i 3** 52 ± 2** 52 ± 3**
Dentate Gyrus 62 ± 2 47 ± 3** 46 ± 3** 46 ± 3**
Septal Nucleus 42 ± 3 40 i 2 37 ± 2 35 ± 2
Nucleus Accumbens 68 ± 4 63 ± 6 65 ± 4 57 ± 5
Amygdala 69 ± 2 54 ± 3* 58 ± 3 50 ± 6**
L ateral Habenular Nucleus 112 + 10 112 ± 6 159 ± 5** 144 ± 11*
Mediodorsal Thalamus 99 ± 4 83 ± 7 94 ± 3 85 ± 6
Hypothalamus 46 ± 2 38 ± 2 43 ± 3 33 ± 2**
Interpedunclar Nucleus 86 ± 5 70 ± 6 63 ± 6* 62 ± 3*
Anterior Cingulate Cortex 99 ± 5 83 ± 5 80 ± 5* 82 ± 5*
P oster ior  Cingulate Cortex 83 + 3 70 ± 5* 67 ± 3* 63 ± 2**
Anterior Entorhinal Cortex (I) 65 ± 2 43 ± 3** 42 ± 3** 36 ± 1 **
P oster ior  Entorhinal Cortex (I) 61 ± 3 46 ± 2** 45 ± 2** 40 ± 2**
Ventral Tegmental Area 57 ± 1 51 ± 3 58 i 1 53 ± 3
Dorsal Tegmental Nucleus 84 + 2 71 ± 4 77 ± 3 79 ± 3
Dorsal Raphe Nucleus 78 ± 2 64 ± 4* 69 ± 2 65 ± 4*
Median Raphe Nucleus 90 ± 1 79 ± 5 81 ± 1 78 ± 5
Pontine R ecticu lar Nucleus 60 ± 2 50 ± 3 52 ± 2 53 ± 4
Periaqueductal Grey Matter 52 ± 2 45 ± 2 53 ± 3 45 ± 2
Rates of g lucose u t i l i s a t io n  (junol 100g_1min ) are derived from 24 animals and 
presented as mean ± SEM (n=6 per group). Roman numerals in d ica te  c o r t ic a l  layer
examined. *P<0.05, **P<0.01 for s t a t i s t i c a l  comparison between each C I-977-treated  
group and v e h ic le -tr ea ted  co n tro ls  (ANOVA follow ed by Student's unpaired fc-test with  
Bonferroni c o r r e c t io n ) .
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CONTROL
C I-9 7 7
FIG URE 30
[14C]-2-Deoxyglucose autoradiograms prepared from coronal brain sections a t the 
level of the la teral habenular nucleus. Upper: control (saline, lm l/kg, i.v.). 
Lower: CI-977 (0.3mg/kg, i.v.). R elative optical density (which is re la ted  directly  
to ra te  of glucose utilisation) in lateral habenular nucleus is m arkedly g rea ter than 
control. Scale bar = 2mm.
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TABLE 12
MYELINATED FIBRE TRACTS:
GLUCOSE UTILISATION FOLLOWING THE ADMINISTRATION OF CI-977
CI-977 (mg/kg)
STRUCTURE CONTROL 0.03 0.3 3
Corpus Callosum 
Genu of Corpus Callosum 
In ternal Capsule 
C erebellar White Matter
36 * 2 
25 ± 1 
35 ± 1 
34 ± 1
28 ± 2* 
21 ± 2 
25 ± 1** 
25 ± 2**
29 ± 1 
22 ± 2 
24 ± 1** 
24 ± 1**
28 ± 3* 
20 ± 1
24 ± 2**
25 ± 1**
Rates of g lucose u t i l i s a t io n  (p.mol 100g min-1) are derived from 24 animals and 
presented as mean ± SEM (n=6 per group). *P<0.05/ **P<0.01 for  s t a t i s t i c a l  
comparison between each C I-977-treated  group and v e h ic le -tr e a te d  co n tro ls  (ANOVA 
follow ed by Student's unpaired t - t e s t  with Bonferroni c o rr e c tio n ).
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by CI-977 a t 3mg/kg (Table 11). No significant a lterations in glucose 
utilisation were displayed in 8 of the 19 limbic areas examined (Table 11, 
Figure 29).
M yelinated Fibre T racts
CI-977 produced significant decreases in glucose utilisation in the  corpus 
callosum, internal capsule and cerebellar white m a tte r  (Table 12). No 
significant change in glucose use was observed in the  genu of corpus callosum 
a t any dose of CI-977 (Table 12).
3.2 C erebral C irculatory  E ffec ts  o f CI-977
3.2.1 Behaviour and Physiological Variables
The adm inistration of CI-977 (0.3mg/kg, i.v.) produced sim ilar e ffects  
on the behaviour of the  conscious animals and m onitored physiological 
variables (Table 13) to those described in the glucose u tilisation study (Section 
3.1.1).
3.2.2 Local Cerebral Blood Flow
The e ffec ts  of CI-977 (0.3mg/kg) on local cerebral blood flow were 
examined in the sam e 45 brain regions analysed in the glucose utilisation 
study (Section 3.1), defined using identical neuroanatom ical c rite ria .
The cerebral circulatory  e ffec ts  of CI-977 in the  45 CNS regions 
investigated are presented in Table 14. The adm inistration of CI-977 induced 
a significant reduction in local cerebral blood flow in one brain area, the 
posterior entorhinal cortex  (I). In 44 of the  45 regions studied local cerebral 
blood flow was not a lte red  significantly with CI-977 trea tm en t, and no 
significant increases in cerebral blood flow were observed (Table 14).
*
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TABLE 13
CEREBRAL CIRCULATORY STUDY:
CARDIOVASCULAR. RESPIRATORY AND OTHER PHYSIOLOGICAL VARIABLES 
AFTER ADMINISTRATION OF CI-977 TO CONSCIOUS RATS
TIME AFTER 
DRUG (min)VARIABLE CONTROL CI-977
R ectal Temperature (°C) 0 36.9 ± 0.3 37.0 ± 0.2
10 37.0 ± 0.1 36.5 ± 0.1**
Mean A rter ia l Blood 0 133 ± 6 132 ± 4
Pressure (mmHg) 10 135 ± 4 133 ± 5
A rter ia l Plasma 0 8 .7  ± 0 .3 8 .4  ± 0 .4
Glucose (mM) 10 8 .9  ± 0 .2  • 11.2 ± 0.5**
pCC>2 (mmHg) 0 38.3 ± 0.7 39.6 ± 1.1
10 37.1 ± 0.5 37.3 ± 1.3
p0o (mmHg) 0 96 ± 3 96 ± 4c. 10 97 ± 2 103 ± 2
PH 0 7.41 ± 0.02 7.41 ± 0.01
10 7.42 ± 0.01 7.41 ± 0.02
Number of Animals 7 8
Data are presented as mean ± SEMv. Data represent va lues a t tim es 0 and 10 min 
fo llow ing adm inistration  of CI-977 (0.3mg/kg) or v e h ic le  (c o n tr o ls ) . **P<0.01 
for s t a t i s t i c a l  comparison between v e h ic le -tr e a te d  co n tro ls  and C I-977-treated  
animals (unpaired, tw o -ta iled  S tudent's t - t e s t ) .
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TABLE 14
THE EFFECTS OF CI-977 (0.3mg/kg. i.v.) UPON LOCAL CEREBRAL BLOOD FLOW 
AND LOCAL CEREBRAL GLUCOSE UTILISATION IN CONSCIOUS RATS
CEREBRAL BLOOD FLOW 
(ml lOOg ’min ’)
GLUCOSE UTILISATION 
(pmol lOOg ’min- ’)
BRAIN REGION CONTROL CI--977 CONTROL CI-977
Medulla/pons
Inferior Olivary Nucleus 130 ± 15 117 ± 7 69 ± 2 6 6 ± 1
Pontine Reticular Formation 99 ± 1 0 91 ± 5 60 ± 2 52 ± 2
Vestibular Nucleus 175 ± 13 150 ± 8 1 0 1 ± 4 92 ± 3
Cochlear Nucleus 175 ± 13 175 ± 1 2 137 ± 7 135 ± 7
Superior Olivary Nucleus 163 ± 13 150 ± 9 124 ± 9 98 ± 5
Dorsal Raphe Nucleus 125 ± 1 2 1 1 2 ± 5 78 ± 2 69 ± 2
Median Raphe Nucleus 126 ± 1 2 119 ± 6 90 ± 1 81 ± 1
Cerebellum
Cerebellar Cortex 94 ± 1 1 74 ± 4 49 ± 2 41 ± 2
Cerebellar Nucleus 164 ± 13 136 ± 8 8 6 ± 4 71 ± 1
Cerebellar White Matter 54 ± 7 44 ± 2 34 ± 1 24 ± 1 **
Mesencephalon
Inferior Colliculus 236 ± 2 2 189 ± 1 2 162 ± 6 106 ± g**
Superior Colliculus 
Substantia Nigra,
123 ± 13 109 ± 5 82 ± 8 6 8 ± 1
pars reticulata 71 ± 4 67 ± 3 50 ± 2 42 ± 2 *
pars compacta 79 ± 3 78 ± 4 64 ± 3 54 ± 3*
Red Nucleus 1 1 0 ± 1 1 99 ± 4 77 ± 3 69 ± 4
Ventral Tegmental Area 75 ± 9 63 ± 3 57 ± 1 58 ± 1
Dorsal Tegmental Nucleus 137 ± 14 1 2 0 ± 5 84 ± 2 77 ± 3
Periaqueductal Grey Matter 92 ± 8 74 ± 4 52 ± 2 53 ± 3
Interpeduncular Nucleus 103 ± 7 103 ± 5 8 6 ± 5 63 ± 6 *
Diencephalon
Medial Geniculate Body 163 ± 18 127 ± 8 105 ± 6 82 ± 2 **
Lateral Geniculate Body 1 2 0 ± 15 107 t 8 70 ± 3 61 ± 1
Subthalamic Nucleus 117 ± 13 1 1 0 ± 7 77 ± 3 6 8 ± 2
Hypothalamus 75 ± 7 63 ± 5 46 ± 2 43 ± 3
Lateral Habenular Nucleus 138 ± 1 1 160 ± 1 2 1 1 2 ± 1 0 159 ± 5**
Ventrolateral Thalamic Nucleus 125 ± 16 109 ± 8 81 ± 4 57 ± 4 **
Mediodorsal Thalamic Nucleus 148 ± 19 135 ± 8 99 ± 4 94 ± 3
Telencephalon
Hippocampus, molecular layer 95 ± 1 2 82 ± 7 > 1 ± 3 52 ± 2#*
Dentate Gyrus 99 ± 1 1 83 ± 7 62 ± 2 45 ± 3**
Amygdala 78 ± 8 65 ± 5 69 ± 2 58 ± 3
Globus Pallidus 74 ± 1 0 65 ± 4 51 ± 2 40 ± 3*
Septal Nucleus 94 ± 1 2 8 8 i 8 42 ± 3 37 ± 2
Caudate Nucleus 127 ± 16 104 ± 6 1 0 1 ± 4 74 ± 4 *#
Nucleus Accumbens 118 ± 18 117 ± 1 1 6 8 ± 4 65 ± 4
Visual Cortex (IV) 1 2 0 ± 17 89 ± 7 91 ± 4 69 ± 2**
Auditory Cortex (IV) 228 ± 37 170 t 14 137 ± 4 98 ± 3**
Posterior Parietal Cortex (IV) 154 ± 2 2 133 t 19 96 ± 5 74 ± 2**
Sensory Motor Cortex (IV) 167 + 25 140 t 9 113 ± 6 75 ± 2**
Frontal Cortex (IV) 161 ± 2 1 157 ± 13 1 0 1 ± 6 82 ± 1
Anterior Cingulate Cortex 144 + 27 136 ± 15 99 ± 5 80 ± 5*
Posterior Cingulate Cortex 125 ± 19 98 ± 6 83 ± 3 67 ± 3*
Anterior Entorhinal Cortex (I) 70 ± 7 53 ± 4 65 ± 2 42 ± 3**
Posterior Entorhinal Cortex (I) 92 ± 9 63 ± 5* 61 ± 3 45 + 2 *#
Myelinated Fibre Tracts
Corpus Callosum 43 ± 4 39 ± 3 36 ± 2 29 ± 1
Genu of Corpus Callosum 50 ± 5 48 ± 4 25 ± 1 2 2 ± 2
Internal Capsule 47 ± 4 40 ± 2 35 ± 1 24 ± 1 *#
Cerebral blood flow  values are derived from 15 animals and presented as 
mean ± SEM (n=7 con tro l; n=8 CI-977).  Roman numerals in d ica te  c o r t ic a l  
layer  examined. *P<0.05, **P<0.01 for s t a t i s t i c a l  comparison between
v e h ic le -tr e a te d  co n tro ls  and C I-977-treated  group in  each brain region  
(unpaired, tw o -ta iled  Student's t - t e s t ) .
Cerebral g lucose u t i l i s a t io n  data are extracted  from S ection  3 .1 .2  for  
d ir e c t  comparison of the r e la t io n sh ip  between cerebral blood flow and 
glucose use in  a l l  brain regions examined.
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Of the 44 brain regions which failed to display s ta tis tica lly  significant 
a lterations in cerebral blood flow, m odest reductions (about 20%) were 
observed in 16 areas. These included allocortical and neocortical regions, 
and the  cerebellum  (e.g. posterior cingulate cortex: controls = 125 ± 19ml 
100g_1 min-1; CI-977 = 98 ± 6ml 100g-1 min-1). A m odest, non-significant 
elevation (16%) was observed in 1 brain region, the la te ra l habenular nucleus 
(controls = 138 ± 11ml 100g_1 min-1; CI-977 = 160 ± 12ml lOOg"1 min-1. The 
autoradiogram s from  C I-977-treated  ra ts  were indistinguishable from  those 
of veh icle-treated  control ra ts , and on detailed visual inspection no regions 
(not even the posterior entorhinal cortex) could be identified accurately  as 
displaying focal a lterations in local cerebral blood flow.
3.3 Relationship betw een C erebai Blood Flow and Glucose U tilisation
D ata from the studies on glucose utilisation (Section 3.1) and cerebral 
blood flow (Section 3.2) in conscious ra ts  were combined to investigate the 
consequences of CI-977 (0.3mg/kg) adm inistration on the  coupling of blood 
flow to oxidative m etabolism  in normal brain (Table 14).
3.3.1 Flow-Metabolism Coupling and CI-977
In veh icle-trea ted  control animals, there  was an excellent linear 
relationship (/^0.93, p<0.001) betw een local cerebral blood flow and local 
cerebral glucose u tilisation (Figure 31). The average ra tio  of local cerebral 
blood flow to glucose use in the  45 regions examined was 1.52ml/)junol (range 
1.08 - 2.24ml/jomol). Areas in which blood flow is g rea tes t, e.g. inferior 
colliculus and auditory cortex  (IV) displayed also the  highest ra te s  of glucose 
utilisation, whereas areas in which local cerebral blood flow is lowest, such 
as in white m a tte r  tra c ts , consistently display the  lowest ra te s  of glucose use
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FIGURE 31
E ffects of CI-977 (0.3mg/kg, i.v.) on the relationship between local cerebral blood 
flow and local cerebral glucose use. Upper: veh icle-treated  control animals.
Lower: C I-977-treated animals. Each point represents the mean cerebral blood 
flow and mean glucose use in one brain region. Linear regression analysis of this 
data yielded a slope of 1.37ml/jjLmol and r = 0.93 for controls and a slope of 
1.25ml/)imol and r  = 0.88 for C I-977-treated animals. The regression line in both 
graphs is tha t for control animals. Note the apparent lack of e ffe c t of CI-977 on 
cerebral blood flow rela tive to glucose use in the la teral habenula (L.H.) (increased 
by 16% and 42% from controls respectively).
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(Table 14).
In animals which had received CI-977 (0.3mg/kg) th e re  was a strong 
linear relationship (r=0.88, p<0.001) betw een local cerebral blood flow and 
glucose u tilisation over all regions (Figure 31). The average ra tio  between 
local cerebral blood flow and glucose use in the  45 regions examined in 
animals tre a ted  with CI-977 was 1.60ml/pmol (range 1.01 - 2.24ml/jjLmol). 
In 44 of the  45 brain regions examined, cerebral blood flow rem ained tightly 
coupled to  local oxidative m etabolism  a fte r  CI-977 (Figure 31). In only one 
brain area, the la te ra l habenula, was there  a tendency towards a possible 
uncoupling of cerebral blood flow and glucose use a f te r  drug adm inistration 
(Figure 31), although this did not reach s ta tis tica l significance using repeated 
m easures analysis of variance of log transform ed data.
The transform ation of data to  natural logarithms of the  mean values for 
cerebral blood flow and glucose use (McCulloch e t  al., 1982) reveals a linear 
relationship between the  two param eters, which is characterised  by unit slope 
and in te rcep t a  (Figure 32). S ta tistica l comparison of the  a  values allows 
changes in the overall relationship to  be revealed. Thus, although a  changed 
from  0.80 in veh icle-trea ted  controls to  0.94 in animals tre a ted  with CI-977 
(Figure 32), this change was not significantly d ifferen t. Therefore, the 
association which exists in conscious ra ts  betw een local cerebral blood flow 
and local cerebral glucose utilisation was unaltered by CI-977 trea tm en t.
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FIGURE 32
Relationship betw een local cerebral glucose utilisation and local cerebral blood 
flow presented as a logarithm ic transform ation of mean values for each of 45 
d iscrete  regions of conscious ra t brain in vehicle-treated  control animals (upper) 
and animals th a t received CI-977 (0.3mg/kg, i.v.) (lower). The relationship is 
described by a line with gradient unity and a point of in tercep t (a). There is an 
excellent correlation between local blood flow and glucose use in both the vehicle 
and C I-977-treated groups (r = 0.92 for both groups).
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CHAPTER IV 
DISCUSSION
1. ANTI-ISCHAEMIC EFFICACY OF CI-977
There are no pharm acological interventions designed to  p ro tec t cerebral 
tissue from ischaem ic damage which are in widespread clinical use a t the 
present tim e. The results presented in this thesis represen t fundamental 
observations th a t adm inistration of the /c-opioid recep to r agonist CI-977 
before and a fte r  perm anent MCA occlusion in the  r a t  and c a t reduces the 
volume of ischaem ic brain dam age th a t develops subsequently. Such data 
therefo re  substantiates and extends previous evidence th a t k -opioid agonists 
can am eliorate the  consequences of cerebral ischaem ia in certa in  animal 
models.
Animal models of focal ischaemia were used in this thesis. Perm anent 
occlusion of the MCA in both the ra t and c a t have generated the  most 
consistent dem onstrations of anti-ischaem ia efficacy  of NMDA recep tor 
antagonists, and provided the basis th a t modulation of excitotoxic mechanisms 
is a sound therapeutic  stra tegy  with which to approach the developm ent of 
neuroprotective agents. However, as crucial as the choice of animal model 
of ischaemia, is the selection of the  experim ental endpoint: H itherto , almost 
all investigations of the beneficial e ffects  of k-agonists have been res tric ted  
to  rodent models of global ischaem ia, with many using experim ental endpoints 
such as brain w ater content, m ortality  ra te , neurological deficits and duration 
of survival as m easures of cerebral protection (Silvia & Tang, 1986; Silvia e t 
al., 1987; Tang, 1985). These param eters however are not sufficiently 
unambiguous for use as determ inants of anti-ischaem ic efficacy. It is now 
accepted th a t the  dem onstration of a reduction in the  am ount of brain 
damage (assessed histologically or with MRI) with drug trea tm en t is an 
absolute requirem ent in anti-ischaem ic drug evaluation. As such, models of 
focal ischaemia are advantageous in th a t they lend them selves to  volum etric
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assessm ent of lesion size, and therefo re  the  neuroprotective efficacy of 
CI-977 was assessed using quantita tive  neuropathology a t both the  microscopic 
and m acroscopic level.
The present studies provide definitive evidence th a t k-opioid agonists 
are neuroprotective following focal cerebral ischaemia in both a lissencephalic 
and gyrencephalic species where key system ic variables which are believed 
to  influence outcom e were continuously m onitored throughout the  post- 
ischaem ic survival period. A previous study describing the  efficacy of 
CI-977 in a r a t  model of focal ischaem ia (perm anent MCA occlusion and 
ipsilateral caro tid  arte ry  occlusion) assessed outcom e a t 48h post-ischaem ia, 
which precluded the monitoring of these variables (Boxer e t  al., 1991), when 
CI-977 was adm inistered as bolus injections a t 30 min and 24h a fte r the  
ischaem ic insult only. The plasma half-life of CI-977 is approxim ately lh  
in the r a t  (G.N. Woodruff, unpublished observations), and this suggests th a t 
the  dosing regimen used was insufficient for a 48h survival period (Figure 
33). In order to negate sim ilar criticism  given such pharm acokinetic 
considerations, a m ultiple drug trea tm en t schedule-w as' employed (CI-977 
adm inistered 30 min pre- and post-ischaem ia and every 6 hrs thereafter) to 
try  and m aintain adequate plasm a levels of CI-977 throughout the post- 
ischaem ic survival period when outcom e was assessed a t 24h a f te r  perm anent 
MCA occlusion in the ra t  (Figure 33).
The pivotal observation th a t CI-977 reduces ischaem ic dam age in the c a t 
is particularly  im portant for a number of reasons. F irst, as the  u ltim ate 
clinical ta rg e t (humans) for anti-ischaem ic drugs is a gyrencephalic species, 
i t  would be imprudent to proceed to clinical trials  on the  basis of solely 
lissencephalic evidence. Second, the ease with which waves of spreading 
depression (in which glutam ate plays a role) are propagated in the
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FIGURE 33
C alculated plasma levels of CI-977 (in absolute units) following the adm inistration 
of CI-977 30 min before and 30 min a fte r MCA occlusion in the ra t and a t 6 hourly 
intervals th e rea fte r until sacrifice a t 24h. These values are based on a simple one- 
com partm ent pharm acokinetic model assuming a linear exponential c learance. The 
dotted line represents the calculated plasma levels following a single bolus of 
CI-977 30 min a fte r the induction of ischaemia as used by Boxer e t al., 1991. 
Plasma levels of CI-977 are apparently g rea ter throughout the experim ental duration 
using the m ultiple dosing paradigm when compared to a single bolus injection. 
However, recen t evidence suggests th a t there  may be a second, slower clearing 
com partm ent a t approximately 6h a fte r CI-977 adm inistration (Hayward e t al., 
1993b).
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lissencephalic brain and the  debate about the contribution of suppression of 
spreading depression for the  anti-ischaem ic efficacy  of NMDA antagonists 
(Gill e t  al., 1992a; Iijima e t al., 1992) fu rther emphasise the  im portance of 
data  from  gyrencephalic species. Third, CI-977 was adm inistered as an i.v. 
bolus followed by a continuous i.v. infusion to  m aintain constant plasma drug 
levels for the  duration of the study; this dosing regim en is m ost pertinen t 
to  use in humans in the  clinical situation.
The re la tive  neuroprotective efficacy  of the k-opioid agonist CI-977 with 
postsynaptic NMDA recep to r blockade and AMPA recep to r blockade remains 
to  be fully established. In the ra t, the reduction in the  volume of ischaem ic 
damage with CI-977 is of a slightly lesser magnitude to  th a t observed 
previously with the non-com petitive NMDA antagonist MK-801 (Gill e t  al., 
1991a; H atfield e t  al., 1992; Park e t al., 1988b), but com parable to th a t 
obtained with the AMPA antagonist NBQX (Gill e t  al., 1992b), in sim ilar ra t  
models of focal cerebral ischaemia. In the  ca t, in the  p resent study, the 
volume of tissue salvaged with CI-977 (776mm ) is sm aller than th a t noted 
with com petitive and non-com petitive NMDA receptor-antagonists (1300mm 
and 1600mm3, respectively) (Bullock e t al., 1990; O zyurt e t  al., 1988) but 
sim ilar to th a t salvaged with polyamine s ite -recep to r antagonists (750- 
800mm3) (Gotti e t  al., 1988) and the AMPA recep tor antagonist LY-293558 
(600mm3) (Bullock e t al., 1994). One im portant caveat is th a t extrem e 
caution m ust be exercised in comparing data  from d ifferen t research  groups 
and d ifferen t studies because of subtle but potentially  im portant differences 
in experim ental design (e.g. type of anaesthesia, surgical technical, survival 
period etc .). It should be recognised th a t for k-opioid recep to r agonists, 
including CI-977 in the  present study (as well as for AMPA antagonists 
elsewhere), much less atten tion  has been focused upon optimising dosing
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regimen, ra th e r than establishing anti-ischaem ic efficacy, than for NMDA 
recep tor antagonists (see G otti e t  al., 1988; Gill e t  al., 1991a; Chen e t  al., 
1991b for precise definition of dose dependency of the  response to  NMDA 
antagonists).
The degree of neuroprotection afforded by CI-977 is sim ilar to  th a t 
obtained by the /c-agonist GR89696. The repeated  adm inistration of GR89696 
produced 35% reduction in cerebrocortical in farc t volume in a mouse model 
of focal ischaem ia when trea tm en t was in itiated  6h a fte r  the  induction of 
ischaemia (Birch e t  al., 1991). This observation also suggests th a t a window 
of therapeutic  opportunity may exist for CI-977 following perm anent MCA 
occlusion in the r a t  and cat.
The adm inistration of CI-977 reduced the volume of ischemic damage 
only within the  cerebral cortex following perm anent MCA occlusion in the  ra t 
and cat. Minimal protection was observed in the  basal ganglia. These 
e ffec ts  are consistent with o ther anti-ischaem ic agents, m ost notably the 
NMDA recep tor antagonists and AMPA recep to r antagonists in sim ilar models 
of focal ischaemia (Bullock e t  al., 1990, 1994; Gill e t  al., 1991a, 1992b). The 
in farct rim  of the cerebral cortex where neuroprotection is seen is described 
as a region which has the characteristics of the  ischaem ic penumbra (Astrup 
e t  al., 1981). Following MCA occlusion, this area has a regional blood flow 
of approximately 20% normal levels (Tamura e t  al., 1981b; Tyson e t  al., 1984), 
which is the threshold level a t which synaptic transmission is abolished, but 
normal ionic homeostasis is m aintained. The penumbra displays an increase 
in glucose use, putatively  due to  an increased demand on ionic pumps to 
m aintain ionic homeostasis (Nedergaard & Astrup, 1986). The lack of e ffe c t 
of CI-977 in the  caudate putam en is probably due to  the fa c t th a t the 
len ticu lostria te  branches which supply this region are effectively  end a rteries
173
(Tamura e t  al., 1981a), and occlusion of these  branches markedly reduces 
blood flow to  less than 10% of normal levels (Tamura e t  al., 1981b; Tyson 
e t  al., 1984). Consequently, there  is insufficient energy to enable a re tu rn  
to  normal ionic homeostasis (Siesjo & Bengtsson, 1989), even in the presence 
of CI-977. Thus, as is the  case with the  NMDA antagonists and presumably 
AMPA antagonists in models of focal ischaem ia, the lack of protection in the 
caudate nucleus indicates th a t a minimal level of cerebral blood flow is 
required for anti-ischaem ic efficacy  of k-opioid agonists like CI-977.
In the  present investigations, the  e ffe c t of CI-977 on histologically 
defined ischaem ic brain damage was assessed a t 4h and 6h a f te r  the  induction 
of ischaemia in the r a t  and c a t respectively. The principal advantage of 
assessing early  infarction ra th e r than overt infarction which is identifiable 
1-7 days a f te r  the induction of ischaemia, is th a t c ritica l physiological 
variables can be repeatedly  assessed (e.g. MABP, plasm a glucose) or 
m aintained within defined lim its (e.g. core body tem peratu re, respiratory 
blood gas status). In the absence of such inform ation, th e  ex ten t to which 
such system ic factors have contributed or confounded assessm ent a t anti- 
ischaemic drug action cannot be determ ined with certain ty . However, by 
assessing drug-induced reductions in early  cerebral infarction, it  could be 
argued th a t CI-977 is delaying the  developm ent of, but not actually  preventing 
ischaemic cell death. While such an e ffe c t cannot be dismissed absolutely, 
the dem onstrations th a t perm anent MCA occlusion in the  r a t  produces a 
sim ilar degree of ischaem ic brain damage and com parable neuroprotective 
e ffe c t of CI-977 (0.3mg/kg) when outcom e is assessed a t both 4h and 24h 
a fte r the induction of ischaemia suggests th a t CI-977 is not neuroprotective 
by m erely delaying ischaem ic cell death in this model. This is concordant 
with the observations th a t maximal infarction is seen 3-4h a f te r  focal
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cerebral ischaemia in the ra t (Kaplan e t  al., 1991; Memezawa e t  al., 1992) 
and th a t, unlike transien t models of global ischaemia, there  is no delayed 
neuronal degeneration following perm anent MCA occlusion in the ra t  
(Nedergaard, 1988).
The im portance of monitoring and controlling physiological variables in 
studies of neuroprotective drugs in animal models of cerebral ischaemia is 
increasingly recognised (Ginsberg & Busto, 1989; Graham, 1988). In the 
m ajority of investigations, particularly  those with outcom e assessed 24h or 
more a f te r  the insult, monitoring is effectively  re s tric ted  to the surgical and 
im m ediate post-operative period (Buchan e t  al., 1991c; Gill e t  al., 1992b). 
The results of the present studies provide evidence th a t the  benefit conveyed 
by the  /c-agonist CI-977 in focal cerebral ischaem ia is unlikely to  be 
a ttribu ted  to a rte f  actual or indeed drug-induced a lterations in key 
physiological variables such as MABP or tem perature.
CI-977 induced a m arked and sustained hypotension throughout the post- 
ischaemic period in halothane-anaesthetised ra ts . Hypotension is an 
im portant fac to r in the evolution of ischaemic brain damage. A fte r the 
induction of ischaemia, blood flow to perischaem ic tissue is linearly re la ted  
to perfusion pressure, and small reductions in a rte ria l pressure can increase 
the severity  of the insult (Hossmann, 1982). It has been shown in a r a t  MCA 
occlusion model th a t a period of transien t haem orrhagic hypotension (MABP 
of 60mmHg for 30 min) im m ediately a fte r  occlusion of the MCA increased 
the volume of ischaemic brain damage by m ore than 50% from  th a t observed 
in normotensive animals (Osborne e t al., 1987) by reducing blood flow to  the 
ischaemic penumbra to even lower levels (Dirnagl & Pulsinelli, 1990). Thus, 
the  hypotension th a t following the adm inistration of CI-977 m ight have been 
expected to  exacerbate  ischaemic brain damage. The volume of infarction
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was, in fac t, reduced with CI-977 despite the  induced hypotension thereby 
dem onstrating the  m arked neuroprotective efficacy  of this agent. 
Consequently, it  is also possible th a t the neuroprotection afforded by CI-977 
was underestim ated. In addition, the hypotensive e ffe c t of CI-977 may 
underpin the  U-shaped dose-response curve to  CI-977 when outcom e was 
assessed 24h a f te r  the induction of ischaemia in the  ra t. Progressive 
hypotension with increasing doses of CI-977 would tend to  counterbalance the 
neuroprotective e ffec ts  of this drug. This would account for the U-shape 
neuroprotection dose-response curve to CI-977 and the  failure of the  highest 
concentration of CI-977 (3mg/kg) to display significant neuroprotection. A 
U-shaped response of infarction volume versus dose has also been observed 
with MK-801 in focal ischaemia in the halothane-anaesthetised ra t  which was 
a ttribu ted  to  hypotension induced by the highest doses of MK-801 (Gill e t  al., 
1991a).
The adm inistration of CI-977 also induced a decrease in MABP in 
halothane-anaesthetised cats. In con trast to the hypotensive e ffe c t observed 
in the ra t, the reduction in MABP was transien t, such th a t a t the  tim e of 
MCA occlusion, MABP had returned  to pre-adm inistration levels, and did not 
significantly deviate from control levels throughout the  en tire  post-ischaem ic 
period. A t present there  is no reliable evidence th a t transien t, m oderate 
hypotension prior to  the induction of ischaemia by perm anent occlusion of the 
MCA is neuroprotective. R ecent evidence suggests th a t a prior reduction 
of cerebral blood flow, produced by brief, sublethal periods of global 
ischaem ia reduces the  volume of infarction produced by subsequent perm anent 
MCA occlusion in the  ra t  (Simon e t  al., 1993) and p ro tec ts  hippocampal 
pyramidal neurones to  subsequent, lethal periods of global ischaem ia in both 
ra ts  and gerbils (Kirino e t  al., 1991; Liu e t al., 1992), putatively  by inducing
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the  expression of heat shock proteins (HSP70, HSP72). Thus, if a sim ilar 
phenomenon of ischaem ic to lerance was to  occur as a resu lt of the transient, 
hypotensive e ffe c t prior to MCA occlusion in the ca t, it  may contribute to 
the  neuroprotective e ffe c t of CI-977. However, the  autoregulatory 
mechanism will a tten u a te  the  reduction in cerebral blood flow in response to 
the hypotensive episode prior to the  induction of ischaem ia and the  tim e 
constant (10-20 sec) will allow episodes of only transien t hypoperfusion, and 
thereby have negligible influence on the neuroprotective efficacy  of CI-977.
There is conflicting evidence available regarding the  e ffec ts  of 
alterations in plasma glucose concentration upon ischaem ic brain damage in 
animal models of cerebral ischaemia (Marie & B ralet, 1991). In models of 
perm anent focal ischaemia, several studies suggest th a t hyperglycaemia 
increases the  volume of infarction (de Courten-M eyers e t al., 1988; Duverger 
& M acKenzie, 1988; Prado e t al., 1988), whereas others suggest th a t it e ither 
decreases (Ginsberg e t  al., 1987b; K raft e t al., 1990; Zasslow e t al., 1989) or 
has no e ffe c t (Nedergaard & Diemer, 1987). A t present, th e re  is no reliable 
evidence describing the  e ffec ts  of reduced plasma glucose on ischaem ic brain 
damage following perm anent focal ischaemia. The adm inistration of CI-977 
reduced plasma glucose by 10% throughout the  post-ischaem ic survival period 
in halothane-anaesthetised ra ts . However, huge a lterations (3-fold) in plasma 
glucose are required to  a lte r lesion size by 25% a fte r  perm anent MCA 
occlusion in the  r a t  (Duverger & MacKenzie, 1988). Thus, it  is unlikely th a t 
the  m odest reduction in plasma glucose concentration produced by CI-977 has 
a m ajor e ffec t, e ither beneficial or detrim ental, on the  final volume of 
infarction.
The issue of brain tem peratu re  in the evaluation of anti-ischaem ic 
efficacy  of drugs is of m ajor im portance (see Ginsberg e t  al., 1992 for
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review). In particu lar, there  is om nipresent concern w hether observed anti- 
ischaem ic efficacy  can be attribu ted /ascribed  to a rte fac tu a l a lterations in 
brain tem peratu re. There are th ree  reasons why the neuroprotective e ffec ts  
of CI-977 in the  p resent investigations with perm anent occlusion of the  MCA 
(where ex tracranial perfusion is preserved) are unlikely to be due to  such an 
a rte fa c t. F irst, deep body tem perature  was sim ilar in both veh icle-treated  
and C I-977-treated animals. Second, the  experim ental design and conduct 
did not involve any procedure (such as compromising ex tracranial blood flow 
or d irec t heating of the  head) which could a lte r a r te f  actually the  relationship 
betw een deep body tem peratu re  and brain tem peratu re  in some animals. 
Third, unlike global ischaemia (Busto e t  al., 1987) and reperfusion a f te r  focal 
ischaem ia (Chen e t al., 1992a; Moyer e t  al., 1992; Zhang e t  al., 1993), brain 
tem peratu re  has only a minor influence on the amount of ischaem ic brain 
dam age a fte r  perm anent MCA occlusion (Morikawa e t  al., 1992; Ridenour e t 
al., 1992).
Previous evidence th a t k -opioid agonists are neuroprotective was derived 
alm ost exclusively from investigations in rodent models of global ischaemia 
with outcom e assessed a t long periods a fte r the ischaem ic insult. The 
observations in this thesis makes th ree  im portant contributions to  support this 
therapeu tic  approach. F irst, unequivocal benefit a f te r  tre a tm en t with the 
k -opioid agonist has been shown in both a lissencephalic species (rat) and 
gyrencephalic species (cat). Second, the  anti-ischaem ic efficacy  has been 
dem onstrated in models of perm anent MCA occlusion. Third, the  reduction 
in infarction which CI-977 confers is not dependent upon alterations in c ritica l 
system ic variables (MABP, tem perature, plasma glucose) which are thought 
to  influence outcome; for the firs t tim e with k-opioid agonists, all of these 
variables have been m onitored continuously from the  onset of ischaem ia until
178
sacrifice.
2. MECHANISM OF ANTI-ISCHAEMIC ACTION
2.1 Brain Swelling
The pharm acological mechanism to which the neuroprotective e ffe c t of 
/r-opioid agonists is commonly a ttribu ted  to  a reduction in cerebral oedema 
(Silvia & Tang, 1986; Silvia e t al., 1987). There is a 40-50% m ortality  ra te  
among severely head-injured patien ts arising prim arily as a resu lt of raised 
in tracranial pressure and subsequent reduced cerebral perfusion due to 
cerebral oedema and/or non-recovery lesion developm ent (i.e. subdural 
haem atom as, contusions, lacerations) (Lobato e t al., 1988; Luersson e t  al., 
1988). This underscores the  decision to investigate the efficacy  of CI-977 
24h a fte r perm anent MCA occlusion in the ra t. By assessing outcom e a t 24h, 
infarction and brain swelling are well developed, and thus it is possible to 
examine both param eters in the sam e animal and determ ine any in ter­
relationship betw een the volume of swelling and the  volume of infarction 
a f te r  drug trea tm en t.
k-Opioid agonists are known to possess diuretic actions and m odulate the 
release of vasopressin (Peters e t al., 1987; Slizgi e t al., 1984; Wells & 
Forsling, 1991). The induction of w ater diuresis produces an increase in 
plasma osm olality and the subsequent hyperosmotic s ta te  resu lts in the 
restric tion  of oedema developm ent and secondary neuronal dam age (Silvia & 
Tang, 1986; Silvia e t al., 1987). In addition, prelim inary data  with MCA 
occlusion in the  ra t  indicate th a t CI-977 does not reduce in fa rc t size in 
Brattleboro ra ts  (in which it  does not produce diuresis), although in the 
Fischer 344 stra in  CI-977 reduces the volume of infarction to  a sim ilar ex ten t 
as th a t observed in the present studies (Boxer e t al., 1991). On the  basis of
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such evidence, it was postulated th a t the  prim ary m echanism to account for 
the neuroprotection conferred by k-opioid agonists is to  reduce cerebral 
oedema through a w ater diuresis.
However, evidence is presented in this thesis to  suggest th a t this 
pharm acological action is not the principal mechanism to explain the 
anti-ischaem ic efficacy  of CI-977 and o ther k -opioid recep to r agonists. 
Comparison of the potency of CI-977 as a d iuretic  (Hunter e t  al., 1990) and 
neuroprotective agent in the  ra t indicate th a t, a t the  dose producing 
maximum diuresis, CI-977 has no significant e ffe c t on the  volume of 
ischaemia following MCA occlusion. In addition, CI-977 is neuroprotective 
in the gerbil model of global ischaemia in spite  of the  absence of diuresis, 
whilst the  diuretic  furosemide affords no neuroprotection a t doses th a t 
produce a m arked diuresis (Hayward e t al., 1992). Furtherm ore, although 
brain swelling (an indirect m easure of oedema) was clearly  reduced by 
CI-977 trea tm en t when outcom e was assessed 24h a f te r  the  onset of 
ischaemia, there  was no disproportionate reduction in swelling re la tive  to 
infarction in the  ra t. A parallel reduction in infarction and swelling has been 
described with nimodipine, for which no prim ary anti-oedem a action has ever 
been proposed (rather, the  converse) (Harris e t  al., 1982; Hossmann, 1982; 
Jacewicz e t  al., 1990a). In the  ca t, CI-977 produced a progressive increase 
in plasma osmolality throughout the post-occlusion period. The m agnitude 
a t the increase in plasma osm olality induced by CI-977 is com parable to th a t 
obtained clinically in man using the  hyperosmolar agent m annitol (Marshall 
e t  al., 1978; Wise & C hater, 1962). Mannitol is putatively neuroprotective 
in some animal models of cerebral ischaemia (L ittle, 1978; Sutherland e t al., 
1988). This suggests th a t the e ffec t of CI-977 is th e re fo re  potentially 
biologically significant. However, clear increases in plasma osm olality were
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not observed until 2-3h a fte r MCA occlusion in the  cat. The window of 
therapeu tic  opportunity in large animal MCA occlusion models is 2-3h 
(McCulloch e t al., 1991), and thus the a lterations in plasm osmolality and 
reductions in size of the  ischaem ic lesions; ca ts  tre a ted  with CI-977 with the 
num erically g rea tes t a lterations in plasma osm olality had larger lesions than 
those with sm allest a lterations in plasma osmolality.
Cumulatively, these data suggest th a t k -opioid agonists may not produce 
th e ir neuroprotective e ffec ts  principally by reducing cerebral oedema and 
secondary neuronal death. However, although the  reduction in brain swelling 
may be a consequence of a reduction in infarction, it cannot be discounted 
absolutely th a t an increase in plasma osmolality may contribute to  the 
neuroprotection afforded by CI-977 by prolonging the window of therapeutic  
opportunity.
2.2 C erebral Blood Flow
The identification of the enkephalins (Hughes e t al., 1975) in itiated  the 
in te rest in opioid peptides as possible neurotransm itters or neuromodulators 
within the CNS. Cerebrovascular in te rest in opioid peptides originated with 
the  report th a t the  opioid recep to r antagonist naloxone reverses ischaemic 
neurological deficits in man (Baskin & Hosobuchi, 1981). The stra teg ic  
location of opioid peptides and opioid receptors in cen tral and peripheral 
struc tu res involved in autonomic function suggests th a t the opioid system  may 
be involved in cerebrovascular control, e ither d irectly  or indirectly. 
Although th e re  have been a number of reports in which opioid-induced 
contraction or dilatation of cerebral vessels has been dem onstrated, there  is 
no clear evidence available a t the present tim e th a t opioid recep to r agonists 
(or antagonists) have d irect vasom otor e ffec ts  in the  cerebral circulation a t
181
concentrations th a t are pharm acologically selective  and clinically relevant.
High concentrations (10'4M) of morphine and o ther opioid receptor 
agonists (including U-50,488H) e lic it cerebral vasoconstriction, putatively via 
the  activation of opioid receptors (Altura e t al., 1984; Recio e t al., 1986). 
The concentrations required are a t least 100 tim es g rea te r than those required 
in o ther pharmacological investigations. Relaxation of cerebral a rteries has 
been reported  with enkephalin and o ther opioid agonists, putatively via 
/e-opioid receptors (Hanko & Hardebo, 1978; A ltura e t  al., 1984; Harder & 
Madden, 1984). However, the  cerebrovascular relaxations are  very small 
(Hanko & Hardebo, 1978; H arder & Madden, 1984) or are achieved with very 
high agonist concentrations (Altura e t al., 1984). The observations of Wahl 
(1985) with perivascular m icroapplication of agents in anaesthetised  cats are 
possibly the m ost pertinent: leu-enkephalin and morphine are without
cerebrovascular e ffec ts  in the  concentration range 10“11 to 10”5M, although 
small increases in pial a rte rio la r d iam eter (5-14%) were observed with very 
high concentrations (10"3M) of opioid agonists. The opioid recep tor 
antagonist naloxone has little  d irect e ffe c t on th e -ce reb ra l vasculature, 
except a t high concentrations, where a relaxation is observed (Brandt e t al., 
1983; Wahl, 1985; Sasaki e t al., 1984). In addition, the  endogenous k -opioid 
peptide dynorphin has been detec ted  in nerve fibres surrounding intracranial 
blood vessels (Moskowitz, 1987), and the /c-agonist U-50,488H constricts ra t  
cerebral vessels, an e ffe c t which is nalm efene reversible (Chen e t  al., 1991a).
The m echanistic basis for the  e ffec ts  of opioid agonists and antagonists 
on cerebral vessels is unknown a t the present tim e. Pial vessels are richly 
innervated with noradrenergic fibres of sym pathetic origin which may 
m anifest them selves through m aintenance of vascular tone (Edvinsson & 
MacKenzie, 1977). Agonists a t the pi, 6 and k-opioid recep tors inhibit
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noradrenaline re lease (Werling e t al., 1987), and thus opioid agonists may 
produce the ir e ffec ts  on the cerebral vasculature indirectly by modulating 
sym pathetic activ ity .
The results of the  present studies fail to  provide any c lear evidence to 
indicate th a t the k-opioid CI-977 has any significant cerebrovascular effects. 
In conscious ra ts  CI-977 (at the neuroprotective dose of 0.3mg/kg) produced 
modest, non-significant a lterations in cerebral blood flow in the  m ajority of 
brain regions examined (Figure 34). A significant decrease in local cerebral 
blood flow was observed only within the  entorhinal cortex  (posterior) following 
CI-977. In contrast, the  adm inistration of NMDA recep to r antagonists 
produce m arked changes in cerbral blood flow in normal, lightly restrained 
ra ts  using the sam e techniques as in the present study. Significant increases 
in local cerebral blood flow have been observed in the limbic system  
(hippocampus, den tate  gyrus, entorhinal cortex , an terior and posterior 
cingulate cortex), in neocortex (e.g. visual and parie tal cortices), in 
subcortical nuclei (e.g. septal nucleus, caudate nucleus, nucleus accumbens) 
and even in white m a tte r  (corpus callosum), and a significant reduction in 
local cerebral blood flow in the inferior colliculus following MK-801 (Nehls 
e t  al., 1990). A sim ilar p a tte rn  of response is seen with ketam ine although 
no increases in cerebral blood flow were observed in neocortical and other 
forebrain areas (Cavazzuti e t al., 1987).
Evidence is also available from the studies in halothane-anaesthetised 
ra ts  and ca ts  to  indicate th a t CI-977 may have minimal cerebral circulatory 
e ffec ts. In the hemisphere con tra la tera l to  the  focal ischaem ia, an 
essentially normal, non-ischaemic hemisphere, CI-977 failed to display 
significant alterations in the  level of cerebral blood flow in any of the brain 
regions examined (Figure 34). Moreover, in the  absence of definitive studies,
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FIG URE 34
The e ffe c t of CI-977 upon cerebral blood flow in the parietal cortex in the non- 
ischaem ic hemisphere of conscious, lightly restrained ra ts  and mechanically 
ventilated  halothane-anaesthetised ra ts  and cats. D ata are presented as mean ± 
SEM (n=4-8 per group). There are no significant differences between the vehicle- 
trea ted  control groups and the CI-977 trea tm en t groups.
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these results suggest th a t halothane-anaesthesia may have a minor influence 
on the  cerebrovascular e ffec ts  of CI-977 and other k -opioid agonists.
The level of cerebral oxidative m etabolism  is a crucial determ inant of 
the level of cerebral tissue perfusion under normal circum stances (Kuschinsky 
& Wahl, 1978). In the  present studies, there  was no c lear evidence th a t 
cerebral blood flow and glucose use could be uncoupled locally, numerically 
or neuroanatom ically in conscious ra ts  a f te r  CI-977. There was, however, a 
suggestion of a possible uncoupling of cerebral blood flow and glucose use in 
the  la te ra l habenula following CI-977 adm inistration. This apparent e ffe c t 
may have been a consequence of the lack of spatial resolution in the la teral 
habenula produced with highly diffusable [14C]-iodoantipyrine when compared 
to  [14C]-2-deoxyglucose, ra th e r than as a response to  CI-977. A local 
dissociation betw een cerebral blood flow and glucose use has been 
dem onstrated following adm inistration of NMDA recep to r antagonists 
(Cavazzuti e t  al., 1987; Nehls e t al., 1990). The level of cerebral blood flow 
was increased in excess of m etabolic demand in neocortex, cingulate cortex  
(anterior and posterior), interpeduncular nucleus, and caudate nucleus although 
the  m echanistic basis for such an e ffe c t rem ains to  be fully resolved. The 
principal conclusion which can be drawn from the present study is th a t the  
relationship which exists betw een local cerebral blood flow and glucose in 
each region of the CNS examined in normal animals is unaltered  by CI-977 
adm inistration. It would thus appear possible th a t the  alterations in 
cerebral blood flow observed a fte r  CI-977 are a consequence of the  reductions 
in m etabolic activ ity  which resu lt from CI-977 trea tm en t, ra th e r than a 
d irec t action on cerebral vessels.
The ex ten t to which alterations in cerebral blood flow may contribute 
to  or com plicate (e.g. via stea l phenomenon) the  neuroprotective e ffec t of
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CI-977 a fte r perm anent MCA occlusion is unknown. Prior to  the advent of 
the  excitotoxic hypothesis, anti-ischaem ic drug developm ent had been 
dom inated by a ttem pts  to  convey benefit through im provem ent in blood flow 
to ischaem ic tissue. The k-agonist U-50,488H has been reported to a tten u a te  
post-ischaem ic hypoperfusion in a mouse head injury model (Hall e t  al., 1987), 
suggesting th a t cerebral circulatory e ffec ts  may contribu te to  the anti- 
ischaem ic benefit observed a fte r k-opioid agonists. There has long been 
concern, however, th a t increasing blood flow to ischaem ic brain tissue may 
have adverse consequences such as increased cerebral oedema and raised 
in tracranial pressure, haem orrhagic transform ation or generation of free  
radicals (Harris e t  al., 1982; Hossmann, 1982).
There is considerable debate over w hether the improved neuro- 
pathological outcom e a f te r  experim ental focal ischaemia with NMDA recep tor 
antagonists is a ttribu tab le  to their cerebrovascular e ffec ts . Increased 
cerebral blood flow to  the ischaemic areas has been reported  with MK-801 
and CGS-19755 in the  ra t MCA occlusion model (Buchan e t  al., 1992; 
Takizawa e t al., 1991). The non-com petitive NMDA antagonists 
dextrom ethorphan has been shown to increase blood flow to  perifocal tissue 
a fte r  focal ischaemia in rabbits, although global cerebral blood flow values 
did not d iffer significantly from control values (Lo & Steinberg, 1991). 
However, in iodoantipyrine studies conducted in parallel to histopathological 
studies, Park and associates (1988b, 1989) have described reduced in farc t with 
no a lterations in cerebral blood flow within (or adjacent to) the  ischaem ic 
te rrito ry  a f te r  MK-801 (Figure 35). Similarly, MK-801 has recen tly  been 
found to improve the  outcom e a fte r  MCA occlusion in the c a t  independent 
of changes in cortical blood flow (Dezsi e t  al., 1992). These seemingly 
conflicting results may be due to differences in the  animal model,
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Comparison of the e ffec ts  of p re trea tm en t with MK-801, nimodipine and CI-977 
and post-trea tm en t with nimodipine upon cerebral blood flow in the sensory m otor 
cortex  ipsilateral to perm anent MCA occlusion in halothane-anaesthetised ra ts. 
D ata are presented as mean ± SEM (n=4-8 per group). *P<0.05 for the difference 
betw een vehicle and nimodipine p re trea tm en t. Note th a t in con trast to nimodipine 
p re trea tm en t, the neuroprotection afforded by MK-801 and CI-977 p re trea tm en t can 
be dissociated from their e ffec ts  on cerebral blood flow. (Redrawn from the data 
of Gotoh e t al., 1986; Mohammed e t al., 1985; Park e t al., 1989.)
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anaesthesia, or m ethod of blood flow determ ination. In contrast, the 
reduction in cortical infarction th a t was observed with nimodipine in the ra t 
MCA model could not be dissociated from an increase in blood flow towards 
the  margins of MCA te rrito ry  (Gotoh e t  al., 1986; Jacew icz e t al., 1990b; 
Mohamed e t al., 1985) (Figure 35).
In the  present study, veh icle-treated  animals exhibited an area of 
profound hypoperfusion th a t conforms to  the p a tte rn  of cerebral blood flow 
previously described in the  hemisphere ipsilateral to MCA occlusion in 
halothane-anaesthetised ra ts  (Tamura e t al., 1981b; Tyson e t al., 1984). The 
adm inistration of CI-977 30 min prior to the  induction of ischaem ia failed to  
produce marked alterations in cerebral blood flow within the  te rrito ry  of the 
occluded MCA. In particu lar, CI-977 failed to  dem onstrate a significant 
e ffe c t on cortical blood flow in any of the 5 cortical areas comprising the 
ischaemic cortex (Figure 35), the s ite  a t which the neuroprotective e ffec ts  
of CI-977 are observed. Focal increases in cerebral blood flow in 
circum scribed brain regions in the ipsilateral hemisphere w ere observed in 
animals tre a ted  with CI-977. The structu res involved are  the la teral 
thalam us and medial caudate nucleus ipsilateral to  the MCA occlusion. Each 
of these regions has neuronal connections (putatively glutam atergic) with the 
ischaem ic cortex  via corticothalam ic and co rtico stria te  pathways (Fonnum, 
1984). The delayed degeneration of the la te ra l thalam us observed several 
months a fte r  MCA occlusion'has been a ttribu ted  to  its neuronal connections 
to  the ischaem ic cortex  (Fujie e t al., 1990). The m echanistic basis for the 
acu te  increases in blood flow in these regions with CI-977 rem ains unknown 
although presynaptic modulation of altered  corticothalam ic and co rticostria te  
activ ity  would be a possible mechanism (Pinnock, 1992).
CI-977 produced a m oderate and sustained hypotension throughout the
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cerebral circulatory  study, and low arte ria l blood pressure may be detrim ental 
to  local cerebral perfusion. It is generally accepted th a t cerebrovascular 
autoregulation to  reduced blood pressure is severely impaired by an ischaemic 
insult (Dirnagl & Pulsinelli, 1990; Symon e t  al., 1976). Thus, in the present 
study it is noteworthy th a t th e re  was no a lteration  in cerebral blood flow in 
the  ischaem ic hemisphere despite the combined e ffec ts  of impaired 
autoregulation and a drug-induced reduction in blood pressure, k-Opioid 
recep to r agonists may a tten u a te  sym pathetic activ ity  (Gulati & Bhargava, 
1988), and a reduction in sym pathetic activ ity  extends (at least in normal 
animals) the  autoregulatory range (Paulson e t al., 1990).
While the sam e experim ental design has been used with success to 
identify the  contribution of cerebrovascular events to  neuroprotective agents 
such as nimodipine (Jacewicz e t  al., 1990b; Mohamed e t al., 1985), it has 
been unable to dem onstrate any contribution of cerebral circulatory  e ffec ts  
to  the neuroprotection afforded by CI-977 in the present study. However, 
as with any negative observation, one cannot conclude absolutely th a t 
CI-977 is to ta lly  devoid of e ffec ts  on cerebral blood flew, but ra th e r whether 
the  e ffec ts  are within the s ta tis tica l power of the  design. Post hoc power 
analysis (a  = 0.05, (3 = 0.2) in the present study indicate th a t the  m agnitude 
of changes in cerebral blood flow would have had to  be in the order of 35% 
in the  non-ischaem ic hemisphere and in excess of 40% in the  ischaemic 
hemisphere to be consistently detec ted  (sta tistica l power 80%). However, 
th e  s ta tis tica l power is sim ilar to, if not b e tte r  than, previous studies using 
nimodipine in the  sam e model (Jacewicz e t al., 1990b; Mohamed e t  al., 1985). 
Thus, w hatever changes CI-977 may have on cerebral blood flow in the 
p resent study, they are not so readily dem onstrable as those seen with 
nimodipine in this model.
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An im portant general conclusion can be drawn from the  results of the 
present investigation. The improved histological outcom e a fte r  CI-977 can 
be dissociated from its e ffec ts  on cerebral blood flow and suggests th a t the 
neuroprotective e ffec ts  of CI-977 in this model are not principally 
a ttribu tab le  to  cerebral circulatory  e ffec ts , but via an action on neuronal 
tissue.
2.3 G lutam ate R elease
The pivotal observation describing elevations in the  ex tracellu lar 
concentrations of g lu tam ate and asparta te  measured by microdialysis during 
ischaem ia was reported  in the ra t  hippocampus by Benveniste and colleagues 
in 1984 (Benveniste e t  al., 1984). A plethora of studies have since confirmed 
and characterised  this phenomenon, in d ifferen t brain regions, with various 
animal models of global (Globus e t al., 1988; Hagberg e t  al., 1985; Shimada 
e t  al., 1989, 1990) and focal (Butcher e t al., 1990; H illered e t  al., 1989; 
M atsumoto e t al., 1992, 1993; Takagi e t al., 1993) ischaem ia, spinal cord and 
head injury (Katayama e t al., 1990; Panter e t al., 1D90F, and also in man 
(Baker e t  al., 1993; Persson & Hillered, 1992) (Table 15). The increase in 
g lu tam ate release a fte r  the  induction of ischaemia has been shown to range 
from  5 to  27 fold in the  cerebral cortex (Table 15). It has been estim ated 
th a t the extracellu lar glutam ate concentration within the  synaptic c left, 
taking into account shrinkage of the ex tracellu lar space of 50% of the normal 
value during ischaemia, the  in vitro  recovery of the microdialysis probe, and 
the  tortuosity  fac to r (non-linearity of the extracellu lar diffusion path), can 
reach  up to  ImM (Benveniste e t  al., 1991).
The precise origin of the  elevated levels of g lu tam ate  observed during 
cerebral ischaemia is a contentious issue. The level of g lu tam ate within
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neurones is around 4 orders of magnitude higher than th a t in the extracellu lar 
space, a gradient m aintained across the  plasma mem brane by Na+/K +- 
dependent carrier-m ediated  uptake into both neurones and glia (Nicholls & 
A ttw ell, 1990). It is generally accepted th a t g lu tam ate is present in e ither 
cytosolic (metabolic) or neurotransm itter (vesicular) pools, which can be 
discrim inated by studying the Ca2+-dependency of g lu tam ate release 
(Kauppinen e t  al., 1988; Nicholls & A ttw ell, 1990). Two distinct mechanisms, 
alone or combined, may be responsible for the  ischaem ia induced increase in 
ex tracellu lar g lu tam ate concentration; Ca2+-dependent exocytotic release of 
vesicular glu tam ate (Kauppinen e t al., 1988) and reversal of the electrogenic 
uptake transport system s on neurones and glia (Szatkowski e t al., 1990).
Under the ionic conditions which prevail during cerebral ischaemia, there  
is an initial increase in Ca2+-dependent vesicular re lease of g lu tam ate by 
ATP-dependent exocytosis (Katayama e t al., 1991; Nicholls & A ttw ell, 1990). 
T hereafter, as ATP levels decline during the  ischaem ic episode, the high- 
affin ity  energy-dependent uptake system s on neurones and glia, which 
normally remove extracellu lar glutam ate, fail. There is evidence in severe 
energy failure th a t the plasma membrane-bound glu tam ate uptake carriers can 
reverse, and pump glu tam ate out of cells into the ex tracellu lar space, a 
process which is Ca2+-independent (Kauppinen e t  al., 1988; Nicholls & A ttw ell, 
1990; Szatkowski e t al., 1990). The initial increase in g lu tam ate  observed 
a f te r  the  onset of cerebral ischaemia has been shown to  depend on C a2+ 
(Katayam a e t  al., 1991). In addition phenlysuccinate, which prevents the 
biosynthesis of vesicular g lu tam ate but leaves the  m etabolic g lu tam ate pool 
unaffected , has a minimal e ffec t on glu tam ate released in the ra t 
hippocampus a fte r transien t, severe forebrain ischaemia (Christensen e t  al., 
1991). Such evidence suggests th a t both Ca2+-dependent and C a2+-
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independent mechanisms are involved in the ischaemia-induced elevation of 
ex tracellu lar g lutam ate.
The re la tive  contribution of these two d istinct mechanisms to the 
elevation in extracellu lar g lu tam ate levels will depend upon the  severity  of 
the  ischaem ic insult. During global ischaemia, ATP levels fall to negligible 
values within a few m inutes (Nordstrom & Siesjo, 1978; Pulsinelli & Duffy, 
1983; Welsh e t  al., 1978, 1982) (Figure 36). However, in animal models of 
MCA occlusion, although there  are  m arked reductions of ATP levels in the 
ischaem ic focus, there  is no com plete cessation in cellular energy s ta te  
(Folbergrova e t al. 1992; Nowicki e t al., 1988; Welsh e t  al., 1980) (Figure 36). 
Furtherm ore, in the ischaem ic penumbra a fte r  perm anent MCA occlusion 
where residual blood flow rem ains between 10-20ml 100g-1 min-1 (Astrup e t 
al., 1981), there  are only mild to m oderate a lterations in ATP levels over 
several hours (Folbergrova e t  al., 1992; Nowicki e t  al., 1988; Welsh e t al., 
1980) (Figure 36). The residual blood flow in the cerebral cortex  would allow 
replenishm ent of energy substrates suggesting th a t g lu tam ate re lease into the 
ex tracellu lar space by ATP-dependent exocytosis in focal cerebral ischaemia 
rem ains possible for long periods.
In the present study, increases in the levels of g lu tam ate  and asparta te  
are observed when cerebral blood flow is reduced to below 20ml I00g~1 
min-1 in the  cerebral cortex a f te r  perm anent MCA occlusion in the  ca t. The 
m agnitude of the elevations in the  concentrations of g lu tam ate and asparta te  
(approxim ately 3-8 fold and 4-12 fold respectively re la tive  to  pre-ischaem ic 
basal levels) are  in general agreem ent with observations reported  previously 
in this model of focal ischaem ia (Matsumoto e t  al., 1992, 1993) (Table 15). 
The elevations in glutam ate re lease appear to  occur a t cerebral blood flow 
values of approxim ately 15-20ml 100g-1 min-1, which represents 27-36% of
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Levels of ATP, determ ined using biochemical enzym atic techniques, following global 
and focal cerebral ischaemia in the ra t (upper) and ca t (lower). Note th a t ATP 
levels are only minimally reduced in the ischaemic penumbra a fte r the induction of 
focal ischaemia in both the ra t and the cat. D ata are presented as m ean ± SEM 
and calculated  from mean values given in tables and figures from Pulsinelli & Duffy, 
1983; Folbergrova e t al., 1992; Welsh e t al., 1978, 1980.
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pre-ischaem ic control levels, and thereby is suggestive of a threshold-like 
e ffe c t for ischaemia-induced g lu tam ate release. There are  several reports 
in which the existence of a threshold-type relationship betw een cerebral blood 
flow and ex tracellu lar g lu tam ate re lease has been seen (Matsumoto e t  al., 
1992; Shimada e t  al., 1989; Takagi e t  al., 1993). Although these studies 
differed  in the m anner in which ex tracellu lar g lu tam ate  levels were 
expressed, they dem onstrated generally sim ilar ischaem ic cerebral blood flow 
thresholds for g lu tam ate release. Following severe global ischaem ia in cats, 
Shimada and co-workers (1989, 1990) found th a t the  blood flow threshold for 
g lu tam ate  release was 20ml lOOg”1 min"1 (36% of pre-ischaem ic cerebral blood 
flow), a value confirm ed in the cerebral cortex  of ca ts  a f te r  perm anent MCA 
occlusion (Matsumoto e t  al., 1992). G lutam ate re lease  in the  dorsolateral 
parie ta l cortex of ra ts  subjected to transien t focal ischaem ia was found when 
cerebral blood flow was less than 48% of control levels (Takagi e t al., 1993). 
Thus the  apparent cerebral blood flow threshold value for g lu tam ate release 
in the  present study is com parable to those previously reported.
It has been established th a t the Ca2+-dependent~release of endogenous 
L-aspartate from isolated term inal preparations is around 10% of th a t seen 
for g lu tam ate  (McMahon & Nicholls, 1990). This observation is consistent 
w ith the  specificity  of the synaptic vesicle g lu tam ate transporter (Nicholls 
& A ttw ell, 1990) and represents a ra tio  of g lu tam ate to  asp arta te  of 10:1 
within the  vesicle. The ra tio  of glutam ate to  asp arta te  in the  cytosol is 
approxim ately 3:2 (Nicholls & A ttw ell, 1990). In the  p resent study, the ratio  
of g lu tam ate  to asp arta te  released in the cerebral cortex  a t blood flow levels 
of less than 20ml I00g"1 min"1 is about 8:1. This observation suggests th a t 
a proportion of the g lu tam ate released is of vesicular origin, and not to tally  
a consequence of g lu tam ate uptake reversal. Moreover, this ra tio  is
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approxim ately 6:1 in d rug-treated  animals, which implies th a t a fraction  of 
ischaemia-induced g lu tam ate re lease a ttenuated  by CI-977 may be Ca2+- 
dependent in origin.
A mechanism of action for the  neuroprotective e ffec ts  of /c-opioid 
agonists in experim ental models of cerebral ischaem ia is not known with 
certain ty . In the  present studies, CI-977 was found to  a tten u a te  the  release 
of g lu tam ate in the  cerebral cortex  a fte r  focal ischaem ia in the  cat. 
Furtherm ore, CI-977 failed to  a lte r the  amount of neuronal necrosis produced 
by exogenous g lu tam ate in the r a t  cortex; the postsynaptic NMDA and AMPA 
recep to r antagonists MK-801 and NBQX significantly reduced the  lesion 
volume. These results thus provide two lines of evidence which suggest th a t 
CI-977 may m odulate the neurotoxic action of g lu tam ate  in ischaem ia via 
presynaptic inhibition of its release, and such an e ffe c t may contribute, a t 
least in part, to the  anti-ischaem ic efficacy  of k-agonists.
Excitatory amino acid antagonists have also been reported  to  reduce the 
increases in neurotransm itters and other compounds induced by ischaem ia or 
hypoglycaemia. The non-NMDA antagonist GYKI 52466 reduces g lutam ate, 
bu t not asparta te , release from the stria tum  following transien t forebrain 
ischaem ia (Arvin e t  al., 1994), although neuroprotection is observed in this 
model in both the cortex and stria tum  (Le P e ille t e t  al., 1992). MK-801 
reduces the  re lease of glutam ate and asparta te  induced by hypoglycaemia 
(W esterberg e t  al., 1988), and NMDA recep tor antagonists also a tten u a te  the 
re lease  of purine catabolites (Hagberg e t al., 1987) and la c ta te  (K atayam a e t 
al., 1992) following transien t ischaem ia. These observations a re  in terpreted  
to  resu lt from  the neuroprotection afforded by these agents ra th e r than a 
presynaptic modulation of glutam ate release. Similarly it  is possible th a t part 
of the  attenuation  in ischaemia-induced glutam ate re lease  in C I-977-treated
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cats  is a ttribu tab le  to the neuroprotective e ffe c t of the drug, and re flec ts  a 
reduction in the  number of neurons irreversibly damaged.
The m echanistic hypothesis th a t CI-977 acts presynaptically to m odulate 
g lu tam ate  re lease is substantiated  by evidence obtained both in vitro  and in 
vivo. Prelim inary data indicates th a t CI-977 inhibits the  re lease of g lu tam ate 
in the  ischaem ic cortex  a f te r  perm anent MCA occlusion in the ra t  (Hayward 
e t  al., 1993a). In vitrot k-agonists inhibit the  evoked release of g lu tam ate 
and asp arta te  from  ra t  cortical slices (Bradford e t al., 1986; Lam bert e t  al.,
1991) and guinea pig hippocampal mossy fibre synaptosomes (Gannon & 
Terrian, 1991a,b, 1992). The inhibition of neuro transm itter release by k- 
agonists is thought to occur by restric ting  the  entry  of C a2+ into presynaptic 
term inals (Gannon & Terrian, 1991a,b, 1992), putatively by closing N-type 
C a2+ channels (Gross & MacDonald, 1987; Xiang e t al., 1990) or by enhancing 
C a2+ extrusion (Olson & Welch, 1991). Thus k-receptor activation by CI-977 
may a tten u a te  the  rise in presynaptic in tracellu lar Ca2+ levels and thereby 
reduce Ca2+-dependent glu tam ate release. This is supported by evidence 
from  electrophysiological studies where k-agonists, " including CI-977, 
reduce excitato ry  postsynaptic potentials in the  ra t locus coeruleus and guinea 
pig hippocampus, prim arily by acting a t presynaptic receptors to  inhibit 
calcium  influx into the nerve term inal via voltage-sensitive C a2+ channels and 
subsequent excitato ry  amino acid release (McFadzean e t  al., 1987; Pinnock, 
1992; Wagner e t  al., 1992a).
The reduction in the  volume of ischaem ic damage w ith CI-977 is less 
than  th a t observed previously with p re trea tm en t with NMDA recep tor 
antagonists in sim ilar models of focal cerebral ischaem ia (see McCulloch e t 
al., 1991 for review), and may re fle c t a d ifferen t m echanistic basis of the  two 
classes of drugs. NMDA recep to r antagonists will block the  neurotoxic
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effec ts  of g lu tam ate irrespective of w hether the  elevated levels are a 
consequence of C a2+-dependent or Ca2+-independent release. k-Opioid 
agonists such as CI-977 would be beneficial only against the  portion of 
g lu tam ate released by ATP-dependent exocytosis but in doing so reduce 
activation, not just of NMDA receptors, but also of AMPA receptors which 
may also contribute to ischaem ic brain damage (Buchan e t al., 1993; Bullock 
e t  al., 1994; Gill e t  al., 1992b; Xue e t al., 1994).
There is evidence th a t agents which putatively inhibit g lu tam ate release 
afford neuroprotection in animal models of cerebral ischaem ia and the  
magnitude of the benefit conveyed is com parable to th a t obtained with 
CI-977 in the  present study. Most a tten tion  has been paid to  adenosine 
analogues which ac t on presynaptic adenosine A l receptors, such as 2- 
chloroadenosine. These compounds have been reported  to  decrease ischaemic 
brain injury in models of focal and global cerebral ischaem ia by inhibiting 
recep to r activated  calcium  entry  and the concom itant re lease  of g lutam ate 
(Rudolphi e t  al., 1992). Riluzole (2-am ino-6-trifluorom ethoxy benzothiazole) 
and BW 1003C87 (5-(2,3,5-trichlorophenyl0-2,4-diaminopyrimidine) are agents 
which putatively block sodium channels and both drugs have been shown to 
reduce ischaem ic brain damage when adm inistered e ither before or a fte r  the 
induction of global or focal cerebral ischaem ia (Graham e t  al., 1993a; 
Lekieffre & Meldrum, 1993; Meldrum e t al., 1992; P ra tt  e t  al., 1992; Wahl e t 
al., 1993). BW 1003C87 inhibits glu tam ate re lease following perm anent MCA 
occlusion in the  ra t  in both the cortex and caudate, although neuroprotection 
is only afforded in the  cortex  (Graham e t al., 1993a; Meldrum e t al., 1992).
Interestingly, BW 619C89 (4-am ino-2-(4-m ethyl-l-piperazinyl)-5-(2,3,5- 
trichlorophenyDpyrimidine), a structural analogue of BW 1003C87, has recently  
been reported  to  reduce both glutam ate re lease  and brain dam age in the
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cortex  and caudate a f te r  focal ischaemia in the r a t  (Graham e t al., 1994; 
Leach e t  al., 1993). Methionine sulfoxamine, an inhibitor of glial glutam ine 
synthetase, which depletes brain glutam ine stores and decreases K+-evoked 
glu tam ate  release, reduces the volume of infarction a f te r  perm anent MCA 
occlusion in the r a t  (Swanson e t al., 1990). In addition, hypotherm ia has been 
shown to a tten u a te  g lu tam ate re lease  and the  ex ten t of ischaem ic damage 
in various models of cerebral ischaemia (see Ginsberg e t  al., 1992 for review). 
These studies support the  hypothesis th a t inhibition of excitato ry  amino acid 
re lease  during ischaem ia is an e ffective  stra tegy  for reducing ischaem ic brain 
injury.
The neuroprotection afforded by CI-977 is only observed in the cerebral 
cortex . This may be a consequence of neuropeptide co-existence and 
neuromodulation. There is evidence th a t prodynorphin derived peptides co­
exist with g lu tam ate in cortical neurones (Gannon & Terrian, 1991b; Terrian 
e t  al., 1990) and th a t glu tam ate and dynorphin peptides are co-released from 
hippocampal mossy fibre synaptosomes (Terrian e t  al., 1988). Moreover, 
th e  /c-agonist U-50,488H inhibits both dynorphin and g lu tam ate  release from 
mossy fibre term inals (Gannon & Terrian, 1991a). Recently, it  has been shown 
th a t the  synaptic re lease  of dynorphin produces a presynaptic inhibition of 
neighbouring mossy fibres and the  induction and expression of long-term  
po ten tia tion  (Weisskopf e t al., 1993). Furtherm ore, the  activation of 
/c-opioid receptors by the  endogenously released peptide dynorphin or the 
exogenous /c-agonist U-69593 reduces excitato ry  transm ission in the guinea 
pig den ta te  gyrus (Wagner e t al., 1993). These observations suggest 
dynorphin may normally function to  p ro tec t hippocampal neurones from 
overstim ulation during the  intense nervous activ ity  involved in learning by 
providing a presynaptic feedback control of a ffe ren t input to  the
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hippocampus. Thus, the use of /c-agonists like CI-977 as neuroprotective 
agents, and the  observations th a t they may m odulate excitato ry  amino acid 
release, suggests th a t they could be viewed as a form  of endogenous /c-opioid 
replacem ent or supplem ent therapy.
The pharm acologic inhibition of g lu tam ate release may have several 
advantages for neuroprotection over drugs which block postsynaptic excitatory  
amino acid receptors. The presynaptic inhibition of g lu tam ate release 
prevents activation of both NMDA and non-NMDA receptors and thus 
conceptually, with an optimum dosing regimen, could be m ore effec tive  in 
reducing ischaem ic brain damage than NMDA or AMPA recep tor blockade 
alone. Agents which a tten u ate  ischaemia-induced g lu tam ate re lease  may 
lack the  behavioural and morphological side-effects  found with NMDA 
recep to r antagonism. Presynaptic inhibition of g lu tam ate re lease may also 
provide a b e tte r  therapeutic  index and offer the  possibility of combination 
therapy with agents acting postsynaptically, including free  radical scavengers 
and drugs modulating calcium toxicity  via in tracellu lar mechanisms such as 
calpain inhibitors.
3. LOCAL CEREBRAL GLUCOSE UTILISATION
The [14C]-2-deoxyglucose technique allows an anatom ically 
comprehensive assessm ent of function-related alterations in cerebral glucose 
use in vivo (Sokoloff e t  al., 1977; Sokoloff, 1981). Glucose u tilisation 
constitu tes the  prim ary energy-generating m etabolic process in cerebral tissue 
of well-nourished m ature  animals (Sokoloff e t al., 1977). As a consequence 
of the  close coupling between neuronal activ ity  and the  energetic  requirem ent 
for such activ ity , local a lterations in glucose utilisation have been used to 
dem onstrate the  involvement of d iscrete  brain areas during various
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pharm acological interventions (Kurumaji e t  al., 1993; McCulloch, 1982). In 
addition, functional mapping with [u C]-2-deoxyglucose has proven useful as 
a potential index of s truc tu ra l abnorm alities within the brain following drug 
trea tm en t. A lterations in gene expression and neuronal morphology (cell 
swelling, vacuolisation) a fte r  NMDA antagonists have been shown to be co­
incident anatom ically with areas of increased cerebral glucose metabolism  
(Allen & Iversen, 1990; Auer & C oulter, 1994; Fix e t  al., 1993; Hargreaves e t 
al., 1993b; Olney e t  al., 1989, 1991; Sharp e t  al., 1991, 1992).
The use of the [14C]-2-deoxyglucose technique as a m easure of CNS 
function receives its m ost definitive support from the application of the 
technique itse lf in simple sensory stim ulation and deprivation experim ents. 
Deprivation of visual stim uli results in reductions of glucose utilisation in 
neuroanatom ical components of the visual system  (i.e. dorsal la teral 
geniculate body, superficial layer of the superior colliculus, and area 17 of 
the  neocortex), whereas stim ulation with diffuse light results in intensely- 
re la ted  increm ents in their glucose use (Kennedy e t  al., 1975; Miyaoka e t  al., 
1979; Toga & Collins, 1981). Similarly, auditory stim ulation or occlusion of 
the  external auditory canals is associated with increases and decreases in 
glucose utilisation throughout the  prim ary auditory pathway from  the  cochlear 
nucleus to  the  auditory cortex  (Sokoloff, 1977). Circum scribed areas of 
enhanced glucose u tilisation can be dem onstrated in specific areas of the 
olfactory bulb in response to stim ulation w ith d ifferen t odours (Sharp e t  al., 
1975). Furtherm ore, enhanced glucose utilisation, seen in a d iscrete  column 
of the som atosensory cortex of the  ra t  brain and resulting from  stim ulation 
of a single whisker, can be readily identified (Ginsberg e t al., 1987a). Thus, 
a correlation does appear to  exist between the  level of glucose u tilisation in 
neuroanatom ical components of well-defined functional system s and the
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processing of inform ation in those systems.
The present study provides a comprehensive description of th e  regional 
changes in functional activ ity  (as re flec ted  in local cerebral glucose use) in 
the  CNS which are involved in the response to the  system ic adm inistration 
of the  /c-opioid agonist CI-977. The results show th a t CI-977 produces a 
widespread depression of local cerebral glucose use throughout th e  CNS. A 
striking fea tu re  of the e ffec ts  of trea tm en t with CI-977 is how lim ited in 
m agnitude the  alterations in glucose utilisation are  in comparison to  o ther 
neuroprotective agents which m odulate excito toxicity  a t postsynaptic NMDA 
receptors (Kurumaji e t  al., 1989; McCulloch & Iversen, 1991; Nehls e t  al., 
1988; Weissman e t  al., 1987) and AMPA receptors (Browne & McCulloch, 1994; 
Suzdak & Sheardown, 1993).
The e ffe c t of k -agonists on cerebral glucose use has been minimally 
investigated (Beck & Krieglstein, 1986; Fanelli e t  al., 1987). Previously, it 
has been difficu lt to ascribe with certa in ty  the e ffec ts  on glucose use to a 
specific action a t the  /c-opioid recep to r because of the  poor pharm acological 
selectiv ity  of the agents used. The in vitro  and iir vivo pharm acological 
profile of CI-977 dem onstrates th a t it is a potent and highly selective  agonist 
a t  the  /c-opioid recep tor (Hunter e t al., 1990). Thus, it  has been possible to 
a ttrib u te  the a lterations in glucose utilisation in the  present study to a k- 
m ediated action.
The doses of CI-977 in the  present study correspond to those used to  
investigate the  neuroprotective e ffec ts  of this agent 24h a f te r  perm anent 
MCA occlusion in the  ra t. Maximum neuroprotection with CI-977 was 
observed a t the  in term ediate  dose examined in the  p resent study (0.3mg/kg). 
The apparent lack of dose-dependent changes in local cerebral glucose 
utilisation in many of the areas examined may be a ttribu ted  to  a ceiling
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e ffe c t across the 100-fold dose range used. Thus, although the range of 
doses used in this study was broad it is possible th a t significant changes in 
glucose use might occur a t even lower doses. However, the analgesic effec ts  
of CI-977 in ra ts  are  also observed within the dose range examined (Hunter 
e t  al., 1990). This suggests therefore , th a t the  [14C]-2-deoxyglucose 
technique is as sensitive an end point as is analgesia for CI-977.
The regional hierarchy of changes in glucose utilisation a fte r  the 
adm inistration of CI-977 do not co rre la te  simply with the  topography and 
associated densities of /c-opioid receptors in the ra t  brain identified on the 
basis of radioligand binding (Boyle e t al., 1990; Mansour e t  al., 1987; Tempel 
& Zukin, 1987). In some regions th a t exhibit high densities of receptors, such 
as the  nucleus accumbens, CI-977 failed to  induce any prom inent alterations 
in glucose utilisation. However, CI-977 reduced the ra tes  of glucose use in 
the  neocortex and m olecular layer of the hippocampus, and increased glucose 
u tilisation in the la te ra l habenula, areas in which the lowest densities of k- 
opioid receptors are observed in the ra t  CNS. Although all structural 
elem ents within a region will contribute to  its ra te  "of glucose utilisation, 
dynamic alterations in glucose use appear to  re fle c t predom inantly activ ity  
in the  axonal term inal of neuronal pathways (Kadekaro e t  al., 1985). In 
neuropharmacological studies, alterations in glucose utilisation are not 
re s tric ted  to  regions rich in specific receptors for the  agent being studied, 
but are  observed also in areas with prim ary and secondary neuronal 
connections with the  recep tor-rich  regions (Kurumaji e t  al., 1993; McCulloch, 
1982; Sokoloff, 1981). A lterations in glucose u tilisation are  thus associated 
both with the initiation of the pharmacological response and with the 
polysynaptic neural pathways involved functionally in the  expression of the  
response. However, extrem e caution m ust be exercised as to  how such data
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can be in terpreted . F irst, the function-related  alterations in glucose use 
are a synthesis of all the pharm acological e ffec ts  of CI-977 including 
antinociception, behaviour e ffec ts  e tc ., and thus it is impossible to a ttr ib u te  
alterations in glucose use to a specific  e ffec t. Second, the alterations in 
glucose utilisation observed a f te r  CI-977 in the p resent study in lightly 
restra ined  animals may not accurately  re fle c t the e ffec ts  of CI-977 in freely 
moving animals.
The patterns of response to  the  /c-agonist CI-977 in the  presen t study 
bear no obvious sim ilarity  to those reported  previously with NMDA recep tor 
antagonists acting a t either the g lu tam ate recognition site , the  glycine 
modulatory site , or the ion channel s ite  within the  recep to r complex 
(Hargreaves e t al., 1993a,b; Kurumaji e t  al., 1989; McCulloch & Iversen, 1991; 
Nehls e t  al., 1988; Weissman e t al., 1987). The adm inistration of non­
com petitive NMDA antagonists (such as MK-801 and phencyclidine) or 
com petitive NMDA antagonists (such as CPP and CGP 37849) produces 
heterogeneous alterations in glucose use, with marked increases noted in 
anatom ical components of the limbic system  (posterior cingulate and 
entorhinal cortices, hippocampus, m am illary body, substantia nigra in ter  
alia) (Figures 37 & 38). In contrast, AMPA recep tor blockade induces marked 
reductions in glucose use throughout the  brain, with g rea tes t reductions 
observed in prim ary auditory areas, limbic s truc tu res (particularly 
hippocampal regions and cingulate cortex), neocortex and some thalam ic 
nuclei (Browne & McCulloch, 1994; Suzdak & Sheardown, 1993) (Figures 37 
& 38). However, although the  e ffec ts  of CI-977 on glucose u tilisation 
vaguely resem ble those induced by AMPA antagonists, they are quantitatively  
of a lesser magnitude. Indeed the  magnitude of response a f te r  AMPA 
recep to r blockade is such th a t it  has been previously observed only with
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FIGURE 37
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Comparison of the e ffec ts  of the non-com petitive NMDA antagonist MK-801 and the 
AMPA antagonist NBQX with CI-977 on glucose use in the posterior cingulate cortex 
(upper) and posterior entorhinal cortex (I) (lower) in conscious ra ts . D ata are 
presented as mean ± SEM (n=4-9 per group). *P<0.05, **P<0.01 re la tive  to vehicle- 
trea ted  controls. (Redrawn from the data of Browne & McCulloch, 1994; Kurumaji 
e t al., 1989.)
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FIGURE 38
Comparison of the effects  of the non-com petitive NMDA antagonist MK-801 and the 
AMPA antagonist NBQX with CI-977 on glucose use in the hippocampus (molecular 
layer) (upper) and the la teral habenular nucleus (lower) in conscious ra ts . D ata are 
presented as mean ± SEM (n=4-9 per group). *P<0.05, **P<0.01 re la tive  to vehicle- 
trea ted  controls. (Redrawn from the data of Browne & McCulloch, 1994; Kurumaji 
e t al., 1989.)
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barbiturates a t doses which produce com plete e lec trocortica l silence (Crane 
e t al., 1978).
A prominent finding of the present study is th a t CI-977 markedly 
increases functional activ ity  in only one of the  brain regions examined, the 
la teral habenular nucleus (Figure 38). Glucose use in the la tera l habenula 
has previously been found to  be enhanced by a number of pharmacological 
agents including haloperidol (McCulloch e t  al., 1980), caffeine (Nelig e t  al., 
1984) and oxotrem orine (Dow-Edwards e t  al., 1980). In addition, NBQX 
reduces glucose use in this nucleus (Browne & McCulloch, 1994) whilst 
MK-801 has no e ffe c t (Kurumaji e t  al., 1989) (Figure 38). It is noteworthy 
th a t previous studies involving non-selective /c-agonists observed no a lteration  
in glucose utilisation in the la teral habenula (Beck & Krieglstein, 1986; Fanelli 
e t al., 1987). Fibres and cell-containing opioid receptors (Mansour e t  al., 
1987) and opioid peptides (Khachaturian e t al., 1983) have been dem onstrated 
in the la teral habenula, thus justifying the sensitivity  of this nucleus to 
CI-977 in the present study. The la te ral habenula may serve as a relay 
station between limbic and s tria ta l forebrain areas and the mensencephalon 
(Aghajanian & Wang, 1977; Wang & Aghajanian, 1977), and is one of the  few 
forebrain regions which project to nuclei known to  be involved in pain 
modulation such as the  dorsal and median raphe, periaqueductal grey m a tte r, 
and ventral tegm ental area (Sutherland, 1982). Stim ulation of the  habenula 
is known to induce antinociception which is naloxone reversible (Mahieux & 
Benabid, 1987; Terenzi & Prado, 1990). Thus, the  observation in the  present 
study suggests th a t th e  la tera l habenular nucleus may be involved in a 
centrally-m ediated mechanism of analgesia of CI-977. Interestingly, CI-977 
altered  glucose utilisation in only one of the four m ajor habenular e ffe ren t 
projection areas, the  dorsal raphe. The reasons for the  absence of e ffec ts
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in the o ther projection areas are uncertain . The lack of e ffec ts  may be due 
to normally low discharge ra tes  in the  a ffe ren t pathways to those areas which 
are insensitive to  modulation by CI-977.
In m ost of the neocortical areas examined, marked reductions in glucose 
u tilisation w ere observed in cortical layer IV a fte r  the  adm inistration of 
CI-977. C ortical afferen ts from the specific thalam ic relay nuclei term inate  
predominantly in cortical layer IV (Herkenham, 1980). GABA agonists have 
also been shown to reduce glucose utilisation in cortical layer IV, with parallel 
reductions in glucose use in thalam ic relay nuclei (Cuddenec e t  al., 1987; 
Kelly & McCulloch, 1982). In the present study CI-977 also reduced glucose 
use in the  medial geniculate body and ven tro la teral thalam us, specific 
thalam ic relay nuclei which project to cortical areas with depressed glucose 
utilisation. This suggests th a t the observed functional disturbances in 
cerebral cortex  following CI-977 adm inistration are thalam ocortical in nature. 
A previous study using the putative /c-opioid agonist tifluadom  also detected  
depressed glucose use in a variety  of co rtical areas, but not in thalam ic relay 
nuclei (Beck & K rieglstein, 1986). The reductions in glucose use were sm aller 
in magnitude, and may be a consequence of an inadequate dose or of poorer 
selectiv ity  and potency of the agent utilised.
The ra te s  of glucose utilisation in the  den ta te  gyrus and hippocampus 
(stratum  lacunosum moleculare) displayed significant reductions 
following CI-977 (Figure 38), in spite of the  low density of kappa receptors 
in these regions of the  limbic system in the  r a t  (Boyle e t al., 1990; Mansour 
e t  al., 1987). A marked depression in glucose use has been observed in the 
hippocampus a f te r  NBQX (Browne & McCulloch, 1994; Suzdak & Sheardown, 
1993) (Figure 38). In contrast, NMDA antagonists have been shown to 
markedly enhance glucose use in these limbic regions (Kurumaji e t  al., 1989;
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Nehls e t al., 1988; Weissman e t al., 1987 (Figure 38). The hippocampus 
m olecular layer and den ta te  gyrus receive a m ajor g lu tam ateric/asparterg ic  
innervation from the  entorhinal cortex  via the perforan t pathway (White 
e t  al., 1977). Prodynorphin-derived opioid peptides have been localised to 
specific neuronal pathways within the  hippocampus, namely the  excitatory  
mossy fibre and perforan t pathways (Chavkin e t  al., 1985; McGinty e t  al., 
1983; McLean e t al., 1987). This suggests a potential role of the  endogenous 
dynorphin system  in the regulation of normal hippocampal function. In the 
present study, the reduction in glucose use observed within the  hippocampal 
form ation may be a consequence of CI-977 acting on presynaptic /c-opioid 
receptors to  inhibit excitato ry  input into both the  den ta te  gyrus and m olecular 
layer of hippocampus. This is substantiated  by electrophysiological studies 
dem onstrating th a t activation of /c-opioid receptors decrease excitatory  
synaptic transmission from the perforant path to  the  den tate  gyrus (Wagner 
e t  al., 1992a), and th a t /c-opioid agonists inhibit g lu tam ate  release from 
hippocampal mossy fibre synaptosomes (Gannon & Terrian, 1991a,b).
The m arked focal increases in glucose use a f te r  adm inistration of NMDA 
antagonists (phencyclidine, MK-801, CGP 37849) in components of the limbic 
system  (hippocampus, entorhinal cortex, m am illary body, posterior cingulate 
cortex) have been of m ajor concern with respec t to the  clinical use of NMDA 
recep to r antagonists as neuroprotectants (McCulloch e t  al., 1991; McCulloch 
& Iversen, 1991). The alterations in glucose use not only provide an 
anatom ical basis for the psychotom im etic properties of agents such as 
phencyclidine, but in areas of the m ost intense increases in glucose use, such 
as the posterior cingulate cortex, these functional alterations have been 
found to precede the  appearance of morphological alterations in neurones 
(swelling, appearance of cytosolic vacuoles) (Allen & Iversen, 1990; Auer &
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Coulter, 1994; Fix e t  al., 1993; Hargreaves e t  al., 1993b; Olney e t  al. 1989,
1991). In contrast, CI-977 induces a marked depression of glucose use in the  
posterior cingulate cortex. The absence of any focal increases in glucose use 
following CI-977 adm inistration in the  present study suggests th a t the 
morphologic changes observed with com petitive and non-com petitive NMDA 
antagonists are an unlikely consequence of /c-opioid agonist adm inistration. 
Thus, the use of /c-opioid recep to r agonists such as CI-977 in the  tre a tm en t 
of cerebral ischaemia in man is unlikely to  be com plicated by concerns over 
adverse e ffec ts  on CNS function and structu re .
The cingulate cortex  may also be involved in nociception (Sikes & Vogt,
1992). However, the reductions in glucose utilisation observed in the 
cingulate cortex are not disproportionately d ifferen t from those in o ther 
co rtical areas not involved in pain processing. This suggests therefo re , th a t 
it  is inappropriate to  ascribe with certa in ty  the alterations in glucose use in 
the  cingulate cortex to a possible mechanism of analgesia for CI-977.
In conclusion, the  present investigation provides a com prehensive 
description of the alterations in local cerebral glucose utilisation associated 
with system ic adm inistration of the /c-opioid agonist CI-977. The resu lts 
highlight the  m odest nature of the  reductions in glucose use, and the  lack of 
dose-dependency with the doses of CI-977 used. Unlike NMDA recep to r 
antagonists, the  neuroprotective dose of CI-977 does not produce anatom ically 
widespread elevations in glucose utilisation.
4. CONCEPT TO THERAPY
One of the  m ost pressing issues within the field of cerebrovascular 
disease research  is to discover an e ffective  pharm acological agent for the  
tre a tm e n t of ischaemic brain damage in man. The work carried  out in this
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thesis sought to  explore the concept th a t the selective  /c-opioid recep tor 
agonist CI-977 may o ffer a potential therapeutic  approach to  a tten u a te  
excitotoxic brain damage in stroke or head injury in humans.
The arylacetam ide CI-977 was firs t synthesised by Parke-Davis, Ann 
Arbor, U.S.A. in early  1987. Its p a ten t was applied for in July 1987 and was 
received (U.S. P a ten t Number: 4,737,493) in 1988. Although CI-977 is 
currently  undergoing clinical tria ls  as an analgesic agent in man, considerable 
a tten tion  has recently  focused on the potential of CI-977 as a neuroprotective 
agent.
The first dem onstration of the anti-ischaem ic efficacy  of CI-977 was 
reported  in abstrac t form  in 1991 by Boxer and co-workers. The intravenous 
adm inistration of CI-977 once a t 30 min and once again a t 24h a f te r  the 
induction of ischaemia conferred neuroprotection in a r a t  model of focal 
ischaem ia when outcom e was assessed a t 48h. Given th a t the half life of 
CI-977 is about lh  in the ra t  (G.N. Woodruff, unpublished observations), the 
dosing regim en employed in th a t study is suggestive of a less than adequate 
pharm acokinetic design. In the present investigations therefore , a m ultiple 
dosing regim en was utilised to  circum vent such criticism , and the 
neuroprotective efficacy  of CI-977 was subsequently confirm ed a t 24h a fte r 
perm anent MCA occlusion the in the ra t.
The e ffec ts  of CI-977 were also determ ined a t 4h a f te r  the  induction 
of ischaem ia in the ra t. This is im portant, because a t this tim e point, key 
physiological variables which may influence outcom e (e.g. MABP, core 
tem peratu re , plasma glucose e tc.) can be m onitored throughout the post- 
ischaem ic survival period. It was shown th a t CI-977 reduces the  volume of 
in fa rc t assessed a t 4h to a sim ilar degree as observed a t 24h despite a m arked 
and sustained hypotension. For the  first tim e, the neuroprotective efficacy
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of a /c-opioid agonist has been dem onstrated with full m onitoring of 
physiological variables throughout the experim ental period. Furtherm ore, by 
assessing the ex ten t of histopathological dam age a t both 4h and 24h a fte r 
MCA occlusion, the  present studies negate the possible critic ism  th a t CI-977 
m erely delays the  developm ent of ischaem ic cell changes. The observations 
th a t CI-977 conveyed benefit in the  ra t  MCA models of focal ischaem ia (at 
4h and 24h) w ere integral to  the developm ent of this thesis because were it 
not possible to  substan tia te  and extend the  initial observation of the efficacy 
of CI-977 (Boxer e t al., 1991), this thesis may well have followed a d ifferent 
direction, possibly an autoradiographic study investigating the  e ffec ts  of 
d ifferen t disease s ta tes , e.g. A lzheim er’s disease, schizophrenia, head injury, 
stroke e tc . on the distribution and density of /c-opioid receptors (see Ikeda e t 
al., 1993 and Mackay e t al., 1994 for studies in A lzheim er’s disease).
The dem onstration th a t CI-977 reduced the volume of ischaem ic damage 
a fte r perm anent MCA occlusion in the ca t is pivotal to  the pre-clinical 
evaluation of CI-977 as an anti-ischaem ic agent. It is necessary to  establish 
efficacy in a gyrencephalic species for a number of reasons. F irst, the c a t 
has a sim ilar cortical a rch itec tu re  to man, the  u ltim ate  clinical ta rg e t; the 
ra t  has a lissencephalic brain. Second, the  c a t has g rea te r cardiovascular 
stability  under anaesthesia than the ra t. Third, the  absolute amount of 
ischaemic tissue which is potentially  salvageable in the c a t is g rea te r than 
in the ra t, thereby elim inating the concern of m easurem ent bias. All these 
factors add to  the credence th a t clinicians place in the validity of findings 
in c a t (and o ther gyrencephalic species) models of ischaem ia. It is 
noteworthy th a t many of the NMDA antagonists th a t are in (or have been in) 
clinical tria ls  have all produced neuroprotective e ffec ts  in th e  c a t model of 
MCA occlusion.
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A precise m echanistic basis underlying the neuroprotective e ffec ts  of 
CI-977 and other k-agonists was unknown a t the ou tset of the  investigations 
in this thesis. The neuroprotective actions of k-agonists was generally 
a ttribu ted  to a reduction in cerebral oedem a via an overt diuresis (Silvia & 
Tang, 1986; Silvia e t  al., 1987). However, although CI-977 failed to  reduce 
the  volume of infarction a fte r  MCA occlusion in the  B rattleboro ra t  (where 
no diuresis was observed) (Boxer e t  al., 1991), the  NMDA antagonist, 
MK-801, also failed to  dem onstrate any neuroprotection in th a t model (G.N. 
Woodruff, unpublished observations). This suggests th a t an anti-oedem a 
action may not be the  principal mechanism of neuroprotection. Indeed, the 
present studies a fte r MCA occlusion in the r a t  (outcome assessed a t 24h) and 
c a t provide no definitive evidence to support an anti-oedem a mechanism of 
action. In addition, the absence of any m ajor e ffec ts  of CI-977 
adm inistration on cerebral blood flow in e ither conscious or halothane- 
anaesthetised animals indicates th a t a cerebral circulatory action is not the 
principal mechanism underpinning the anti-ischaem ic efficacy  of CI-977.
There are however, two lines of evidence in the  p resent thesis which 
suggest th a t a major mechanism of the neuroprotective e ffe c t of CI-977 is 
via inhibition of glu tam ate release. F irst, CI-977 reduces the  increase in 
ex tracellu lar g lutam ate concentration a fte r  perm anent MCA occlusion in the 
c a t which occurs with cerebral blood flow values of less than 20ml 100g-1 min 
a fte r  perm anent MCA occlusion in the ca t. Second, CI-977 has no e ffec t 
on the  volume of damage a f te r  the perfusion of exogenous g lu tam ate (0.5M) 
into the  ra t  cortex, whereas the  postsynaptic NMDA and AMPA receptor 
antagonists MK-801 and NBQX reduce the  volume of neuronal necrosis by 
around 30%. Taken together, these observations indicate th a t CI-977, and 
o ther k-agonists, may m odulate the excitotoxic action of g lu tam ate  a t pre-
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synaptic sites by attenuating  its release, and this would provide a plausible 
and rational explanation for the anti-ischaem ic efficacy  of this class of 
compound.
It is in teresting to  com pare the re la tive  tim e scales for the /c-agonist 
CI-977 and the  com petitive NMDA antagonist CGS 19755 from compound 
developm ent to  pre-clinical and clinical neuroprotective efficacy  trials. 
CGS 19755 was firs t reported  to  be a selective and com petitive NMDA 
antagonist in 1988 (Lehmann e t al., 1988), and its neuroprotective efficacy  
described a fte r  MCA occlusion in the ra t two years la te r (Simon & Shiraishi, 
1990). However, it  has only been recen tly  th a t reports are  emerging from  the 
lite ra tu re  regarding the safety , to lerability  and efficacy  of CGS 19755 in 
stroke patien ts (Clark & Coull, 1994; G rotta , 1994). In comparison, the  first 
dem onstration of the  anti-ischaem ic e ffec ts  of CI-977 in a model of focal 
ischaemia to  appear in peer-review ed form was made in 1992 (Kusumoto e t 
al., 1992) and CI-977 is about to en ter clinical tria ls  in head injury in humans 
in la te  1994. The shorter duration of taking the  concept of k -agonists as 
neuroprotective agents through system atic pre-clinical evaluation of anti- 
ischaem ic efficacy  in experim ental models of cerebral ischaem ia into the 
clinical setting  when compared to  CGS 19755, serves to  highlight the u tm ost 
im portance and urgency in acquiring an e ffective  therapeu tic  agent for use 
in man.
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APPENDIX
G lutam ate  Release and C erebral Blood Flow a f te r  MCA Occlusion in th e  C at: 
E ffe c t of CI-977 on Physiological Variables and Amino Acid Levels 
in th e  Ipsilateral Hemisphere before and a f te r  the  Induction of Ischaemia.
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perm anent MCA occlusion in halothane-anaesthetised cats. D ata are presented as 
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